Margus Viigimaa

https://www.etis.ee/CV/Margus_Viigimaa/est
24.04.1958
5110070
margus@cb.ttu.ee
Loen loenguid, viin läbi praktikume ja eksamineerin tudengeid Tallinna Tehnikaülikoolis ja Tartu Ülikoolis. Sügissemestritel on olnud õppeaineks "Inimese anatoomia ja haigusõpetus", maht EAP-des 6.0 ja "Tervisetehnoloogiad", maht EAPdes 6.0. Kevadsemestritel on olnud õppeaineks "Füsioloogiline regulatsioon ja adaptatsioon", maht EAPdes 6.0. Olen valitud Tallinna Tehnikaülikooli parimaks õppejõuks aastal 2007.

Teenistuskäik

Töökohad ja ametid
01.01.2017–...   
Tallinna Tehnikaülikool, Infotehnoloogia teaduskond, Tervisetehnoloogiate instituut, Professor (0,50)
01.01.2011–...   
Põhja-Eesti Regionaalhaigla kardioloogiakeskuse teadusjuht
Muu ...
01.01.2017–31.12.2018   
Tallinna Tehnikaülikool, Infotehnoloogia teaduskond, Tervisetehnoloogiate instituut, Vanemteadur (0,35)
01.09.2014–31.12.2016   
Tallinna Tehnikaülikool, TTÜ Tehnomeedikum, Kardiovaskulaarse meditsiini instituut, Professor (0,50)
01.03.2014–31.12.2016   
Tallinna Tehnikaülikool, TTÜ Tehnomeedikum, Biomeditsiinitehnika instituut, Teadur (0,50)
01.03.2014–31.08.2014   
Tallinna Tehnikaülikool, TTÜ Tehnomeedikum, Kardiovaskulaarse meditsiini instituut, Külalisprofessor, direktor (0,50)
01.09.2010–28.02.2014   
Tallinna Tehnikaülikool, TTÜ Tehnomeedikum, Biomeditsiinitehnika instituut, Biomeditsiinitehnika õppetool, külalisprofessor (0,50)
2005–31.08.2010   
Tallinna Tehnikaülikool, TTÜ Tehnomeedikum, Biomeditsiinitehnika instituut, Meditsiinifüüsika õppetool, Professor (0,50)
01.01.2004–31.12.2011   
SA Põhja-EEsti Regionaalhaigla, Kardioloogiakeskuse juhataja
1996–2004   
Tartu Ülikool, Arstiteaduskond, Dotsent (1,00)
 
 
Haridustee
01.01.1976–...   
Tartu Ülikool 1982 - arstidiplom (kiitusega), Kaunase Meditsiiniakadeemia 1989 - meditsiinikandidaat, Tartu Ülikool 1994 - meditsiinidoktor, postdok. stažeerimine Kyoto Ülikoolis (Japan)1990-1991
1976–1982   
Tartu Ülikool
 
 
Teadusorganisatsiooniline ja -administratiivne tegevus
2018−...   
Balti Ateroskleroosi Ühingu president
2018−...   
Eesti Tervishoiumuuseumi nõukogu liige
2015−...   
Eesti Kardioloogide Selts, juhatuse liige
2007−...   
Euroopa Hüpertensiooni Ühingu teadusgrantide komisjoni liige
2006−...   
Ajakirja "Blood pressure" toimetuskolleegiumi liige
2005−...   
Euroopa Kardioloogide Seltsi südamehaiguste preventsiooni rahvuslik koordinaator
2005−...   
Tallinna Tervisenõukogu liige
2001−...   
Ajakirja "Vererõhk" toimetuskolleegiumi liige
2000−...   
X Euroopa Hüpertensiooni konverentsi Tallinna satelliitsümpoosiumi peakorraldaja.
1998−...   
WHO CINDI programmi Eesti direktor
1995−...   
Eesti Hüpertensiooni Ühingu asutaja, esimene president ja juhatuse liige
2015−2018   
Eesti Teadusagentuur, Hindamisnõukogu liige
2015−2015   
XXV Põhjamaade-Balti Kardioloogia kongressi president
2013−2015   
Eesti Kardioloogide Seltsi president
2010−2010   
Balti Hüpertensiooni Kongressi peakorraldaja
2009−2011   
GSK Arstide Täiendamise Sihtasutuse grantinõukogu liige
2007−2007   
Balti Ateroskleroosi Kongressi peakorraldaja Tallinnas
2007−2010   
Balti Ateroskleroosi Ühingu president
2005−2013   
Ajakirja "Journal of Hypertension" toimetuskolleegiumi liige
2005−2013   
Euroopa Hüpertensiooni Ühing, juhatuse liige
2004−2007   
Balti Ateroskleroosi Ühingu valitud president
2003−2005   
Eesti Kardioloogide Seltsi president
2003−2003   
I Balti Kardioloogide Kongressi peakorraldaja (Pärnu)
2003−2005   
Eesti Kardioloogide Seltsi teaduspreemia komisjoni esimees
2002−2006   
Euroopa Kardioloogide Seltsi Crentials committee liige
2002−2009   
Ajakirja "Seminars in Cardiology" asepeatoimetaja
2001−2001   
Eesti Lipiidijuhiste koostetoimkonna esimees
1999−1999   
Eesti Hüpertensioonijuhiste koostetoimkonna esimees
1998−1998   
I Balti riikide ja Põhjamaade Hüpertensiooni Konverentsi peakorraldaja (Tallinn)
1998−1998   
I Balti Lipiidikongressi peakorraldaja (Tallinn)
1997−1997   
Euroopa Kliiniliste Uuringute Ühingu 31. aastakonverentsi (Kielis, Saksamaa) trombotsüütide aktivatsiooni sektsiooni üks organisaatoreid, istungi juhataja.
1997−2000   
Balti Ateroskleroosi Ühingu asutaja ja esimene president
1997−2000   
Ajakirja "Baltic Atherosclerosis Journal" peatoimetaja
1995−1995   
Eesti I Südametervise konverentsi pôhiorganisaator (Tallinn)

Kvalifikatsioon

Teaduskraadid
Margus Viigimaa, doktorikraad, 1994, (juh) Rein Teesalu, Müokardiinfarkti antiagregant- ja antikoagulantravi, Tartu Ülikool.
 
 
Teaduspreemiad ja tunnustused
2018, Margus Viigimaa, Eesti Konverentsisaadik
2018, Margus Viigimaa, Eesrti aasta tervisesõber
2016, Margus Viigimaa, Tallinna teenetemärk-aukodanik
2015, Margus Viigimaa, Tallinna Tehnikaülikooli aasta teadlane
2015, Margus Viigimaa, Ameerika Kardioloogide Kollegiumi erisaatusega liige
2013, Margus Viigimaa, Ukraina Arstiteaduste Akadeemia kuldmedali laureaat
2012, Margus Viigimaa, Ungari Hüpertensiooni Ühingu auliige
2012, Margus Viigimaa, Kasahstani Kardioloogide Assotsiatsiooni auliige
2008, Margus Viigimaa, Bulgaaria Hüpertensiooni Liiga auliige
2007, Margus Viigimaa, Eesti Vabariigi Punase Risti III klassi aumärk
2004, Margus Viigimaa, Euroopa Hüpertensiooni Spetsialist
2001, Margus Viigimaa, Euroopa Kardioloogia Ühingu eristaatusega liige
2000, Margus Viigimaa, Rootsi Hüpertensiooni Ühingu auliige
 
 
Teadustöö põhisuunad
ETIS KLASSIFIKAATOR: 3. Terviseuuringud; 3.7. Kliiniline meditsiin
 
 
Lisainfo
Meditsiinikandidaat
Meditsiinidoktor
Kaunase Meditsiiniakadeemia 1989
Tartu Ülikool 1994
Euroopa Hüpertensiooni Spetsialist 2004
Ameerika Kardioloogide Kolleegiumi eristaatusega liige 2015
Euroopa Hüpertensiooni Ektsellentsikeskuse juht 2006

Jooksvad projektid

Lõppenud projektid

Juhendamisel väitekirjad

Juhendatud väitekirjad

Publikatsioonid

Klass
Aasta
Publikatsioon
 
1.1.
2020
Viigimaa, M.; Sachinidis, A.; Toumpourleka, M.; Koutsampasopoulos, K.; Alliksoo, S.; Titma, T. (2020). Macrovascular complications of type 2 diabetes mellitus. Current Vascular Pharmacology, 18 (2), 110−116.10.2174/1570161117666190405165151.
1.1.
2019
Titma, T.; Shin, M-J.; Ludwig, C.; Günther, U.; Pikta, M.; Zemtsovskaja, G.; Viigimaa, M.; Tanner, R.; Samoson, A. (2019). The metabolic profile of stable ischemic heart disease by serum 1H NMR. Applied Magnetic Resonance, 50 (4), 527−539.10.1007/s00723-018-1084-0.
1.1.
2019
Einstein, S.; Pilt, K.; Palmar, M.; Meigas, K.; Viigimaa, M. (2019). Aortic Augmentation Index is Dependent on Bodyside in Healthy Young Subjects. High Blood Pressure & Cardiovascular Prevention.10.1007/s40292-019-00335-3.
5.1.
2019
Zemtsovskaja, G.; Pilt, K.; Abina, J.; Meigas, K.; Viigimaa, M. (2019). The Association Of Pulse Wave Velocity With Blood Pressure And Biochemical Cardiovascular Risk Markers In Young Tallinn Adults. Atherosclerosis, 287. Elsevier, e167−e168.10.1016/j.atherosclerosis.2019.06.506.
1.1.
2018
Pikta, M.; Zemtsovskaja, G.; Bautista, H.; Nouadje, G.; Szanto, T.; Viigimaa, M.; Banys, V. (2018). Preclinical evaluation of a semi-automated and rapid commercial electrophoresis assay for von Willebrand factor multimers. Journal of clinical laboratory analysis.10.1002/jcla.22416.
1.1.
2018
Vallejo-Vaz, A. J.; De Marco, M.; Stevens, C. A. T.; Akram, A.; Freiberger, T.; Hovingh, G. K.; Kastelein, J. J. P.; Mata, P.; Raal, F. J.; Santos, R. D.; Soran, H.; Watts, G. F.; Abifadel, M.; Aguilar-Salinas, C. A.; Al-Khnifsawi, M.; AlKindi, F. A.; Alnouri, F.; Alonso, R.; Al-Rasadi, K.; Al-Sarraf, A. ... Ray, K. K. (2018). Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). Atherosclerosis, 277, 234−255.10.1016/j.atherosclerosis.2018.08.051.
1.1.
2018
Viigimaa, M.; Heinsar, S.; Lovic, D.; Katsimardou, A.; Piperidou, A.; Duishvili, D. (2018). New horizons in the pathogenesis, pathophysiology and treatment of familial hypercholesterolaemia. Current Pharmaceutical Design.10.2174/1381612824666181009105305.
1.1.
2018
Talvik, A.; Rebora, P.; Heinpalu-Kuum, M.; Salerno, S.; Miszkowska-Nagórna, E.; Liu, X.; Comotti, T.; Świerblewska, E.; Valsecchi, M. G.; Fadl Elmula, F. E. M.; Larstorp, A. C.; Narkiewicz, K.; Parati, G.; Laurent, S.; Viigimaa, M. (2018). Non-invasive hemodynamic monitoring as a guide to drug treatment of uncontrolled hypertensive patients: effects on home blood pressure in the BEAUTY study. Blood Pressure, 27 (6), 368−375.10.1080/08037051.2018.1505425.
1.1.
2018
Sammul, S.; Viigimaa, M. (2018). Rapid socio-economic changes, psychosocial factors and prevalence of hypertension among men and women aged 55 years at baseline in Estonia: a 13-year follow-up study. Blood Pressure, 27 (6), 351−357.10.1080/08037051.2018.1476054.
3.1.
2018
Titma, T.; Günther, U.L; Ludwig, C.; Pikta, M.; Zemtsovskaja, G.; Shin, M.-J.; Viigimaa, M.; Tanner, R.; Samoson, A. (2018). The metabolic pattern could be used for early detection of stable ischemic heart disease and hypertensive heart disease. Revue d’Épidémiologie et de Santé Publique. Epidemiology and Public Health., 66: EUROEPI2018, Lyon, France;. Academic Press Inc Elsevier Science, S328. (S5; iii).10.1016/j.respe.2018.05.243.
3.1.
2018
Pilt, K.; Silluta, S.; Palmar, M.; Karai, D.; Meigas, K.; Viigimaa, M. (2018). Second derivative photoplethysmographic signal analysis of differences between fingers in healthy subjects. 2018 16th Biennial Baltic Electronics Conference (BEC): 16th Biennial Baltic Electronics Conference (BEC), Tallinn, 8-10 Oct. 2018. IEEE, 1−4.10.1109/BEC.2018.8600985.
5.2.
2018
Titma, T.; Günther, U. L.; Ludwig, C.; Pikta, M.; Zemtsovskaja, G.; Shin, M.-J.; Viigimaa, M.; Tanner, R.; Samoson, A. (2018). The metabolic profile of ischemic heart disease patients with or without previous MI by serum 1H NMR is similar. Eesti Arst, 97: 7th Baltic Atherosclerosis Congress, Tallinn, Estonia on April 6-7, 2018. Celsius Healthcare OÜ, 47−48. (Lisa 1).
5.2.
2018
Titma, T.; Shin, M.-J.; Ludwig, C.; Günther, U. L.; Pikta, M.; Zemtsovskaja, G.; Viigimaa, M.; Tanner, R.; Samoson, A. (2018). The metabolic pattern could be useful for better understanding of the etiology of cardiovascular diseases. 1st Nordic Metabolomics Conference, Örebro, Sweden: 1st Nordic Metabolomics Conference, Örebro (Sweden), 26.-28. August 2018. Örebro Universitet: Örebro University, 92−93.
5.2.
2018
Pikta, M.; Kütt, M.; Schneider, S.; Zolotarjova, V.; Viigimaa, M.; Marandi, T.; Arjakse, J.; Banys, V. (2018). Qualitative screening of DOAC-induced anticoagulation in emergency clinical situations. Clinical Chemistry and Laboratory Medicine (CCLM), 56(11):: 5th EFLM-UEMS European Joint Congress in Laboratory Medicine: Laboratory Medicine at the Clinical Interface Antalya, Turkey, October 10-13, 2018. Ed. Gillery, P.; Lackner, K. J.; Lippi, G.; Melichar, B.; Payne, D. A.; Schlattmann, P.; Tate, J. R. European Federation of Clinical Chemistry and Laboratory Medicine (EFLM, eA303 .10.1515/cclm-2018-1038.
1.1.
2017
Ferrari, Roberto; Aguiar, Carlos; Alegria, Eduardo; Bonadonna, Riccardo C; Cosentino, Francesco; Elisaf, Moses; Farnier, Michel; Ferrières, Jean; Filardi, Pasquale Perrone; Hancu, Nicolae; Kayikcioglu, Meral; Mello E Silva, Alberto; Millan, Jesus; Reiner, Željko; Tokgozoglu, Lale; Valensi, Paul; Viigimaa, Margus; Vrablik, Michal; Zambon, Alberto; Zamorano, José Luis ... Catapano, Alberico L (2017). Current practice in identifying and treating cardiovascular risk, with a focus on residual risk associated with atherogenic dyslipidaemia. European heart journal supplements : journal of the European Society of Cardiology, 18 (Suppl C), C2−C12.10.1093/eurheartj/suw009.
1.1.
2017
Kaldmäe, Margit; Zemtsovskaja, Galina; Abina, Jelena; Land, Tiit; Viigimaa, Margus (2017). Prevalence of cardiovascular disease risk factors in Tallinn, Estonia. Medicina, 53 (4), 268−276.10.1016/j.medici.2017.07.002.
1.1.
2017
Giugliano, R. P.; Mach, F.; Zavitz, K.; Kurtz, C.; Im, K.; Viigimaa, M. et al. (2017). Cognitive Function in a Randomized Trial of Evolocumab. New England Journal of Medicine, 377, 633−643.10.1056/NEJMoa1701131.
1.1.
2017
Sabatine, M. S.; Giugliano, R. P.; Keech, A.C.; Honarpour, N.; Viigimaa, M. et al (2017). Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. New England Journal of Medicine, 376, 1713−1722.10.1056/NEJMoa1615664.
1.3.
2017
Viigimaa, M. (2017). Revolutsioon ateroskleroosi ravis: LDL-kolesterooli sisalduse maksimaalne vähendamine bioloogilise raviga. Eesti Arst, 96(4), 233−237.
1.3.
2017
Viigimaa, M. (2017). Kas 2017. aasta muudab hüpertensiooni ravi eesmärkväärtusi? Eesti Arst, 96(3), 161−164.
3.1.
2017
Pilt, K.; Silluta, S.; Kööts, K.; Karai, D.; Meigas, K.; Viigimaa, M. (2017). Investigation of photoplethysmographic signal augmentation index estimation differences between fingers. EMBEC & NBC 2017: Joint conference of the European Medical and Biological Engineering Conference (EMBEC) and the Nordic-Baltic Conference on Biomedical Engineering and Medical Physics (NBC), Tampere, Finland, in 11-15 June 2017. _EditorsAbbr Eskola H., Väisänen O., Viik J., Hyttinen J. Springer, 819−822. (IFMBE Proceedings; 65).10.1007/978-981-10-5122-7_205.
3.1.
2017
Silluta, S.; Pilt, K.; Elja, B.; Kööts, K.; Meigas, K.; Viigimaa, M. (2017). Stroke volume assessment by impedance cardiography: Comparative analysis with transthoracic echocardiography. EMBEC & NBC 2017: Joint conference of the European Medical and Biological Engineering Conference (EMBEC) and the Nordic-Baltic Conference on Biomedical Engineering and Medical Physics (NBC), Tampere, Finland, in 11-15 June 2017. _EditorsAbbr Eskola H., Väisänen O., Viik J., Hyttinen J. Springer, 398−401. (IFMBE Proceedings; 65).10.1007/978-981-10-5122-7_100.
5.2.
2017
Shin, M.; Titma, T.; Ludwig, C.; Günther, U. L.; Pikta, M.; Zemtsovskaja, G.; Viigimaa, M.; Tanner, R.; Samoson, A. (2017). The Metabolic Profile of Ischemic Heart Disease by Serum 1H NMR. The Toxicologist: Late-Breaking Supplement, a supplement of Toxicological Sciences, 151: 56th Annual Meeting of the Society of Toxicology. US: Oxford University Press, 154. (1; 2).
5.2.
2017
Pikta, M.; Saks, K.; Lepik, K.; Zemtsovskaja, G.; Villemson, K.; Bautista, H.; Nouadje, G.; Viigimaa, M.; Banys, V. (2017). Assessment of biological response to desmopressin using von willebrand factor multimers analysis. Clinical Chemistry and Laboratory Medicine, 55, .S727.
1.1.
2016
Zanchetti, Alberto; Liu, Lisheng; Mancia, Giuseppe; Parati, Gianfranco; Grassi, Guido; Stramba-Badiale, Marco; Silani, Vincenzo; Bilo, Grzegorz; Corrao, Giovanni; Zambon, Antonella; Scotti, Lorenza; Zhang, Xinhua; Guan, Ting Rui; Zhang, Yuqing; Zhang, Xuezhong; Berge, Eivind; Redon, Josep; Narkiewicz, Krzysztof; Dominiczak, Anna; Nilsson, Peter ... , (2016). Continuation of the ESH-CHL-SHOT trial after publication of the SPRINT: rationale for further study on blood pressure targets of antihypertensive treatment after stroke. Journal of Hypertension, 34 (3), 393−396.10.1097/HJH.0000000000000853.
1.1.
2016
Vedin, Ola; Hagström, Emil; Budaj, Andrzej; Denchev, Stephan; Harrington, Robert A; Koenig, Wolfgang; Soffer, Joseph; Sritara, Piyamitr; Stebbins, Amanda; Stewart, Ralph Ha; Swart, Henk P; Viigimaa, Margus; Vinereanu, Dragos; Wallentin, Lars; White, Harvey D; Held, Claes (2016). Tooth loss is independently associated with poor outcomes in stable coronary heart disease. European Journal of Preventive Cardiology, 23 (8), 839−846.10.1177/2047487315621978.
1.1.
2016
Catapano AL, Graham I, De Backer G, Wiklund O, Viigimaa M, et al (2016). 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. European Heart Journal, 37 (39), 2999−3058.
1.1.
2016
Wallentin L, Held C, Armstrong PW, Cannon CP, Davies RY, Viigimaa M, et al. (2016). Lipoprotein-Associated Phospholipase A2 Activity Is a Marker of Risk But Not a Useful Target for Treatment in Patients With Stable Coronary Heart Disease. Journal of the American Heart Association, e003407−e003407.
1.1.
2016
Aguiar C, Alegría E, Bonnadonna RC, Catapano AL, Consentido F, Viigimaa M, et al. (2016). Versión Española del Grupo de trabajo sobre Dislipemia Aterogénica. Clínica e Investigación en Arteriosclerosis, 87−93.
1.1.
2016
Pattaro, Cristian; Teumer, Alexander; Gorski, Mathias; Chu, Audrey Y; Li, Man; Mijatovic, Vladan; Garnaas, Maija; Tin, Adrienne; Sorice, Rossella; Li, Yong; Taliun, Daniel; Olden, Matthias; Foster, Meredith; Yang, Qiong; Chen, Ming-Huei; Pers, Tune H; Johnson, Andrew D; Ko, Yi-An; Fuchsberger, Christian; Tayo, Bamidele ... Fox, Caroline S (2016). Genetic associations at 53 loci highlight cell types and biological pathways relevant for kidney function. Nature Communications, 7 (10023), 10023−10023.10.1038/ncomms10023.
1.1.
2016
Galina Zemtsovskaja, Andrei Samarin, Jelena Abina, Kalju Meigas, Margus Viigimaa (2016). Determinants and a Predictive Equation for the Aortic Length Estimation. International Journal of Innovative Research in Science, Engineering and Technology, 5 (3), 3336−3350.DOI:10.15680/IJIRSET.2016.0503115.
1.1.
2016
Lankin, V. Z; Konovalova, G. G; Tikhaze, A. K; Shumaev, K. B; Belova Kumskova, E. M; Grechnikova, M. A; Viigimaa, M. (2016). Aldehyde inhibition of antioxidant enzymes in the blood of diabetic patients. Journal of Diabetes, 8 (3), 398−404.10.1111/1753-0407.12309.
1.1.
2016
Ferrari, R.; Aguiar, C.; Alegria, E.; Bonadonna, R.C.; Cosentino, F.; Elisaf, M.; Farnier, M.; Ferrières, J.; Filardi, P.P.; Hancu, N.; Kayikcioglu, M.; Mello E Silva, A.; Millan, J.; Reiner, Z.; Tokgozoglu, L.; Valensi, P.; Viigimaa, M.; Vrablik, M.; Zambon, A.; Zamorano, J.L. ... (2016). Current practice in identifying and treating cardiovascular risk, with a focus on residual risk associated with atherogenic dyslipidaemia. European Heart Journal, Supplement, 18, C2−C12.10.1093/eurheartj/suw009.
1.2.
2016
Misjuk, Mikola; Kaldmäe, Margit; Annuk, Margus; Viigimaa, Margus (2016). CHARACTERISTICS OF LEISURE SPORTS ACTIVITY IN A POPULATION WITH HIGH CARDIOVASCULAR DISEASE MORTALITY. Baltic Journal of Health and Physical Activity, 8 (1), 7−17.
1.3.
2016
Viigimaa M (2016). Traditsioonilised ja uued ravimid aterogeense düslipideemia ravis. Eesti Arst, 299−306.
1.3.
2016
Pikta, M.; Zolotareva, V.; Tõnne, J.; Viigimaa, M.; Banys, V. (2016). Implementation and Verification of New VWF:Ac Assay System with Components from Different Manufacturers. Laboratorine Medicina, 4, 185−188.
1.3.
2016
Lilles, Eli (2016). Uudiseid AHA kongressilt: hüpertensiooni ravi peaks enamikul patsientidest olema agressiivsem. Perearst, (2016) jaanuar, lk. 19-23 : foto, 19−23.
1.3.
2016
Viigimaa, Margus (2016). Huvitavat AHA kongressist. Perearst, (2016) detsember, lk. 73-77 : foto, 73−77.
5.1.
2016
Pikta, M.; Tõnne, J.; Tirkkonen, N.; Zolotarjova,V.; Titova, T.; Marandi, T.; Arjakse, J.; Viigimaa, M. (2016). Rivaroxaban: evaluation of analytical performance. Clin Chem Lab Med 2016; 54(10): eA259–eA260. De Gruyter, .DOI10.1515/cclm-2016-0657.
5.1.
2016
Galina Zemtsovskaja, Julia Borissova, Küllike Palk, Ulvi Sorro, Katrin Gross-Paju, Vadim Brjalin, Mihhail Zemtsovski, Katrin Nõukas, Katrin Eino, Katrin Tammeväli, Viive Pille, Katrin Rebane, Kristi Lepik, Merike Luman, Margus Viigimaa (2016). The importance of front-line tests in diagnosis of porphyrias: 12 years of experience in North Estonia Medical Centre. Clinical Chemistry and Laboratory Medicine (CCLM): The 4th Joint EFLM-UEMS Congress “Laboratory Medicine at the Clinical Interface” Warsaw, Poland, 21th–24th September, 2016. De Gruyter: De Gruyter, 143. ( Volume 54; Issue 10).DOI:10.1515/cclm-2016-0657.
5.1.
2016
Galina Zemtsovskaja, Mihhail Zemtsovski, Merike Luman, Margus Viigimaa (2016). Lipid profile in a patient with familial hyperlipidemia during 18 years of treatment. Clinical Chemistry and Laboratory Medicine (CCLM): The 4th Joint EFLM-UEMS Congress “Laboratory Medicine at the Clinical Interface” Warsaw, Poland, 21th–24th September, 2016. De Gruyter, 72. (Volume 54, Issue 10).DOI:10.1515/cclm-2016-0657.
5.2.
2016
Zemtsovskaja, Galina; Pikta, Marika; Borissova, Julia; Palk, Küllike; Sorro, Ulvi; Gross-Paju, Katrin; Brjalin, Vadim; Zemtsovski, Mihhail; Nõukas, Katrin; Eino, Katrin; Tammeväli, Katrin; Pille, Viive; Lotkova, Olga; Lepik, Kristi; Luman, Merike; Viigimaa, Margus (2016). Brain-to-brain loop concept in application to porphyrias: 10-year experience at North Estonia Medical Centre. Eesti Arst, 95 (Supplement 1). Eesti Arst, 61.
5.2.
2016
Zemtsovskaja, Galina; Pikta, Marika; Borissova, Julia; Palk, Küllike; Sorro, Ulvi; Gross-Paju, Katrin; Brjalin, Vadim; Zemtsovski, Mihhail; Nõukas, Katrin; Eino, Katrin; Tammeväli, Katrin; Pille, Viive; Lotkova, Olga; Lepik, Kristi; Luman, Merike; Viigimaa, Margus (2016). Investigation of porphyrias: 10-year experience at the North Estonia Medical Centre. Eesti Arst, 95 (Supplement 1), 61.
6.6.
2016
Viigimaa, M. (2016). ACC konverents: ülevaade värsketest arengutest kardioloogias. Perearst, (2016) mai, lk. 69-71 : foto, 69−71.
1.1.
2015
Fadl Elmula, Fadl Elmula M; Rebora, Paola; Talvik, Anneli; Salerno, Sabrina; Miszkowska-Nagórna, Eliza; Liu, Xiaoqiu; Heinpalu-Kuum, Marika; Comotti, Tommaso; Larstorp, Anne C; Rostrup, Morten; Świerblewska, Ewa; Valsecchi, Maria Grazia; Kjeldsen, Sverre E; Viigimaa, Margus; Narkiewicz, Krzysztof; Parati, Gianfranco; Laurent, Stéphane (2015). A randomized and controlled study of noninvasive hemodynamic monitoring as a guide to drug treatment of uncontrolled hypertensive patients. Journal of Hypertension, 33 (12), 2534−2545.10.1097/HJH.0000000000000749.
1.1.
2015
Lankin, Vadim Z; Konovalova, Galina G; Tikhaze, Alla K; Shumaev, Konstantin B; Belova Kumskova, Elena M; Grechnikova, Maria A; Viigimaa, Margus (2015). Aldehyde inhibition of antioxidant enzymes in the blood of diabetic patients. Journal of Diabetes, 1−7.10.1111/1753-0407.12309.
1.1.
2015
Huffman, JE; Albrecht, E; Teumer, A; Mangino, M; Kapur, K; Johnson, T; Kutalik, Z; Pirastu, N; Pistis, G; Lopez, LM; Haller, T; Salo, P; Goel, A; Li, M; Tanaka, T; Dehghan, A; Ruggiero, D; Malerba, G; Smith, AV; Nolte, IM ... Vitart, V. (2015). Modulation of genetic associations with serum urate levels by body-mass-index in humans. PLoS ONE, 3, e0119752−e0119752.10.1371/journal.pone.0119752.
1.1.
2015
Locke, AE.; Kahali, B.; Berndt, SI.; Justice, AE.; Pers, TH.; Day, FR.; Powell, C.; Vedantam, S.; Buchkovich, ML.; Yang, J.; Croteau-Chonka, DC.; Esko, T.; Fall, T.; Ferreira, T.; Gustafsson, S.; Kutalik, Z.; Luan, J.; Mägi, R.; Randall, JC.; Winkler, TW. ... Speliotes, EK. (2015). Genetic studies of body mass index yield new insights for obesity biology. Nature, 518 (7538), 197−206.10.1038/nature14177.
1.1.
2015
Aguiar, Carlos; Alegria, Eduardo; Bonadonna, Riccardo C; Catapano, Alberico L; Cosentino, Francesco; Elisaf, Moses; Farnier, Michel; Ferrières, Jean; Filardi, Pasquale Perrone; Hancu, Nicolae; Kayikcioglu, Meral; Mello E Silva, Alberto; Millan, Jesus; Reiner, Željko; Tokgozoglu, Lale; Valensi, Paul; Viigimaa, Margus; Vrablik, Michal; Zambon, Alberto; Zamorano, José Luis ... Ferrari, Roberto (2015). A review of the evidence on reducing macrovascular risk in patients with atherogenic dyslipidaemia: A report from an expert consensus meeting on the role of fenofibrate-statin combination therapy. Atherosclerosis. Supplements, 19, 1−12.10.1016/S1567-5688(15)30001-5.
2.3.
2015
Kaldmäe, Margit; Viigimaa, Margus; Land, Tiit; Annuk, Margus (2015). Biomarkers for cardiovascular disease in Estonian adults. (Doktoritöö, Tallinna Ülikool). Tallinn: Tallinna Ülikool.
3.1.
2015
Pilt, Kristjan; Kööts, Kristina; Meigas, Kalju; Šamarin, Andrei; Zemtsovskaja, Galina; Viigimaa, Margus (2015). The Aortic Pulse Wave Velocity Estimation for Arterial Stiffness Assessment. IFMBE Proceedings, 45: MBEC 2014, Dubrovnik, 7-11 September 2014. IFMBE, 294−297.
3.1.
2015
Pilt, K.; Leier, M.; Silluta, S.; Koots, K.; Meigas, K.; Viigimaa, M. (2015). Pulse wave registration from radial artery using photoplethysmographic method. 37th Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC): 37th Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC), Milan, Italy, 25-29 August 2015. IEEE, 6425−6428.10.1109/EMBC.2015.7319863.
4.1.
2015
Viigimaa, Margus; Vlachopoulos, Charalambos; Doumas, Michael (2015). Erectile dysfunction in hypertension and cardiovascular disease : a guide for clinicians. Cham [etc.]: Springer.
5.1.
2015
Tikhaze, A.; Lankin, V.; Konovalova, G.; Zemtsovskaja, G.; Pikta, M.; Viigimaa, M. (2015). A common molecular mechanism of vascular wall injure in atherosclerosis and diabetes. Cardiology 2015;131(suppl 1). 43−44.DOI:10.1159/000431390.
5.1.
2015
Pikta, M.; Zemtsovskaja, G.; Zemtsovski, M.; Duishvili, D.; Tikhaze, A., Lankin, V.; Viigimaa, M. (2015). Level of plasma coenzyme Q10 in patients on statin treatment. Cardiology 2015;131(suppl 1). 36.DOI:10.1159/000431390.
5.1.
2015
Zemtsovski, M.; Zemtsovskaja, G; Pikta, M; Luman, M;Viigimaa, M (2015). Benefit from lipoprotein apheresis in severe case of coronary heart disease patient with high level of lipoprotein (a). Cardiology, 131 (Suppl 1), 35−36.
5.1.
2015
Pikta, M.; Viigimaa, M.; Pilt, K.; Kööts, K.; Meigas, K. (2015). Early diagnosis of cardiovascular diseases using Arteriograph (TensioMed, Hungary). Cardiology 2015;131(suppl 1). 32.DOI:10.1159/000431390.
5.1.
2015
Zemtsovskaja, G.; Zemtsovski, M.; Abina, J.; Samarin, A.; Meigas, K.; Viigimaa, M. (2015). Correlation between aortic stiffness and conventional risk factors with coronary atherosclerosis. Cardiology, 131 (Suppl 1) (1), 39−P-31.
1.1.
2014
Fox, K.; Ford, I.; Steg, P.G.; Tardif, J-C.; Viigimaa, M et al. (2014). Ivabradine in stable coronary artery disease without clinical heart failure. New England Journal of Medicine, 371(12):1091−1099.
1.1.
2014
Jensen-Urstad, Mats; Viigimaa, Margus; Sammul, Sirje; Lenhoff, Hanna; Johansson, Jan (2014). Impact of smoking: All-cause and cardiovascular mortality in cohort of 55-year-old Swedes and Estonians. Scandinavian Journal of Public Health, 42(8):780−785.
1.1.
2014
Ryden, L.; Grant, PJ.; Anker, SD.; Berne, C.; Cosentino, F.; Danchin, N.; Deaton, C.; Escaned, J.; Hammes, HP.; Huikuri, H.; Marre, M.; Marx, N.; Mellbin, L.; Ostergren, J.; Patrono, C.; Seferovic, P.; Sousa, M.; Taskinen, MR.; Tendera, M.; Tuomilehto, J. ... Xuereb, RG. (2014). ESC Guidelines on diabetes, pre- diabetes, and cardiovascular diseases developed in collaboration with the EASD - Summary. Diabetes and Vascular Disease Research, 11, 133−173.10.1177/1479164114525548.
1.1.
2014
Kaldmäe, Margit; Viigimaa, Margus; Zemtsovskaja, Galina; Kaart, Tanel; Abina, Jelena; Annuk, Margus (2014). Prevalence and determinants of hypertension in Estonian adults. Scandinavian Journal of Public Health, 42 (6), 504−510.10.1177/1403494814532565.
1.1.
2014
White, HD.; Held, C.; Stewart, R.; Tarka, E.; Brown, R.; Davies, RY.; Budaj, A.; Harrington, RA.; Steg, PG.; Ardis-Sino, D.; Armstrong, PW.; Avezum, A.; Aylward, PE.; Bryce, A.; Chen, H.; Chen, MF.; Corbalan, R.; Dalby, AJ.; Danchin, N.; De Winter, RJ. ... Wallentin, L. (2014). Darapladib for Preventing Ischemic Events in Stable Coronary Heart Disease. New England Journal of Medicine, 370, 1702−1711.10.1056/NEJMoa1315878.
1.1.
2014
Zanchetti, A.; Liu, LS.; Mancia, G.; Parati, G.; Grassi, G.; Stramba-Badiale, M.; Silani, V.; Bilo, G.; Corrao, G.; Zambon, A.; Scotti, L.; Zhang, XH.; Wang, HY.; Zhang, YQ.; Zhang, XZ.; Guan, TR.; Berge, E.; Redon, J.; Narkiewicz, K.; Dominiczak, A. ... Ford, G. (2014). Blood pressure and LDL-cholesterol targets for prevention of recurrent strokes and cognitive decline in the hypertensive patient: design of the European Society of Hypertension-Chinese Hypertension League Stroke in Hypertension Optimal Treatment randomized trial. Journal of Hypertension, 32, 1888−1897.10.1097/HJH.0000000000000254.
1.1.
2014
Mancia, G.; Fagard, R.; Narkiewicz, K.; Redon, J.; Zanchetti, A.; Bohm, M.; Christiaens, T.; Cifkova, R.; De Backer, G.; Dominiczak, A.; Galderisi, M.; Grobbee, DE.; Jaarsma, T.; Kirchhof, P.; Kjeldsen, SE.; Laurent, S.; Manolis, AJ.; Nilsson, PM.; Ruilope, LM.; Schmieder, RE. ... Zannad, F. (2014). 2013 ESH/ESC Practice Guidelines for the Management of Arterial Hypertension. Blood Pressure, 23, 3−16.10.3109/08037051.2014.868629.
1.1.
2014
Pilt, Kristjan; Meigas, Kalju; Kööts, Kristina; Viigimaa, Margus (2014). Photoplethysmographic signal rising front analysis for the discrimination of subjects with increased arterial ageing. Proceedings of the Estonian Academy of Sciences, 63 (3), 221−226.10.3176/proc.2014.3.03.
1.1.
2014
Zanchetti, A.; Liu, LS.; Mancia, G.; Parati, G.; Grassi, G.; Stramba-Badiale, M.; Silani, V.; Bilo, G.; Corrao, G.; Zambon, A.; Scotti, L.; Zhang, XH.; Wang, HY.; Zhang, YQ.; Zhang, XZ.; Guan, TR.; Berge, E.; Redon, J.; Narkiewicz, K.; Dominiczak, A. ... Ford, G. (2014). Blood pressure and low-density lipoprotein-cholesterol lowering for prevention of strokes and cognitive decline: a review of available trial evidence. Journal of Hypertension, 32, 1741−1750.10.1097/HJH.0000000000000253.
1.1.
2014
Lankin, V.; Konovalova, G.; Tikhaze, A.; Shumaev, K.; Kumskova, E.; Viigimaa, M. (2014). The initiation of free radical peroxidation of low-density lipoproteins by glucose and its metabolite methylglyoxal: a common molecular mechanism of vascular wall injure in atherosclerosis and diabetes. Molecular and Cellular Biochemistry, 395, 241−252.10.1007/s11010-014-2131-2.
1.1.
2014
Viigimaa, Margus; Vlachopoulos, Charalambos; Lazaridis, Antonios; Doumas, Michael. (2014). Management of erectile dysfunction in hypertension: Tips and tricks. World Journal of Cardiology, 6, 908−15.10.4330/wjc.v6.i9.908.
1.1.
2014
Pilt, Kristjan; Meigas, Kalju; Ferenets, Rain; Temitski, Kristina; Viigima, Margus (2014). Photoplethysmographic signal waveform index for detection of increased arterial stiffness. Physiological Measurement, 35, 2027−2036.10.1088/0967-3334/35/10/2027.
1.1.
2014
Viigimaa, M.; Erglis, A.; Latkovskis, G.; Mäeots, E.; Petrulioniene, Z.; Slapikas, R.; Gocentiene, A.; Bramlage, P.; Brudi, P. (2014). Prevalence of dyslipidemia in statin-treated patients in the Baltic states (Estonia, Latvia, and Lithuania): Results of the Dyslipidemia International Study (DYSIS). Medicina-Lithuania, 50 (1), 44−53.10.1016/j.medici.2014.05.003.
1.1.
2014
Kristensen SD, Knuuti J, Saraste A, Anker S, Bøtker HE, Viigimaa M, et al. (2014). 2014 ESC/ESA Guidelines on non-cardiac surgery: cardiovascular assessment and management: The Joint Task Force on non-cardiac surgery: cardiovascular assessment and management of the European Society of Cardiology (ESC) and the European Society of Anaesthesiology (ESA). European Journal of Anaesthesiology, 517−573.
1.1.
2014
Kristensen SD, Knuuti J, Saraste A, Anker S, Bøtker HE, Viigimaa M, et al. (2014). 2014 ESC/ESA Guidelines on non-cardiac surgery: cardiovascular assessment and management: The Joint Task Force on non-cardiac surgery: cardiovascular assessment and management of the European Society of Cardiology (ESC) and the European Society of Anaesthesiology (ESA). European Heart Journal , 2383−2431.
1.3.
2014
Viigimaa, M. (2014). Mida on uut Ameerika äsja ilmunud südameveresoonkonnahaiguste preventsiooni juhendites? Eesti Arst, 103.
3.1.
2014
Viigimaa, Margus; Vlachopoulos, Charalambos; Doumas, Michael (2014). Erectile Dysfunction in Hypertension and Cardiovascular Disease. In: Viigimaa, Margus; Vlachopoulos, Charalambos; Doumas, Michael (_EditorsAbbr). Erectile Dysfunction in Hypertension and Cardiovascular Disease (1−249).. Springer.
3.1.
2014
Viigimaa, Margus (2014). Lifestyle Modification in Erectile Dysfunction and Hypertebnsion. In: Viigimaa, Margus; Vlachopoulos, Charalambos; Doumas, Michael (_EditorsAbbr). Erectile Dysfunction in Hypertension and Cardiovascular Disease (167−174).. Springer.
1.1.
2013
Pilt, Kristjan; Ferenets, Rain; Meigas, Kalju; Lindberg, Lars-Göran; Temitski, Kristina; Viigimaa, Margus (2013). New Photoplethysmographic Signal Analysis Algorithm for Arterial Stiffness Estimation. The Scientific World Journal, 2013, 9 pp.
1.1.
2013
Kottgen, A.; Albrecht, E.; Teumer, A.; Vitart, V.; Krumsiek, J.; Hundertmark, C.; Pistis, G.; Ruggiero, D.; O'Seaghdha, CM.; Haller, T.; Yang, Q.; Tanaka, T.; Johnson, AD.; Kutalik, Z.; Smith, AV.; Shi, JL.; Struchalin, M.; Middelberg, RPS.; Brown, MJ.; Gaffo, AL. ... Gieger, C. (2013). Genome-wide association analyses identify 18 new loci associated with serum urate concentrations. Nature Genetics, 45 (2), 145−154.10.1038/ng.2500.
1.1.
2013
Mancia, Giuseppe; Fagard, Robert; Narkiewicz, Krzysztof; Redon, Josep; Zanchetti, Alberto; Bohm, Michael; Christiaens, Thierry; Cifkova, Renata; De Backer, Guy; Dominiczak, Anna; Galderisi, Maurizio; Grobbee, Diederick E.; Jaarsma, Tiny; Kirchhof, Paulus; Kjeldsen, Sverre E.; Laurent, Stephane; Manolis, Athanasios J.; Nilsson, Peter M.; Ruilope, Luis Miguel; Schmieder, Roland E. ... Zannad, Faiez. (2013). The guidelines of ESH/ESC Guidelines for hypertension in 2013. Kardiologia polska, S27−S116.
1.1.
2013
Mancia, Giuseppe; Fagard, Robert; Narkiewicz, Krzysztof; Redon, Josep; Zanchetti, Alberto; Böhm, Michael; Christiaens, Thierry; Cifkova, Renata; De Backer, Guy; Dominiczak, Anna; Galderisi, Maurizio; Grobbee, Diederick E; Jaarsma, Tiny; Kirchhof, Paulus; Kjeldsen, Sverre E; Laurent, Stéphane; Manolis, Athanasios J; Nilsson, Peter M; Ruilope, Luis Miguel; Schmieder, Roland E ... Wood, David A. (2013). 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). European Heart Journal, 34 (28), 2159−2219.10.1093/eurheartj/eht151.
1.1.
2013
Mancia, Giuseppe; Fagard, Robert; Narkiewicz, Krzysztof; Redon, Josep; Zanchetti, Alberto; Boehm, Michael; Christiaens, Thierry; Cifkova, Renata; De Backer, Guy; Dominiczak, Anna; Galderisi, Maurizio; Grobbee, Diederick E.; Jaarsma, Tiny; Kirchhof, Paulus; Kjeldsen, Sverre E.; Laurent, Stephane; Manolis, Athanasios J.; Nilsson, Peter M.; Miguel Ruilope, Luis; Schmieder, Roland E. ... Windecker, Stephan. (2013). 2013 ESH/ESC Guidelines for the management of arterial hypertension. Blood Pressure, 193−278.10.3109/08037051.2013.812549.
1.1.
2013
Ryden, Lars; Grant, Peter J; Anker, Stefan D; Berne, Christian; Cosentino, Francesco; Danchin, Nicolas; Deaton, Christi; Escaned, Javier; Hammes, Hans-Peter; Huikuri, Heikki; Marre, Michel; Marx, Nikolaus; Mellbin, Linda; Ostergren, Jan; Patrono, Carlo; Seferovic, Petar; Uva, Miguel Sousa; Taskinen, Marja-Riita; Tendera, Michal; Tuomilehto, Jaakko ... Xuereb, Robert G. (2013). ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). European Heart Journal, 34, 3035−87.10.1093/eurheartj/eht108.
1.1.
2013
Doumas, M.; Viigimaa, M.; Papademetriou, V. (2013). Combined Antihypertensive Therapy and Sexual Dysfunction: Terra Incognita. Cardiology, 232−234.10.1159/000351696.
1.1.
2013
Mancia, G.; Fagard, R.; Narkiewicz, K.; Redon, J.; Zanchetti, A.; Bohm, M.; Christiaens, T.; Cifkova, R.; De Backer, G.; Dominiczak, A.; Galderisi, M.; Grobbee, DE.; Jaarsma, T.; Kirchhof, P.; Kjeldsen, SE.; Laurent, S.; Manolis, AJ.; Nilsson, PM.; Ruilope, LM.; Schmieder, RE. ... Zannad, F. (2013). 2013 ESH/ESC Guidelines for themanagement of arterial hypertension The Task Force for the management ofarterial hypertension of the European Society ofHypertension (ESH) and of the European Society of Cardiology (ESC). Journal of Hypertension, 1281−1357.
1.1.
2013
Mancia, G.; Fagard, R.; Narkiewicz, K.; Redon, J.; Zanchetti, A.; Bohm, M.; Christiaens, T.; Cifkova, R.; De Backer, G.; Dominiczak, A.; Galderisi, M.; Grobbee, DE.; Jaarsma, T.; Kirchof, P.; Kjeldsen, SE.; Laurent, S.; Manolis, AJ.; Nilsson, PM.; Ruilope, LM.; Schmieder, RE. ... Zannad, F. (2013). 2013 Practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC). Journal of Hypertension, 1925−1938.
1.1.
2013
Viigimaa M, Talvik A, Wojciechowska W, Kawecka-Jaszcz K, et al. (2013). Identification of the hemodynamic modulators and hemodynamic status in uncontrolled hypertensive patients. Blood Pressure, 362−370.10.3109/08037051.2013.782900.
1.1.
2013
Rydén L, Grant PJ, Anker SD, Berne C, Cosentino F, Danchin N,viigimaa M, et al. (2013). Grupa Robocza Europejskiego Towarzystwa Kardiologicznego (ESC). Kardiologia polska, 319−394.
1.1.
2013
Mancia, G.; Fagard, R.; Narkiewicz, K.; Redon, J.; Zanchetti, A.; Bohm, M.; Christiaens, T.; Cifkova, R.; De Backer, G.; Dominiczak, A.; Galderisi, M.; Grobbee, D.E.; Jaarsma, T.; Kirchhof, P.; Kjeldsen, S.E.; Laurent, S.; Manolis, A.J.; Nilsson, P.M.; Ruilope, L.M.; Schmieder, R.E. ... Zannad, F. (2013). The task force for the management ofarterial hypertension of the european society ofhypertension (esh) and of the european society of cardiology (esc). Journal of Hypertension, 31, 1281−1357.10.1097/01.hjh.0000431740.32696.cc.
1.1.
2013
Mancia, G.; Fagard, R.; Narkiewicz, K.; Redon, J.; Zanchetti, A.; Böhm, M.; Christiaens, T.; Cifkova, R.; Backer, G.D.; Dominiczak, A.; Galderisi, M.; Grobbee, D.E.; Jaarsma, T.; Kirchhof, P.; Kjeldsen, S.E.; Laurent, S.; Manolis, A.J.; Nilsson, P.M.; Ruilope, L.M.; Schmieder, R.E. ... Zannad, F. (2013). 2013 ESH/ESC clinical practice guidelines for the management of arterial hypertension. Revista Espanola de Cardiologia, 66, 880.e1−880.e4.10.1016/j.recesp.2013.07.016.
1.3.
2013
Viigimaa, Margus. (2013). Lipoproteiiniga seostunud fosfolipaas A2 kui uus sõltumatu kardiovaskulaarne riskitegur ja ravi sihtmärk. Eesti Arst, 92, 92−97.
3.1.
2013
Pilt, Kristjan; Meigas, Kalju; Temitski, Kristina; Viigimaa, Margus (2013). The effect of local cold and warm exposure on index finger photoplethysmographic signal waveform. Conference proceedings of the IEEE Engineering in Medicine and Biology Society (Conf. Proc. IEEE Eng. Med. Biol. Soc.): 35th Annual International Conference of the IEEE EMBS. IEEE, 2300−2303.
3.1.
2013
Pilt, Kristjan; Meigas, Kalju; Temitski, Kristina; Viigimaa, Margus (2013). The analysis of finger photoplethysmographic waveform in healthy volunteers and diabetes patients. IFMBE Proceedings, 38: International Symposium on Biomedical Engineering and Medical Physics, Riia, 10-12 Oktoober 2012. IFMBE, 55−58.
3.5.
2013
Pikta M., Zemtsovskaja G., Viigimaa M., Zemtsovski M., Metsik P. (2013). COMPLETE ATHERO PANEL TO DETERMINE RISK OF CORONARY ARTERY DISEASE. Abstract book: The 46th Nordic Coagulation Meeting: Tromsö.
1.1.
2012
Perk J, De Backer G, Gohlke H, Graham I, Reiner Ž, Viigimaa M, et al. (2012). European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). Turk Kardiyoloji Dernegi Arsivi, 1−76.
1.1.
2012
Okada, Y; Sim, X; Go, MJ; Wu, JY; Gu, D; Takeuchi, F; Takahashi, A; Maeda, S; Tsunoda, T; Chen, P; Lim, SC; Wong, TY; Liu, J; Young, TL; Aung, T; Seielstad, M; Teo, YY; Kim, YJ; Lee, JY; Han, BG ... Gieger, C. (2012). Meta-analysis identifies multiple loci associated with kidney function-related traits in east Asian populations. Nature Genetics, 44 (8), 904−909.10.1038/ng.2352.
1.1.
2012
Vaverkova, Helena; Viigimaa, Margus; Farnier, Michel; Averna, Maurizio; Missault, Luc; Dong, Qian; Shah, Arvind; Johnson-Levonas, Amy O.; Brudi, Philippe. (2012). Lipid-Altering Efficacy of Ezetimibe/Simvastatin 10/20 mg Compared to Rosuvastatin 10 mg in High-Risk Patients with and without Type 2 Diabetes Mellitus Inadequately Controlled Despite Prior Statin Monotherapy. Cardiovascular Therapeutics, 30 (2), 61−74.10.1111/j.1755-5922.2010.00181.x.
1.2.
2012
Viigimaa, M.; Doumas, M.; Vlacholpoulos, C. et al. (2012). Nadcisnienie tetnicze a zaburzenia czynnosci seksualnych: czas podjac dzialania. Choroby Serca i Naczyn, (9)1−6.
3.1.
2012
Temitski, Kristina; Lauri, Jaana; Pilt, Kristjan; Meigas, Kalju; Viigimaa, Margus (2012). Assessment of algorithms for detecting an arterial pulse pressure wave equiphase point. Conference Publications: 13th Biennial Baltic Electronics Conference (BEC), Tallinn, 3-5 Oktoober 2012. IEEE, 191−194.
3.1.
2012
Viigimaa, Margus; Lazaridis, Antonios; Doumas, Michael (2012). Management of sexual dysfunction in hypertensive patient. In: Ambrosioni, E:; Borghi, C. (_EditorsAbbr). Cardiology and Clinical Practice (53−60).. Springer.
3.1.
2012
Viigimaa, Margus;l Doumas, Michael (2012). Sexual function in untreated and treated hypertension. In: Berbari, Adel; Mancia, Giuseppe (_EditorsAbbr). Special Isues in Hypertension (389−399).. Springer.
3.1.
2012
Pilt, Kristjan; Meigas, Kalju; Temitski, Kristina; Viigimaa, Margus (2012). Second derivative analysis of forehead photoplethysmographic signal in healthy volunteers and diabetes patients. IFMBE Proceedings, 39: World Congress on Medical Physics and Biomedical Engineering, Peking, 26-31 Mai 2012. IFMBE, 410−413.
3.5.
2012
Pikta, M; Banys, V; Olovjankina, N; Viigimaa, M; Tõnne, J; Titova, T. (2012). Samples storage time influence on whole blood impedance aggregometry results. Abstract book: The 45th Nordic Coagulation Meeting: Stockholm.
6.4.
2012
Ehala-Aleksejev, Kristel; Ausmees, Kristo; Pomerants, Marko; Viigimaa, Margus (2012). Ülekaal ja mehe tervis. [Tartu]: Uomoprint.
6.7.
2012
Kalda, Ruth; Viigimaa, Margus; Irs, Alar; Meren, Mari; Uuetoa, Tiina; Luman, Merike; Muda, Piibe; Oona, Marje; Jaanson, Eret; Martinson, Katrin; Põldema, Ingrid; Ridaste, Kadri; Palm, Kairit; Habicht, Triin; Teeäär, Tuuli; Saluse, Janek; Kropotuhhina, Irina; Heidmets, Lenne-Triin; Laidmäe, Erki; Esnar, Kersti (2012). Täiskasvanute kõrgvererõhktõve käsitlus esmatasandil: Eesti ravijuhend. Eesti Haigekassa, Tartu Ülikool 2012.
1.1.
2011
Viigimaa, M.; Doumas, M.; Vlachopoulos, C. et al. (2011). Hypertension and sexual dysfunction: time to act. Journal of Hypertension, 403−407.
1.1.
2011
Grassi, G.; Cifkova, R.; Laurent, S.; Viigimaa, M., et al. (2011). Blood pressure control and cardiovascular risk profile in hypertensive patients from central and eastern European countries: results of the BP-CARE study. European Heart Journal, 218−225.
1.1.
2011
Averna, M.; Missault, L.; Vaverkova, H.; Farnier, M.; Viigimaa, M. et al. (2011). Lipid-altering efficacy of switching to ezetimibe/simvastatin 10/20 mg versus rosuvastatin 10 mg in hihg-risk patients with and without metabolic syndrome. Diabetes and Vascular Disease Research, 1−9.
1.1.
2011
Vaverkova, H.; Farnier, M.; Averna, M.; Missault, L.; Viigimaa, M.; Dong, Q.; Shah, A.; Johnson-Levonas, A.O.; Brudi, P. (2011). Switching from statin monotherapy to ezetimibe/simvastatin or rosuvastatin modifies the relationships between apolipoprotein B, LDL cholesterol, and non-HDL cholesterol in patients at high risk of coronary disease. Clinical Biochemistry, 44, 627−634.10.1016/j.clinbiochem.2011.02.008.
1.1.
2011
Kaldmäe, Margit; Zilmer, Mihkel; Viigimaa, Margus; Zemtsovskaja, Galina; Tomberg, Karel; Kaart, Tanel; Annuk, Margus. (2011). Cardiovascular disease risk factors in homeless people. Upsala Journal of Medical Sciences, 116 (3), 200−207.10.3109/03009734.2011.586737.
1.1.
2011
Lankin, Vadim; Viigimaa, Margus; Tikhaze, Alla; Kumskova, Elena; Konovalova, Galina; Abina, Jelena; Zemtsovskaya, Galina; Kotkina, Tatyana; Yanushevskaya, Elena; Vlasik, Tatyana (2011). Cholesterol-rich low density lipoproteins are also more oxidized. Molecular and Cellular Biochemistry, 355, 187−191.
1.1.
2011
Johnson, T.; Gaunt, T.R.; Newhouse, S.J.; Padmanabhan, S.; Tomaszewski, M.; Kumari, M.; Morris, R.W.; Tzoulaki, I.; O'Brien, E.T.; Poulter, N.R.; Sever, P.; Shields, D.C.; Thom, S.; Wannamethee, S.G.; Whincup, P.H.; Brown, M.J.; Connell, J.M.; Dobson, R.J.; Howard, P.J.; Mein, C.A. ... The Cardiogenics Consortium, The Global BPgen Consortium (2011). Blood Pressure Loci Identified with a Gene-Centric Array. American Journal of Human Genetics, 89 (6), 688−700.10.1016/j.ajhg.2011.10.013.
1.1.
2011
Putku, M.; Kepp, K.; Org, E.; Sõber, S.; Comas, D.; Viigimaa, M.; Veldre, G.; Juhanson, P.; Hallast, P.; Tõnisson, N.; Shaw-Hawkins, S.; Caulfield, M.J.; Khusnutdinova, E.; Kožich, V.; Munroe, P.B.; Laan, M. (2011). Novel polymorphic AluYb8 insertion in the WNK1 gene is associated with blood pressure variation in Europeans. Human Mutation, 32 (7), 806−814.10.1002/humu.21508.
1.1.
2011
The International Consortium for Blood Pressure Genome-Wide Association Studies, incl. Sõber, S.; Snieder, H.; Org, E.; Veldre, G.; Viigimaa, M.; Laan, M. (2011). Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature, 478 (7367), 103−109.10.1038/nature10405.
1.1.
2011
Org, Elin; Veldre, Gudrun; Viigimaa, Margus; Juhanson, Peeter; Putku, Margus; Rosenberg, Mai; Tomberg, Kärt; Uuetoa, Tiina; Laan, Maris (2011). HYPEST study: Profile of hypertensive patients in Estonia. BMC Cardiovascular Disorders, 11 (55), x−x.10.1186/1471-2261-11-55.
1.1.
2011
Averna, M.; Missault, L.; Vaverkova, H.; Farnier, M.; Viigimaa, M.; Dong, Q.; Shah, A.; Johnson-Levonas, A.O.; Taggart, W.; Brudi, P. (2011). Lipid-altering efficacy of switching to ezetimibe/simvastatin 10/20 mg versus rosuvastatin 10 mg in high-risk patients with and without metabolic syndrome. Diabetes and Vascular Disease Research, 8, 262−270.1479164111418136.
3.1.
2011
Pilt, Kristjan; Meigas, Kalju; Viigimaa, Margus; Temitski, Kristina (2011). Possibility to use Finapres signal for the estimation of aortic pulse wave velocity. IFMBE Proceedings, 37: EMBEC 2011, Budapest, 14-18 September 2011. IFMBE, 524−527.
3.1.
2011
Pilt, Kristjan; Meigas, Kalju; Viigimaa, Margus; Temitski, Kristina (2011). Possibility to use Finapres signal for augmentation index estimation. IFMBE Proceedings, 34: NBC 2011, Aalborg, 14-17 juuni 2011. IFMBE, 25−28.
5.2.
2011
Kaldmäe, Margit; Zilmer, Mihkel; Viigimaa, Margus, Zemtsovskaja, Galina; Tomberg, Karel; Kaart, Tanel; Annuk, Margus. (2011). Südame-veresoonkonna haiguste riskifaktorite määramine kodututel. Teaduskonverentsi teesid: Eesti XXII Keemiapäevade teaduskonverents, 14-15 aprill 2011 Tartu. Toim. Eesti Keemia Selts, Eesti Biokeemia Selts, Tartu Ülikooli Keemia Instituut. Tartu: Tartu Ülikooli Kirjastus, 36.
6.2.
2011
Aaviksoo, Evelyn; Hedman, Anu; Kaljusaar, Heli; Keskpaik, Lauri; Kõrv, Janika; Lukman, Aet; Luman, Merike; Minajeva, Ave; Muda, Piibe; Suurorg, Lagle; Uuetoa, Tiina; Viigimaa, Margus (2011). Hüpertensiooni aastaraamat. Tallinn: MTÜ Eesti Hüpertensiooni Ühing; OÜ Paar.
1.1.
2010
Viigimaa, M.; Vaverkova, H.; Farnier, M.; Averna, M.; Missault, L.; Hanson, M.E.; Dong, Q.A.; Shah, A.; Brudi, P. (2010). Ezetimibe/Simvastatin 10/20 mg versus Rosuvastatin 10 mg in high-risk hypercholesterolemic patients stratified by prior statin treatment potency. Lipids in Health and Disease, 9, 1−8.10.1186/1476-511X-9-127.
1.1.
2010
Tikhaze, A. K.; Viigimaa, M.; Konovalova, G. G.; Kumskova, E. M.; Abina, E. A.; Zemtsovskaya, G.; Yanushevskaya, E. V.; Vlasik, T. N.; Lankin, V. Z. (2010). Interrelation between Malonyl Dialdehyde-Dependent Modi. cation and Cholesterol Content in Low-Density Lipoproteins. Bulletin of Experimental Biology and Medicine, 149 (2), 184−186.doi.org/10.1007/s10517-010-0903-6.
1.1.
2010
Viigimaa, M; Abina, J; Zemtsovskaya, G; Tikhaze, A; Konovalova, G; Kumskova, E; Lankin, V. (2010). Malondialdehyde-modified low-density lipoproteins as biomarker for atherosclerosis. Blood Pressure, 164−168.10.3109/08037051.2010.484158.
1.1.
2010
Kepp, K.; Org, E.; Sober, S.; Kelgo, P.; Viigimaa, M.; Veldre, G.; Tonisson, N.; Juhanson, P.; Putku, M.; Kindmark, A.; Kozich, V.; Laan, M. (2010). Hypervariable intronic region in NCX1 is enriched in short insertion-deletion polymorphisms and showed association with cardiovascular traits. BMC Medical Genetics, 11 (15), 1−15.10.1186/1471-2350-11-15.
1.1.
2010
Olsen, Michael H.; Mallion, Jean-Michel; Rahn, Karl-Heinz; Erdine, Serap; Viigimaa, Margus; Laurent, Stephane; Agabiti-Rosei, Enrico; Mancia, Giuseppe; Schmieder, Roland E.; Cifkova, Renata; Dominiczak, Anna; Kjeldsen, Sverre E.; Redon, Josep; Zanchetti, Alberto; Nilsson, Peter; Narkiewicz, Krzysztof (2010). Agreement within Europe about antihypertensive treatment and education - results from the European Society of Hypertension questionnaire. Journal of Hypertension, 28 (7), 1593−1594.10.1097/HJH.0b013e32833b7b08.
1.1.
2010
Stergiou, G.S.; Myers, M.G.; Reid, J.L.; Burnier, M.; Narkiewicz, K.; Viigimaa, M.; Mancia, G. (2010). Setting-up a Blood Pressure and Vascular Protection Clinic: Requirements of the European Society of Hypertension. Journal of Hypertension, 28, 1780−1781.10.1097/HJH.0b013e32833d1e01.
1.1.
2010
Mancia, G.; Laurent, S.; Agabiti-Rosei, E.; Ambrosioni, E.; Burnier, M.; Caulfield, M.J.; Cifkova, R.; Clément, D.; Coca, A.; Dominiczak, A.; Erdine, S.; Fagard, R.; Farsang, C.; Grassi, G.; Haller, H.; Heagerty, A.; Kjeldsen, S.E.; Kiowski, W.; Mallion, J.M.; Manolis, A. ... (2010). European guidelines on the management of hypertension: The European Society of Hypertension position statement (2009). Nadcisnienie Tetnicze, 14, 1−47.
2.2.
2010
Viigimaa, Margus; Adamson, Agne; Ots, Madis (2010). Südameinvestor. [Tallinn]: Menu Kirjastus.
3.1.
2010
Pilt, K.; Meigas, K.; Viigimaa, M.; Kaik, J.; Kattai, R.; Karai, D. (2010). Arterial pulse waveform dependence on applied pressure. Proc. of the Biennial Baltic Elect. Conf.: 12th Biennial Baltic Electronics Conference (BEC2010). IEEE, 277−280.
3.1.
2010
Pilt, Kristjan; Meigas, Kalju; Viigimaa, Margus; Kaik, Jüri; Kattai, Rain; Karai, Deniss. (2010). Arterial Pulse Transit Time Dependence on Applied Pressure. IFMBE Proceedings, 29: MEDICON 2010. IFMBE, 406−409. (3).
3.1.
2010
Pilt, Kristjan; Meigas, Kalju; Viigimaa, Margus; Temitski, Kristina; Kaik, Jüri. (2010). An Experimental Measurement Complex for Probable Estimation of Arterial Stiffness. Conference proceedings of the IEEE Engineering in Medicine and Biology Society (Conf. Proc. IEEE Eng. Med. Biol. Soc.): 32nd Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE, 194−197.
5.2.
2010
Putku, M.; Kepp, K.; Org, E.; Sõber, S.; Comas, D.; Viigimaa, M.; Veldre, G.; Kelgo, P.; Hallast, P.; Tõnisson, N.; Juhanson, P.; Khusnutdinova, E.; Kožich, V.; Laan, M. (2010). Novel polymorphic AluYb8 insertion in WNK1 Gene associated with blood pressure regulation. Journal of Hypertension, 28: 20th Annual Meeting of the European-Society-of-Hypertension, Oslo, Norway, June 18-21, 2010. Lippincott Williams & Wilkins, E347−E348.
6.3.
2010
Sak, K.; Viigimaa, M. (2010). Tervislik eluviis on heaolu alus. Kodutohter, 8, 16−19.
1.1.
2009
Varis, Juha; Karjalainen, Sampo; Korhonen, Krista; Viigimaa, Margus; Port, Kristjan; Kantola, Ilkka (2009). Experiences of Telemedicine-Aided Hypertension Control in the Follow-Up of Finnish Hypertensive Patients. Telemedicine Journal and e-Health, 15 (8), 764−769.10.1089/tmj.2009.0029.
1.1.
2009
Sõber, S.; Org, E.; Kepp, K.; Juhanson, P.; Eyheramendy, S.; Gieger, C.; Lichtner, P.; Klopp, N.; Veldre, G.; Viigimaa, M.; Döring, A.; Putku, M.; Kelgo, P.; Shaw-Hawkins, S.; Howard, P.; Onipinla, A.; Dobson, R.J.; Newhouse, S.J.; Brown, M.; Dominiczak, A. ... Laan, M. (2009). Targeting 160 candidate genes for blood pressure regulation with a genome-wide genotyping array. PLOS ONE, 4 (6), 1−13.10.1371/journal.pone.0006034.
1.1.
2009
Org, E.; Eyheramendy, S.; Juhanson, P.; Gieger, C.; Lichtner, P.; Klopp, N.; Veldre, G.; Döring, A.; Viigimaa, M.; Sõber, S.; Tomberg, K.; Eckstein, G.; Kelgo, P.; Rebane, T.; Shaw-Hawkins, S.; Howard, P.; Onipinla, A.; Dobson, R.J.; Newhouse, S.J.; Brown, M. ... Laan, M. (2009). Genome-wide scan identifies CDH13 as a novel susceptibility locus contributing to blood pressure determination in two European populations. Human Molecular Genetics, 18 (12), 2288−2296.10.1093/hmg/ddp135.
1.1.
2009
Farnier, M.; Averna, M.; Missault, L.; Viigimaa, M. (2009). Lipid-altering efficacy of ezetimibe/simvastatin 10/20 mg compared with rosuvastatin 10 mg in high-risk hypercholesterolaemic patients inadequately controlled with prior statin monotherapy - The IN-CROSS study. International Journal of Clinical Practice, 547−559.
1.1.
2009
Newhouse, S.; Farrall, M.; Wallace, C.; Hoti, M.; Burke, B.; Howard, P.; Onipinla, A.; Lee, K.; Shaw-Hawkins, S.; Dobson, R.; Brown, M.; Samani, N.J.; Dominiczak, A.F.; Connell, J.M.; Lathrop, G.M.; Kooner, J.; Chambers, J.; Elliott, P.; Clarke, R.; Collins, R. ... Munroe, P.B. (2009). Polymorphisms in the WNK1 Gene Are Associated with Blood Pressure Variation and Urinary Potassium Excretion. PLOS ONE, 4 (4), 1−14.10.1371/journal.pone.0005003.
1.1.
2009
Maneia, G.; Laurent, S.; Agabiti-Rosei, E.; Ambrosioni, E.; Burnier, M.; Caulfield, M.J.; Cifkova, R.; Clément, D.; Coca, A.; Dominiczak, A.; Erdine, S.; Fagard, R.; Farsang, C.; Grassi, G.; Haller, H.; Heagerty, A.; Kjeldsen, S.E.; Kiowski, W.; Mallion, J.M.; Manolis, A. ... Zanchetti, A. (2009). Reappraisal of European guidelines on hypertension management: A European Society of Hypertension Task Force document. Journal of Hypertension, 27, 2121−2158.10.1097/HJH.0b013e328333146d.
2.2.
2009
Viigimaa, Margus; Jaanson, Eret; Gross, Lilli (2009). Õnnelik süda : kuidas vältida haigestumist südame-veresoonkonnahaigustesse? [Tallinn]: Celsius Healthcare.
5.1.
2009
Org, E.; Kepp, K.; Veldre, G.; Viigimaa, M.; Juhanson, P.; Putku, M.; Kelgo, P.; Rebane, T.; Rosenberg, M.; Uuetoa, T.; Laan, M. (2009). Strategies for studying epidemiological and genetic factors for essential hypertension using Estonian HYPEST sample. In: Journal of Hypertension (S450−S450). Elsevier.
1.1.
2008
Redon, J.;Cifkova, R.;Laurent, S.;Nilsson, P.;Narkiewicz, K.;Erdine, S.;Mancia, G.;Viigimaa, M. (2008). The metabolic syndrome in hypertension: European society of hypertension position statement. Journal of Hypertension, 1891−1900.
1.1.
2008
Fox, K.;Ford, I.;Steg, G.;Tendera, M.;Robertson, M.;Ferrari, R.; Group author: Beautiful study group (incl. Eha, J.) (2008). Heart Rate as prognostic risk factor in patients with coronary artery disease and left ventricular systolic dysfunction ( BEAUTIFUL ): a subgroup analysis of a randomised controlled trial. Lancet, 372 (9641), 817−821.10.1016/S0140-6736(08)61171-X.
1.1.
2008
The Beautiful Study Group, ( incl. Eha, J. ) (2008). The BEAUTIFUL study: randomized trial of ivabradine in patients with stable coronary artery disease and left ventricular dysfunction - baseline characteristics of the study population. Cardiology, 110 (4), 271−282.10.1159/000112412.
1.1.
2008
Fox, K.; Ford, I.; Steg, G.; Tendera, M.; Ferrari, R.; The Beautiful study group ( incl. Eha, J. ) (2008). Ivabradine for patients with stable coronary artery disease and left ventricular systolic dysfunction ( BEAUTIFUL ): a randomised, double blind, placebo controlled trial. Lancet, 372 (9641), 807−816.10.1016/S0140-6736(08)61170-8.
1.1.
2008
Juhanson, P.; Kepp, K.; Org, E.; Veldre, G.; Kelgo, P.; Rosenberg, M.; Viigimaa, M.; Laan, M. (2008). N-acetyltransferase 8, a positional candidate for blood pressure and renal regulation: resequencing, association and in silico study. BMC Medical Genetics, 9 (25), 1−12.10.1186/1471-2350-9-25.
1.1.
2008
Caulfield, M.J.; Munroe, P.B.; O'Neill, D.; Witkowska, K.; Charchar, F.; Doblado, M.; Evans, S.; Eyheramendy, S.; Onipinia, A.; Howard, P.; Shaw-Hawkins, S.; Dobson, R.J.; Wallace, C.; Newhouse, S.J.; Brown, M.; Connell, J.M.; Dominiczak, A.; Farrall, M.; Lathrop, G.M.; Samani, N. ... Cheeseman, C. (2008). SLC2A9 Is a High-Capacity Urate Transporter in Humans. PLOS Medicine, 5 (10), 0001−0015.10.1371/journal.pmed.0050197.
1.1.
2008
Viigimaa, M.; Narkiewicz, K.; Kjeldsen, S.E.; Hedner, T. (2008). New ESH Hypertension Excellence centers approved. Blood Pressure, 178−180.
1.2.
2008
Hlimonenko, Irina; Meigas, Kalju; Viigimaa, Margus; Temitski, Kristina (2008). Aortic and Arterial Pulse Wave Velocity in Patients with Coronary Heart Disease of Different Severity. Estonian Journal of Engineering, 14 (2), 167−176.
2.1.
2008
Mancia, G.;Grassi, G; Kjeldsen, SE., Viigimaa M. et al. (2008). Manual of Hypertension of the European Society of Hypertension. Information Press.
3.1.
2008
Hlimonenko, Irina; Meigas, Kalju; Viigimaa, Margus; Temitski, Kristina (2008). Augmentation Index in Different Severity Coronary Heart Disease Patients. IFMBE Proceedings, 20. Springer, 242−244.
3.1.
2008
Erdine S, Viigimaa M (2008). Compliance to treatment of hypertension. In: Mancia G, Grassi G, Kjeldsen S (_EditorsAbbr). Manual of Hypertension of The European Society of Hypertension (354−360). Informa healthcare.
5.1.
2008
Veldre, G.; Viigimaa, M.; Org, E.; Juhanson, P.; Kelgo, P.; Rebane, T.; Laan, M. (2008). HYPEST, first hypertension targeted sample collection in Estonian population. Journal of Hypertension, 26: 18th Scientific Meeting of the European-Society-of-Hypertension/22nd Scientific Meeting of the International-Society-of-Hypertension, Berlin, Germany, JUN 14-19, 2008. Lippincott Williams & Wilkins, 107−107.
5.1.
2008
Kurvinen, E.; Nueganen, K.; Viigimaa, M.; Veske, A.; Aasvee, K. (2008). Matrix metalloproteinase-9 polymorphism in relation to cardiovascular disease complications in patients of type 2 diabetes mellitus. European Journal of Human Genetics, 16(Suppl 2): European Human Genetics Conference 2008, Barcelona, Spain, May 31 - June 3, 2008. 326.
5.1.
2008
Šamarin, A.; Mesikepp, A.; Brand, R.; Nazarenko, S.; Viigimaa, M. (2008). Arterial hypertension and significant coronary artery stenosis: detection by 64 row computed tomography. Journal of Hypertension, 26 (S1), S285.
5.2.
2008
Aasvee, K.; Jauhiainen, M.; Viigimaa, M.; Tupits, H; Sundvall, J.; Kurvinen, E. (2008). Põletikumarkerid ja lipoproteiine remodelleerivad valgud II tüüpi diabeedi (T2DM) haigetel. Eesti Arst, 87(9): TÜ Arstiteaduskonna Päevad 2008, Tartu, 9-10 oktoober 2008. 668−669.
5.2.
2008
Kurvinen, E; Viigimaa, M.; Tupits, H.; Sundvall, J.; Jauhiainen, M.; Aasvee, K. (2008). Lipiidide ainevahetuse näitajate ja süsteemse kroonilise põletiku markerite seos insuliiniresistentsuse väljendumuse astmega. Eesti Arst, 87(9): TÜ Arstiteaduskonna Päevad 2008, Tartu, 9-10 oktoober 2008. 664−665.
5.2.
2008
Laan, M.; Org, E.; Eyheramendy, S.; Gieger, C.; Juhanson, P.; Lichtner, P.; Veldre, G.; Tomberg, K.; Viigimaa, M.; Klopp, N.; Munroe, P.; Shaw-Hawkins, S.; Caulfield, M.J.; investigators, B.R.I.G.H.T; Illig, T.; Wichmann, H.-E.; Meitinger, T. (2008). Genome-wide association study with blood pressure traits. HGM 2008 Programme and Abstract book: HGM 2008: Human Genome meeting; Hyderabad, India; 27-30 Sep 2008. 67−67.
5.2.
2008
Zemtsovskaja, G.; Krjukova, V.; Zemtsovski, M.; Minosenko, A.; Viigimaa, M. (2008). Correlation of N-terminal pro B-type natriuretic peptide with clinical NYHA staging, ventricular ejection fraction and left atrial volume index. Proceedings of the 9th Baltic congress on laboratory medicine. 39.
1.1.
2007
Nilsson, P.M.; Journath, G.; Palm, K.; Viigimaa, M. (2007). Risk factor control in treated hypertensives from Estonia and Sweden. Why the difference? Blood Pressure, 16 (5), 301−304.10.1080/08037050701517224.
1.1.
2007
Mancia, G.; De Backer, G.; Dominiczak, A.; Cifkova, R.; Fagard, R.; Germano, G.; Grassi, G.; Heagerty, AM.; Kjeldsen, SE.; Laurent, S.; Narkiewicz, K.; Viigimaa, M. et al. (2007). Practice guidelines 2007 for the treatment of arterial hypertension. Giornale italiano di cardiologia, 389−479.
1.1.
2007
Mancia, G.; De Backer, G.; Dominiczak, A.; Cifkova, R.; Fagard, R.; Germano, G.; Grassi, G.; Heagerty, AM.; Kjeldsen, SE.; Laurent, S.; Narkiewicz, K.; Viigimaa, M. et al. (2007). ESH/ESC 2007 Guidelines for the management of arterial hypertension. Revista española de cardiología, 968−994.
1.1.
2007
Mancia, G.; De Backer, G.; Dominiczak, A.; Cifkova, R.; Fagard, R.; Germano, G.; Grassi, G.; Heagerty, AM.; Kjeldsen, SE.; Laurent, S.; Narkiewicz, K.; Viigimaa, M. et al. (2007). 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). European Heart Journal, 1462−1536.
1.1.
2007
Viigimaa, M.; Farsang, C.; Kjeldsen, SE.; Narkiewicz, K.; Mancia, G. (2007). ESH Hypertension Excellence Centres: a new strategy to combat an old foe. Journal of Hypertension, 1744−1748.
1.1.
2007
Mancia, G.; De Backer, G.; Dominiczak, A.; Cifkova, R.; Fagard, R.; Germano, G.; Grassi, G.; Heagerty, AM.; Kjeldsen, SE.; Laurent, S.; Narkiewicz, K.; Viigimaa, M. et al. (2007). 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Journal of Hypertension, 1105−1187.
1.1.
2007
Kepp, K.; Juhanson, P.; Kozich, V.; Ots, M.; Viigimaa, M.; Laan, M. (2007). Resequencing PNMT in European hypertensive and normotensive individuals: no common susceptibilily variants for hypertension and purifying selection on intron 1. BMC Medical Genetics, 8 (47), 1−9.
1.2.
2007
Zemtsovskaja, G.; Zemtsovski, M.; Siimann-Häelme, Ü.; Viigimaa, M (2007). N-terminal pro-brain natriuretic peptide - association with extent of CHF in clinical practice. Clinical Chemistry and Laboratory Medicine, 166.
3.1.
2007
Hlimonenko, Irina; Meigas, Kalju; Viigimaa, Margus; Temitski, Kristiina. (2007). Assessment of Pulse Wave Velocity and Augmentation Index in Different Arteries in Patients with Severe Coronary Heart Disease. In: Proceedings of the 29th Annual International Conference of the IEEE EMBS (1703−1706).. IEEE.
5.1.
2007
Kantola, I.; Karjalainen, S; Korhonen, K.; Viigimaa, M.; Port, K. (2007). Home monitoring of blood pressure supported by tele-monitoring system. Journal of Hypertension, 25 (S2): 17th European Meeting on Hypertension, Milan, Italy, Jun 15-19, 2007. S29.
5.2.
2007
Viigimaa, Margus (2007). Programme and abstracts : 4th Baltic Atherosclerosis Congress : September 27-29, 2007, Tallinn, Estonia. Baltic Atherosclerosis Congress(4 :2007 :Tallinn). [Tallinn: Frens Conference Services,.
5.2.
2007
Viigimaa, Margus (2007). Programme and abstracts : 4th Baltic Atherosclerosis Congress : September 27-29, 2007, Tallinn, Estonia. Baltic Atherosclerosis Congress(4 :2007 :Tallinn). [Tallinn: Frens Conference Services,.
5.2.
2007
Zemtsovski, M.; Viigimaa, M.; Zemtsovskaja, G. (2007). Treating of dyslipidaemia to goal - situation in North Estonia Regional Hospital. Proceedings of the 4th Baltic atherosclerosis congress. 61.
1.3.
2006
Viigimaa, Margus; Välkmann, Reet (2006). LDL-aferees väljendunud hüperkolesteroleemia ravis. Eesti Arst, 8, 523−528.
1.3.
2006
Ani, Ülle; Viigimaa, Margus; Kipper, Taivo; Pruunsild, Toomas; Jõgi, Rain (2006). Nikotiinisõltuvuse ravi bupropiooniga kroonilise bronhiidiga haigetel. Eesti Arst, 85 (6), 354−361.
1.3.
2006
Viigimaa, M.; Eha, J.; Hedman, A.; Kampus, P.; Liiver, A.; Maaroos, J.; Marandi, T.; Mesikepp, A.; Muda, P.; Ristimäe, T.; Roose, M.; Suurorg, L.; Teesalu, R.; Tiik, M.; Tupits, H.; Vokk, R.; Zemtsovski, M. (2006). Eesti südame- ja veresoonkonnahaiguste preventsiooni juhend. Eesti Arst, 85 (3), 183−216.
1.3.
2006
Teesalu, Rein; Viigimaa, Margus; Kiudma, Tarvo; Sinisalu, Väino (2006). Südamepuudulikkuse ravi tänapäeval : eksperdihinnangud. Eesti Arst, 10, 689−696.
2.3.
2006
Sammul, Sirje (2006). Hüpertooniatõve diagnoosiga patsientide tervisekäitumine ning perearsti ja pereõe osa selle kujundamisel : magistritöö rahvatervishoius. (Tartu Ülikool.; Tervishoiu instituut.; ). Tartu: Tartu Ülikool.
6.6.
2006
Siidirätsep, Kai;Viigimaa, Margus (2006). Intensiivne mees : Margus Viigimaa : [intervjuu südamearstiga, TTÜ professoriga]. Tervisplus, 46−48.
1.1.
2005
Port, K.; Palm, K.; Viigimaa, M. (2005). Daily usage and efficiency of remote home monitoring in hypertensive patients over a one-year period. Journal of Telemedicine and Telecare, 1 (11), 34−36.
1.2.
2005
Viigimaa M, Hansen S, Shipilova T, Pšenitšnikov I, Kalle A, Puusaag M. (2005). Effect of lisinopril on twenty-four-hour blood pressure in patients with mild to moderate hypertension. Seminars in Cardiology, 11, 106−109.
1.3.
2005
Hansen, Sirje; Šipilova, Tatjana; Pšenitšnikov, Igor; Puusaag, Maie; Kalle, Anneli; Viigimaa, Margus (2005). Lisinopriili ööpäevane vererõhku langetav efektiivsus kerge ja keskmise raskusastmega arteriaalse hüpertensiooni patsientidel. Eesti Arst, 7, 461−465.
6.6.
2005
Viigimaa, Margus (2005). Kõrgvererõhktõve globaalne koormus : ülemaailmse info analüüs. Lege Artis, 17−18,
6.6.
2005
Hansen, Sirje; Šipilova, Tatjana; Pšenitšnikov, Igor; Puusaag, Maie; Kalle, Anneli; Viigimaa, Margus (2005). Lisinopriili vererõhku langetav toime arteriaalse hüpertensiooni patsientidel. Lege Artis, 8, 32.
1.3.
2004
Ragun, Ulvi; Jagomägi, Kersti; Raamat, Rein; Viigimaa, Margus (2004). Õlavarrelt vererõhu mõõtmise protseduuri mõju keskmisele arteriaalsele rõhule hüpertoonikutel. Eesti Arst, 2, 81−86.
1.3.
2004
Soopõld, Üllar; Maarandi, Toomas; Ainla, Tiia (2004). ST-segmendi elevatsiooniga ägeda müokardiinfarkti Eesti ravijuhend : kuukirja Eesti Arst lisa. Viigimaa, Margus; Eha, Jaan; Laks, Toivo... Tartu: Eesti Arst.
1.3.
2004
Soopõld, Ü.; Marandi, T.; Ainla, T.; Liiver, A.; Elmet, M.; Laanoja, J.; Peeba, M.; Ristimäe, T.; Viigimaa, M., Eha, J.; Laks, T.; Reinold, A.; Serka, T.; Teesalu, R.; Vahula, V., Voitk, J. (2004). ST-segmendi elevatsiooniga ägeda müokardiinfarkti Eesti ravijuhend. Eesti Arst, 12(L), 2−47.
3.3.
2004
Soopõld, Ü.; Marandi, T.; Ainla, T.; Liiver, A.; Elmet, M.; Laanoja, J.; Peeba, M.; Ristimäe, T.; Viigimaa, M.; Eha, J.; Laks, T.; Reinold, A.; Serka, T.; Teesalu, R.; Vahula, V.; Voitk, J. (2004). St-segmendi elevatsiooniga ägeda müokardiinfarkti Eesti ravijuhend. Tartu: Eesti Arst.
1.1.
2003
Port, K.; Palm, K.; Viigimaa, M. (2003). Self-reported compliance of patients receiving antihypertensive treatment: use of a telemonitoring home care system. Journal of Telemedicine and Telecare, 9, S65−S66.
1.2.
2003
Välkmann R, Jõudu T, Hansen S, Viigimaa M. (2003). Effects of fenofibrate on platelet aggragation in patients with combined hyperlipidemia. Seminars in Cardiology, 9 (1), 24−27.
1.3.
2003
Viigimaa, Margus (2003). Patsient, perearst, kardioloog. Tohtrile : ajakiri arstidele, 4, 22−:.
1.3.
2003
Ragun, Ulvi; Jagomägi, Kersti; Raamat, Rein; Viigimaa, Margus (2003). Õlavarrelt vererõhu mõõtmise protseduuri mõju keskmisele arteriaalsele rõhule ja pulsisagedusele. Eesti Arst, 9, 649.
5.1.
2003
Viigimaa, M.; Kask, A.; Tiganik, V.; Johansson, J. (2003). Cardiovascular risk factors in 55-year-old women and men in Tartu (Estonia) and Stockholm (Sweden). Atherosclerosis Supplements, 4 (2), 110−110.
6.2.
2003
Uusküla, Maido; Teesalu, Rein; Viigimaa, Margus (2003). Distantskoolitusprogramm "Kardioloogia aktuaalsed küsimused" [Võrguteavik]. [Tartu: Tartu Ülikooli Kliinikum.
1.1.
2002
Johansson, J.; Viigimaa, M.; Jensen-Urstad, M.; Krakau, I.; Hansson, LO. (2002). Risk factors for coronary heart disease in 55-and 35-year-old men and women in Sweden and Estonia. Journal of Internal Medicine, 252 (6), 551−560.
2.2.
2002
Knox, S; Viigimaa, M.; Unden, AL; Elofsson, S.; Johansson, J (2002). Psychosocial Factors and Cardiovascular Risk in the Est-West Divide: The Swestonia Study. In: Heart Disease:Enviroment, Stress and Gender. Nato Science Series (138-152)..
3.4.
2002
Viigimaa, Margus; Jõudu, Tiiu; Välkmann, Reet; Hansen, Sirje (2002). Comparison of effects of fenofibrate and ciprofibrate on plasma lipids and platelet aggregation in patients with combined hyperlipidemia. Proceedings of the Department of Cardiology, 5, 54−58.
5.1.
2002
Muda, P.; Ristimae, T.; Viigimaa, M. (2002). Arterial hypertension among middle-aged Estonians - Prevalence and risk factors. Journal of Hypertension, 20, S85−S85.
5.2.
2002
Viigimaa, Margus (2002). Südame-veresoonkonna haiguste ennetamise programm aastateks 2002-2006. Üle-eestiline teaduskonverents "Tervise edendamine Eestis VI" : 20.-21. märts 2002 a., [Tartu] : konverentsi ettekannete teesid. 64.
6.2.
2002
Viigimaa, Margus (2002). Südamepuudulikkusega haige ravi diureetikumidega. Eesti Arst, 6, 376.
6.2.
2002
Viigimaa, Margus (2002). Kommentaar hüpertooniatõve ja südamepuudulikkuse ravi igapäevase käsitluse uuringule. Hippokrates, 90.
1.1.
2001
Unden, AL.; Elofsson, S.; Viigimaa, M.; Johansson, J.; Knox, S. (2001). A psychosocial comparison of 35- and 55-year-old men and women in Sweden and Estonia: The Swestonia cardiovascular risk factor study. International Journal of Behavioral Medicine, 8 (2), 149−162.
1.3.
2001
Viigimaa, Margus; Palm, K.; Port, Kristjan; Hansen, S.; Laasik, T.; Siim, K. (2001). Arteriaalse hüpertensiooniga patsientide monitoorimine kodujälgimisseadme Docobo abil. Eesti Arst, 12, 591−595.
1.3.
2001
Viigimaa, M.; Tiganik, V (2001). Doppleri ultraheliuuring unearterite aterosklerootilise protsessi hindamisel. Eesti Arst, 1, 35−40.
1.3.
2001
Tiganik, Valeri; Viigimaa, Margus (2001). Unearterite Doppler-spektrogrammide uuring kardiovaskulaarsete haiguste puhul. Eesti Arst, 3, 150−155.
1.3.
2001
Hämmal, Jaanus; Tikk, Viive; Tikk, Harald; Viigimaa, Margus; Kuusik, Sirje (2001). [Oomega]-3-rasvhapete sisalduse suurendamisest linnukasvatussaadustes. Agraarteadus, XII (1), 14−50.
3.4.
2001
Tikk, Harald; Viigimaa, Margus; Tikk, Viive; Hämmal, Jaanus (2001). The effect of consumption of omega-3 fatty acid enriched quail eggs on blood characteristics in hypercholesterolemic men. Proceedings of the IX Baltic Poultry Conference: Tartu, 14th of September 2001, 27.
3.4.
2001
Zemtsovskaja, G.; Ivanov, A.; Melnitchuk, A.; Zemtsovsky, M.; Viigimaa, M. (2001). Comparision of directly deterrnined and calculated LDL cholesterol concentrations in patients of various risk categories. Abstract book: 14 IFCC and European Congress of Clinical Chemistry and Laboratory Medicine, Prague.
5.1.
2001
Allikmets, K.; Starkopf, A.; Svensson, S.; Pokk, T.; Hedner, T.; Viigimaa, M. (2001). Ambulatory blood pressure monitoring in a population of an Estonian island: initial results from the SELECT project. European Heart Journal, 22, 103−103.
5.2.
2001
Tikk, Harald; Viigimaa, Margus; Tikk, V; Hämma, J (2001). The effect of consumption of omega-3 fatty acid enriched guail eggs on blood characteristics in hypercholesterolemic men. Proceedings of the IX Baltic Poultry Conference. 12−14.
5.2.
2001
Viigimaa, Margus (2001). Südame isheemiatõve preventsioon Eestis. Eesti Arst, 6, 332−333.
6.2.
2001
Viigimaa, M.; Aasvee, K.; Eha, J.; Laks, T.; Lember, M.; Maaroos, H.; Mesikepp, A.; Podar, T.; Roose, M.; Saava, M.; Sulling, T.; Suurorg, L.; Teesalu, R.; Tupits, H.; Tur, I.; Uusküla, M.; Vahisalu, R.; Voloz, O.; Välkmann, R.; Zemtsovski, M. (2001). Eesti Lipiidijuhised. (1−24). Eesti Haigekassa : WHO CINDI Programm, 2001.
6.3.
2001
Viigimaa, Margus (2001). Ženšenn annab jõudu. Tervis Pluss, 5, 72.
6.3.
2001
Viigimaa, Margus; Holvandus, Juune (2001). Müstiline kolesterool. Kodutohter, 9, 20−22.
6.3.
2001
Siidirätsep, Kai; Viigimaa, Margus; Aarsalu, Helle; Varendi, Tarmo (2001). Oma arst öökapil : [südameseireaparaat Docobo]. Tervis Pluss, 6, 32−34.
6.3.
2001
Viigimaa, Margus (2001). Miks ei tohi palju soola süüa? Tervis Pluss, 6, 34.
6.3.
2001
Viigimaa, Margus; Holvandus, Juune (2001). Kes palju teeb, see rohkem jõuab : [vestlus kardioloogiga]. Kodutohter, 9, 18−22.
1.1.
2000
Viigimaa, M.; Allikmets, K.; Parik, T.; Skards, J.; Franken, A.; Hass, G. (2000). Tasosartan and hydroclorothiazide as combination therapy in the treatment of severe essential hypertension: Comparison with enalapril. Cardiovascular Drugs and Therapy, 14 (4), 447−449.
3.3.
2000
Viigimaa, M.; Allikmets, K.; Goldštein, G.; Jaagus, H.; Laan, M.; Maaroos, J.; Nazarenko, S.; Ojamaa, M.; Ristimäe, T.; Teesalu, R.; Volož, O. (2000). Arteriaalne hüperetensioon - praktilised aspektid. Tartu: Tartumaa Trükikoda.
3.4.
2000
Viigimaa, Margus; Jõudu, Tiiu; Hämmal, Jaanus; Tikk, Harald; Tikk, Viive (2000). The effect consumption of omega-3-enriched quail eggs on lipid metabolism and platelet aggregation in healthy volunteers. Proceedings of the Department of Cardiology at the University of Tartu, 90−95.
5.1.
2000
Allikmets, K.; Ristimae, T.; Viigimaa, M. (2000). Electrocardiographic detection of left ventricular hypertrophy in severe essential hypertension: Correlations between different models. Journal of Hypertension, 18, S28−S28.
6.2.
2000
Viigimaa, Margus; Allikmets, Kristina; Jaagus, Helgi; Laan, Mari; Maaroos, Jaak; Goldšteine, Gundega; Nazarenko, Sergei; Ojamaa, Maie; Ristimäe, Tiina; Teesalu, Rein; Volož, Olga (2000). Arteriaalne hüpertensioon - praktilised aspektid. Tartu: Eesti Hüpertensiooni Ühing.
6.2.
2000
Viigimaa, Margus; Allikmets, Kristina; Goldšteine, Gundega; Jaagus, Helgi; Maaroos, Jaak; Nazarenko, Sergei; Ojamaa, Maie; Ristimäe, Tiina; Volož, Olga (2000). Eesti hüpertensioonijuhised 1999. Tartu: Eesti Hüpertensiooni Ühing.
6.3.
2000
Viigimaa, Margus (2000). AKE-inhibiitorid vähendavad suremust veel paremini kui loodeti : kõrgvererõhu alandajatest. Hippokrates, 256−257.
6.3.
2000
Murutar, Kati; Hermlin, Toomas; Viigimaa, Margus (2000). Suust sisse läinud haiguse väljaajamine : [südame veresoonte sondeerimisest]. Tervis, 6, 44−46.
6.3.
2000
Viigimaa, Margus (2000). Valud südames. Tervisetrend, 10, 58.
6.6.
2000
Viigimaa, Margus (2000). Kõik apteegid mõõtma : vererõhku. Eesti Rohuteadlane, 30−31.
1.1.
1999
Allikmets, K.; Parik, T.; Viigimaa, M. (1999). The renin-angiotensin system in essential hypertension: Associations with cardiovascular risk. Blood Pressure, 8 (2), 70−78.
1.1.
1999
Viigimaa, M. (1999). The Baltic atherosclerosis journal. Clinical Chemistry and Laboratory Medicine, 37 (8), 841−841.
1.3.
1999
Ojamaa, M.; Siim, K.; Viigimaa, M. (1999). Arteriaalse rõhu näitajate ööpäevane jälgimine firma SpaceLabs Medical ja Meditech monitoridega Tartu Ülikooli Kardioloogiakliinikus. Eesti Arst, 78 (2), 111−117.
3.3.
1999
Viigimaa, M.; Allikmets, K.; Golstein, G; Jaagus, H.; Maaroos, J.; Nazarenko, S.; Ojamaa, M.; Ristimäe, T.; Volozh, O (1999). Eesti Hüpertensioonijuhised. Eesti Hüpertensiooni Ühing.
3.5.
1999
Viigimaa, Margus; Kask, Anne; Johansson, Jan (1999). Psühhosotsiaalsete tegurite osa kardiovaskulaarse riskifaktorina Tartu-Stockholmi kardiovaskulaarsete riskifaktorite uuringus. Haigestumist ja tervenemist soodustavad psühhosotsiaalsed tegurid : interdistsiplinaarne konverents : 13.-14. november 1998. Tallinn: Tallinna Pedagoogikaülikooli Kirjastus, 133−138.
5.1.
1999
Viigimaa, M.; Valkman, R. (1999). Lipid-lowering and antiaggregatory efficacy of atorvastatin in coronary heart disease patients with combined hyperlipidemia. Atherosclerosis, 144, 24−24.
5.1.
1999
Viigimaa, M.; Kask, A.; Tiganik, V.; Johansson, J. (1999). Comparison of the lipid profile and eating habits of 35-year-and 55-year old inhabitants of the city of Tartu (Estonia). Atherosclerosis, 144, 176−176.
5.1.
1999
Viigimaa, M.; Kask, A.; Tiganik, V.; Johansson, J. (1999). A comparison of blood pressure levels, lipid profiles and smoking habits between 35-year olds in Tartu (Estonia) and Stockholm (Sweden). Hypertension, 33 (5), 1320−1320.
5.2.
1999
Viigimaa, Margus; Paesüld, M (1999). Maarjamõisa polikliiniku südamehaiguste ennetamise kabinetis ja Kärdla südametoas konsulteeritud elanike kardiovaskulaarsete riskitegurite võrdlus. Eesti Sisearstide Seltsi X Kongress, 20.-22. mai 1999, Sakala keskus, Tallinn : programm ja teeside kogumik. 55.
5.2.
1999
Zemtsovskaja, G.; Zemtsovski, M.; Viigimaa, M. (1999). The effect of atorvastatin on plasma total antioxidant capasity. Proceedings of the Free radical processes Congress.
5.2.
1999
Viigimaa, Margus; Korrovits, V (1999). Verapamiil-trandolapriili kombinatsiooni vererõhku langetav ja mikroalbuminuuriat vähendav toime II tüüpi diabeediga hüpertoonikutel. Eesti Sisearstide Seltsi X Kongress, 20.-22. mai 1999, Sakala keskus, Tallinn : programm ja teeside kogumik, 54.
6.3.
1999
Klemet, Andres; Viigimaa, Margus (1999). Üks kloun saja arsti asemel : nalja tähtsusest. Tervisetrend, 1, 49−50.
6.3.
1999
Larin, Lea; Viigimaa, Margus (1999). Terviseks! : punane vein on tõeline elupikendaja. Anne, 11, 62−64.
6.3.
1999
Siidirätsep, Kai; Viigimaa, Margus (1999). Vererõhk : kord kõrge, kord madal : [südamearst Margus Viigimaa nõuandeid]. Tervis, 1, 30−32.
6.3.
1999
Ojamaa, Maie; Siim, Kadri; Viigimaa, Margus (1999). Arteriaalse rõhu näitajate ööpäevane jälgimine firma SpaceLabs Medical ja Meditech monitoridega Tartu Ülikooli Kardioloogiakliinikus. Eesti Arst, 2, 111−117.
6.3.
1999
Viigimaa, Margus (1999). Kuidas mõõta vererõhku. Tervis, 1, 33−34.
6.3.
1999
Adorf, Margit; Kull, Mart; Mehik, Heidi; Viigimaa, Margus; Raidma, Liis (1999). Külm kalkun ehk sõda suitsu vastu : suitsetamisest arstide kommentaaridega. Tervis, 2, 10−14.
6.6.
1999
Viigimaa, Margus (1999). Hüpertensiooni monoteraapia versus kombineeritud ravi. Eesti Arstide Liidu Teataja, 12, 8.
6.6.
1999
Viigimaa, Margus (1999). Kardioloogiakliiniku aastakonverentsilt. Hippokrates, 4, 199.
6.6.
1999
Ani, Ülle; Viigimaa, Margus; Sepper, Ruth (1999). Suitsetamisest ja mitte ainult kui nuhtlusest mitte-suitsetajatele ... Hippokrates, 9, 550−555.
1.1.
1998
Viigimaa, M.; Skards, J.; Parik, T.; Allikmets, K.; Franken, A.; Häss, G. (1998). Combination therapy with tasosartan and hydrochlorthiazide in severe essential hypertension: comparison with enalapril. In: Journal of Hypertension..
1.1.
1998
Viigimaa, M.; Valkman, R.; Kask, A.; Joudu, T. (1998). Effect of ciprofibrate on platelet aggregation in patients with combined hyperlipidemia. Platelets, 9, 265−267.
2.2.
1998
Viigimaa, M.; Maaroos, H.; Lember, M.; Lipand, A.; Tohver, M.; Kelk, J.; Maaroos, J.; Mehilane, L.; Valvere, V.; Sarapuu, H.; Voloz, O.; Birkenfeldt, R. (1998). Soovitused perearstile haiguste ennetamiseks. . Tartu: Tartumaa Trükk.
2.2.
1998
Viigimaa, M.; Dominiczak, M. (1998). Development of cardiovaskular prevention in Estonia. In: The Fats of Life..
3.3.
1998
Viigimaa, M.; Maaroos, H.-I.; Lember, M.; Lipand, A.; Tohver, M.; Kelk, J.; Maaroos, J.; Mehilane, L.; Valvere, V.; Sarapuu, H.; Volozh, O.; Birkenfeldt, R. (1998). Soovitused perearstile haiguste ennetamiseks. Tartu: Tartu Ülikool.
3.4.
1998
Ojamaa, Maie; Viigimaa, Margus; Siim, Kadri; Kullus, Ruth (1998). Ambulatory blood pressure monitoring in young males with borderline hypertension. Proceedings of the Department of Cardiology at the University of Tartu, 44−52.
3.4.
1998
Aab, Alar; Zemtsovskaja, Galina; Zemtsovski, Mihhail; Viigimaa, Margus (1998). Lipids and lipoproteins investigation in the Tartu University Hospital. Proceedings of the Department of Cardiology at the University of Tartu, 7−10.
5.1.
1998
Parik, T.; Allikmets, K.; Zilmer, K.; Zilmer, M.; Viigimaa, M.; Teesalu, R. (1998). Associations between oxidative stress, Von Willebrand factor and plasminogen activator Inhibitor 1 in essential hypertension. Journal of Hypertension, 16, S203−S203.
5.1.
1998
Ojamaa, M.; Viigimaa, M.; Slim, K.; Kullus, R. (1998). Ambulatory blood pressure monitoring in young males with borderline hypertension. Journal of Hypertension, 16, S216−S216.
5.2.
1998
Aab, A.; Zemtsovskaja, G.; Zemtsovski, M.; Viigimaa, M. (1998). Lipids and Lipoproteins investigation in Tartu University Hospital. Proceedings of the 1 Baltic Lipid Conference and VI Estonian Heart Health Conference, Tallinn.
1.3.
1997
Viigimaa, M.; Zemtsovski, M.; Lind, M. (1997). Perekondliku hüperkolesteroleemia pikaajaline ravi simvastatiiniga. Eesti Arst, 60−61.
5.1.
1997
Viigimaa, M.; Zemtsovski, M.; Lind, M. (1997). Effect of relative low dose simvastatin on lipid profile in patients with familial hypercholesterolemia. Abstract book of the Seventh International Symposium on cardiovascular pharmacotherapy, Jerusalem, Israel, June 1997: Seventh International Symposium on cardiovascular pharmacotherapy, Jerusalem, Israel, June 1997. 97.
5.2.
1997
Viigimaa, Margus; Kask, Anne; Johansson, Jan (1997). Vere lipiididesisalduse ja toitumisharjumuste võrdlus Tartu keskealistel elanikel. Üle-eestiline teaduskonverents "Tervise edendamine Eestis, 17.-18. aprill 1997.a. : konverentsi ettekannete teesid. 67−68.
6.2.
1997
Viigimaa, Margus (1997). Südametervise käsiraamat. Tallinn: Eesti Tervisekasvatuse Keskus.
6.2.
1997
Viigimaa, Margus; Dominiczak, Marek (1997). Preventiivkardioloogia : õpik. Tartu: Elmatar Publishing House.
1.1.
1996
Viigimaa, M.; Frölich, J.C. (1996). Platelet aggregation, sensitivity to prostaglandin E1 and tromboxane A2 release in recombinant hirudin- and heparin-anticoagulated blood. Blood Coagulation & Fibrinolysis, 7 (2), 259−261.
1.1.
1996
Viigimaa, M.; Tsikas, D.; Frolich, JC. (1996). Platelet aggregation, sensitivity to prostaglandin E(1) and thromboxane A(2) release in recombinant hirudin- and heparin-anticoagulated blood. Blood Coagulation & Fibrinolysis, 7 (2), 259−261.
1.3.
1996
Jagomägi, K.; Viigimaa, M.; Hendrikson, E.; Talts, J.; Raamat, R.; Teesalu, R. (1996). Arteriaalse vererõhu ja südame löögisageduse variaabelsuse määramine funktsionaalsete testide ajal südamelihase infarkti ägedas faasis. Eesti Arst, 75 (2), 105−108.
3.4.
1996
Viigimaa, Margus; Saareoja, Jelena (1996). Prospective study on APC-resistance in patients with acute myocardial infarction. Proceedings of the Department of Cardiology at the University of Tartu, 119−126.
5.2.
1996
Zemtsovski, M.; Zemtsovskaja, G.; Viigimaa, M. (1996). Laboratory control of simvastatin therapy in coronary heart disease patients. Proceedings of the 3rd Baltic Congress of Laboratory Medicine, Jurmala.
6.4.
1996
Lemne, Carola; Lorenz, Karin; Viigimaa, Margus (1996). Vererõhk ja sinu tervis : teavet organismi talitlusest. Tartu: Intermaag.
1.1.
1995
Viigimaa, M.; Joudu, T.; Keis, U.; Saareoja, Y.; Teesalu, R. (1995). Platelet-aggregation, thromboxane a(2), prostacyclin generation and platelet sensitivity to prostacyclin during the first month after myocardial-infarction. Platelets, 6 (6), 402−407.
3.1.
1995
Viigimaa, M.; Zemtsovski, M.; Kiho, U. (1995). Prophylaxis of venous thromboembolism in orthopaedic surgery. Problems in contemporary surgery (141−148).. Tartu: Tartu Ülikool. (Tartu Ülikooli Toimetised ; 969).
3.2.
1995
Viigimaa, M.; Zemtsovski, M. (1995). Blood serum lipids, lipoproteins and thrombocyte aggregation in acute myocardial infarction and unstable angina pectories. II Annual Copenhagen Atherosclerosis conference, 1995. Final programme and abstracts. 49.
3.4.
1995
Viigimaa, M.; Zemtsovski, M.; Välkmann, R. (1995). Simvastatiinravi efektiivsus II tüüpi hüperlipideemiaga südame isheemiatõve haigetel. Eeasti Sisearstide Seltsi IX Kongress. Teesid 1995..
3.4.
1995
Zemtsovski, M.; Zemtsovskaja, G.; Viigimaa, M. (1995). Blood Lipids and Lipoproteins in patients with angiographically determined atherosclerosis of coronary arteries. Abstract book: ll-th IFCC European Congress of Clinical Chemistry, Tampere, Finland.
5.1.
1995
Viigimaa, M.; Saareoja, Y. (1995). Prospective-study on activates protein-c resistance in patients with acute myocardial-infarction. Thrombosis and Haemostasis, 73 (6), 1374−1374.
6.2.
1995
Viigimaa, Margus (1995). Hüperlipideemia käsiraamat. Tartu: Tartu Ülikool.
6.4.
1995
Viigimaa, Margus; Allikmets, Kristina; Parik, Triin (1995). Tea oma kolesterooliväärtust! : meelespea. Tartu: Tartumaa.
1.2.
1994
Viigimaa, M.; Jôudu, T.; Hendrikson, E.; Shandrik, Y.; Teesalu, R. (1994). Antiaggregative therapy with acetylsalicylic acid and diclofenac in patients with acute myocardial infarction. Upsala Journal of Medical Sciences, 99 (2), 131−138.
2.3.
1994
Viigimaa, Margus (1994). Primary haemostasis, antiaggregative and anticoagulant treatment of acute myocardial infarction. (Tartu Ülikool, Arstiteaduskond). Tartu: University of Tartu.
3.2.
1994
Viigimaa, M.; Zemtsovski, M. (1994). Changes in blood coagulation and fibrinolysis parameters in patients with acute myocardial infarction. Laboratory Medicine, Vilnius 1994.
3.4.
1994
Saareoja, Jelena; Jõudu, Tiiu; Viigimaa, Margus (1994). Effect of recombinant hirudin and heparin on platelet aggregation in coronary artery disease patients. Proceedings of the Department of Cardiology at the University of Tartu, 104−108.
3.4.
1994
Ojamaa, Maie; Ulst, Kai; Viigimaa, Margus (1994). Lung perfusion scanning as a screening method in diagnostics of pulmonary embolism in cardiology department. Proceedings of the Department of Cardiology at the University of Tartu, 72−75.
3.4.
1994
Ristimäe, Tiina; Viigimaa, Margus; Teesalu, Rein (1994). Sequential changes in cardiac index in 35 male-patients with first myocardial infarction. Proceedings of the Department of Cardiology at the University of Tartu, 86−103.
5.2.
1994
Zemtsovski, M.; Viigimaa, M.; Zemtsovskaja, G.; Shandrik, J. (1994). Blood coagulation factors after thrombolytic therapy in patients with acute myocardial infarction. University Research in Medicine, Proceedings of the Meeting, 1994, Tartu. 18.
1.1.
1993
Viigimaa, M.; Ohnogi, H.; Hattori, R.; Yui, Y.; Kawai, C. (1993). Antithrombotic effect and reperfusion by low molecular weight heparin in a canine model of coronary artery thrombosis. Japanese circulation journal, 57 (6), 553−557.
1.1.
1993
Viigimaa, M.; Ohnogi, H.; Hattori, R. (1993). Antithrombotic effect and reperfusion by low-molecular-weight heparin in a canine model of coronary-artery thrombosis. Japanese circulation journal, 57 (6), 553−557.
1.1.
1992
Lopp, M.; Kobzar, G.; Bergmann, N.; Pehk, T.; Lopp, A.; Valimae, T.; Viigimaa, M.; Lille, U. (1992). Synthesis and antiaggregative activity of novel omega-achiral carba-analogs of prostacyclin. European Journal of Medicinal Chemistry, 27 (2), 155−159.
6.7.
1979
Viigimaa, Margus (1979). Müokardiinfarkti morfogenees ja tüsistused : referatiivne võistlustöö. Tartu: Tartu Riiklik Ülikool.
25.08.2019

Margus Viigimaa

https://www.etis.ee/CV/Margus_Viigimaa/eng
24.04.1958
5110070
margus@cb.ttu.ee
http://
I am lecturing, carrying out practical lessons and examinations in Tallinn University of Technology and Tartu University. I have developed these teaching subjects and implemented clinical and biotechnological elements. In autumn semesters the subject have been "Human anatomy and diseases", 6.0 EAP and "Health technologies", &.0 EAP.
In spring semesters the subject is "Physiological regulation and adaptation", 6.0 EAP.
In 2007 I was awarded the best lecturer of the Tallinn University of Technology.

Career

Institutions and positions
01.01.2017–...   
Tallinn University of Technology , School of Information Technologies, Department of Health Technologies, Professor (0,50)
01.01.2011–...   
Research chief of the Centre of Cardiology, North Estonia Medical Centre
1982-1991 Researcher of the Laboratory of Clinical Physiology, University of Tartu; 1991-1996 Head of the Laboratory of Clinical Physiology, University of Tartu; 1996-2004 Ass. Prof. of the Clinic of Cardiology, University of Tartu; since 2005 Estonian Institute of Cardiology, Head of the Department, Tallinn University of Technology, Professor.
01.01.2017–31.12.2018   
Tallinn University of Technology , School of Information Technologies, Department of Health Technologies, Senior Researcher (0,35)
01.09.2014–31.12.2016   
Tallinn University of Technology , Technomedicum of TUT, Centre of Cardiology , Professor (0,50)
01.03.2014–31.12.2016   
Tallinn University of Technology , Technomedicum of TUT, Department of Biomedical Engineering, Researcher (0,50)
01.03.2014–31.08.2014   
Tallinn University of Technology , Technomedicum of TUT, Centre of Cardiology , Visiting professor, Director (0,50)
01.09.2010–28.02.2014   
Tallinn University of Technology , Technomedicum of TUT, Department of Biomedical Engineering, Chair of Biomedical Engineering, Visiting professor (0,50)
2005–31.08.2010   
Tallinn University of Technology , Technomedicum of TUT, Department of Biomedical Engineering, Chair of Medical Physics, Professor (0,50)
01.01.2004–31.12.2011   
Head of the Centre of Cardiology, North Estonia Medical Centre
1996–2004   
University of Tartu, Faculty of Medicine, Associate Professor (1,00)
 
 
Education
01.01.1976–...   
University of Tartu 1982 - MD, Kaunas Medical Academy (Lithuania) 1989 - candidate of medical sciences, University of Tartu 1994 - PhD (cardiology), Postdoctoral research in the Kyoto University (Japan) 1990-1991
1976–1982   
 
 
R&D related managerial and administrative work
2018−...   
President of the Baltic Atherosclerosis Society
2018−...   
Council member of the Estonian Healthcare Museum
2015−...   
Estonian Society of Cardiology, Board member
2007−...   
Member of the research grant commission of the European Society of Hypertension
2006−...   
Member of the Editorial Board of the Journal "Vererõhk" (Blood Pressure)
2005−...   
National CVD Prevention Coordinator of the European Society of Cardiology
2005−...   
Member of the Tallinn City Health Council
2001−...   
Editorial board member of the journal "Vererõhk"
2000−...   
2000 X European Meeting on Hypertension, Tallinn Satellite Conference (main organiser)
1998−...   
Estonian WHO CINDI Programme Director
1995−...   
Founder, first President and Board member of the Estonian Society of Hypertension
Member of the Board of the Estonian Society of Hypertension (since 2000)
Meeting organisation:
1995 Estonian I Heart Health Conference in Tallinn (main organiser)
1996 Estonian II Heart Health Conference in Tallinn (main organiser)
1996 Estonian Cardiology Conference (main organiser)
1997 Estonian III Heart Health Conference in Tallinn (main organiser)
1997 Baltic Cardiology Conference in Palanga (main organiser)
1997 Estonian-Finnish Hypertension meeting in Tallinn (main organiser)
2001 II Baltic-Nordic Meeting on Hypertension in Riga (co-organiser)
2001 II Baltic Atherosclerosis Congress in Vilnius (co-organiser)
2004 III Baltic Atherosclerosis Congress in Riga (co-organiser)
2005 III Baltic-Nordic Meeting on Hypertension in Vilnius (co-organiser)
2015−2018   
Estonian Research Council, Member of the Evaluation Council
2015−2015   
President of the XXV Nordic-Baltic Cardiology Congress
2013−2015   
President of the Estonian Society of Cardiology
2010−2010   
Chairman of the Baltic Hypertension Congress
2009−2011   
GSK Doctors Education Foundation grant council member
2007−2007   
Chairman of the Baltic Atherosclerosis Congress in Tallinn
2007−2010   
President of the Baltic Atherosclerosis Society
2005−2013   
Editorial board member of the "Journal of Hypertension"
2005−2013   
Board member of the European Society of Hypertension
2004−2007   
President-Elect of the Baltic Society of Atherosclerosis
2003−2005   
Past-President of the Estonian Society of Cardiology
2003−2003   
2003 I Baltic Cardiology Conference in Pärnu (main organiser)
2003−2005   
Chairman of the research grant commission of the Estonian Society of Cardiology
2002−2006   
Member of the Credentials Committee, European Society of Cardiology
2002−2009   
Editor of the joint Baltic journal “Seminars in Cardiology”
2001−2001   
Chairman of the task force of the Estonian Lipid Guidelines
1999−1999   
Chairman of the task force of the Estonian Hypertension Guidelines
1998−1998   
1998 I Baltic-Nordic Meeting on Hypertension in Tallinn (main organiser)
1998−1998   
1998 I Baltic Lipid Conference in Tallinn (main organiser)
1997−1997   
1997 31. Conference of the European Society for Clinical Research in Kiel (co-organiser)
1997−2000   
Founder and the first President of the Baltic Atherosclerosis Society
1997−2000   
Chief editor of the "Baltic Atherosclerosis Journal"
1995−1995   
1995 Conference of the International Society of Hypertension (main organiser)

Qualifications

Academic degrees
Margus Viigimaa, Doctor's Degree, 1994, (sup) Rein Teesalu, Müokardiinfarkti antiagregant- ja antikoagulantravi (Müokardiinfarkti antiagregant- ja antikoagulantravi), University of Tartu.
 
 
Honours & awards
2018, Margus Viigimaa, Estonian Conference Ambassador
2018, Margus Viigimaa, Estonian Health Friend of the year
2016, Margus Viigimaa, Tallinn Order of honor
2015, Margus Viigimaa, Scientist of the year of the Tallinn University of Technology
2015, Margus Viigimaa, Fellow of the American College of Cardiology
2013, Margus Viigimaa, Gold medallion of the Ukraine Academy of Medical Sciences
2012, Margus Viigimaa, Honorary member of the Hungarian Society of Hypertension
2012, Margus Viigimaa, Honorary Member of the Association of Cardiologists of Kazakhstan
2008, Margus Viigimaa, Honorary member of the Bulgarian Hypertension League
2007, Margus Viigimaa, Red Cross III class Service Order of the Republic of Estonia
2004, Margus Viigimaa, European Hypertension Specialist
2001, Margus Viigimaa, Fellow of the European Society of Cardiology
2000, Margus Viigimaa, Honorary Member of the Swedish Society of Hypertension
 
 
Fields of research
ETIS CLASSIFICATION: 3. Health; 3.7. Clinical Medicine
 
 
Additional information
Candidate of Medical Sciences
PhD (cardiology)
Kaunas Medical Academy (Lithuania) 1989
University of Tartu 1994(cardiology).
European Hypertension Specialist 2004
Fellow of the American College of Cardiology 2015
Head of the European Hypertension Excellence Centre 2006

Projects in progress

Completed projects

Dissertations under supervision

Supervised dissertations

Publications

Category
Year
Publication
 
1.1.
2020
Viigimaa, M.; Sachinidis, A.; Toumpourleka, M.; Koutsampasopoulos, K.; Alliksoo, S.; Titma, T. (2020). Macrovascular complications of type 2 diabetes mellitus. Current Vascular Pharmacology, 18 (2), 110−116.10.2174/1570161117666190405165151.
1.1.
2019
Titma, T.; Shin, M-J.; Ludwig, C.; Günther, U.; Pikta, M.; Zemtsovskaja, G.; Viigimaa, M.; Tanner, R.; Samoson, A. (2019). The metabolic profile of stable ischemic heart disease by serum 1H NMR. Applied Magnetic Resonance, 50 (4), 527−539.10.1007/s00723-018-1084-0.
1.1.
2019
Einstein, S.; Pilt, K.; Palmar, M.; Meigas, K.; Viigimaa, M. (2019). Aortic Augmentation Index is Dependent on Bodyside in Healthy Young Subjects. High Blood Pressure & Cardiovascular Prevention.10.1007/s40292-019-00335-3.
5.1.
2019
Zemtsovskaja, G.; Pilt, K.; Abina, J.; Meigas, K.; Viigimaa, M. (2019). The Association Of Pulse Wave Velocity With Blood Pressure And Biochemical Cardiovascular Risk Markers In Young Tallinn Adults. Atherosclerosis, 287. Elsevier, e167−e168.10.1016/j.atherosclerosis.2019.06.506.
1.1.
2018
Pikta, M.; Zemtsovskaja, G.; Bautista, H.; Nouadje, G.; Szanto, T.; Viigimaa, M.; Banys, V. (2018). Preclinical evaluation of a semi-automated and rapid commercial electrophoresis assay for von Willebrand factor multimers. Journal of clinical laboratory analysis.10.1002/jcla.22416.
1.1.
2018
Vallejo-Vaz, A. J.; De Marco, M.; Stevens, C. A. T.; Akram, A.; Freiberger, T.; Hovingh, G. K.; Kastelein, J. J. P.; Mata, P.; Raal, F. J.; Santos, R. D.; Soran, H.; Watts, G. F.; Abifadel, M.; Aguilar-Salinas, C. A.; Al-Khnifsawi, M.; AlKindi, F. A.; Alnouri, F.; Alonso, R.; Al-Rasadi, K.; Al-Sarraf, A. ... Ray, K. K. (2018). Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). Atherosclerosis, 277, 234−255.10.1016/j.atherosclerosis.2018.08.051.
1.1.
2018
Viigimaa, M.; Heinsar, S.; Lovic, D.; Katsimardou, A.; Piperidou, A.; Duishvili, D. (2018). New horizons in the pathogenesis, pathophysiology and treatment of familial hypercholesterolaemia. Current Pharmaceutical Design.10.2174/1381612824666181009105305.
1.1.
2018
Talvik, A.; Rebora, P.; Heinpalu-Kuum, M.; Salerno, S.; Miszkowska-Nagórna, E.; Liu, X.; Comotti, T.; Świerblewska, E.; Valsecchi, M. G.; Fadl Elmula, F. E. M.; Larstorp, A. C.; Narkiewicz, K.; Parati, G.; Laurent, S.; Viigimaa, M. (2018). Non-invasive hemodynamic monitoring as a guide to drug treatment of uncontrolled hypertensive patients: effects on home blood pressure in the BEAUTY study. Blood Pressure, 27 (6), 368−375.10.1080/08037051.2018.1505425.
1.1.
2018
Sammul, S.; Viigimaa, M. (2018). Rapid socio-economic changes, psychosocial factors and prevalence of hypertension among men and women aged 55 years at baseline in Estonia: a 13-year follow-up study. Blood Pressure, 27 (6), 351−357.10.1080/08037051.2018.1476054.
3.1.
2018
Titma, T.; Günther, U.L; Ludwig, C.; Pikta, M.; Zemtsovskaja, G.; Shin, M.-J.; Viigimaa, M.; Tanner, R.; Samoson, A. (2018). The metabolic pattern could be used for early detection of stable ischemic heart disease and hypertensive heart disease. Revue d’Épidémiologie et de Santé Publique. Epidemiology and Public Health., 66: EUROEPI2018, Lyon, France;. Academic Press Inc Elsevier Science, S328. (S5; iii).10.1016/j.respe.2018.05.243.
3.1.
2018
Pilt, K.; Silluta, S.; Palmar, M.; Karai, D.; Meigas, K.; Viigimaa, M. (2018). Second derivative photoplethysmographic signal analysis of differences between fingers in healthy subjects. 2018 16th Biennial Baltic Electronics Conference (BEC): 16th Biennial Baltic Electronics Conference (BEC), Tallinn, 8-10 Oct. 2018. IEEE, 1−4.10.1109/BEC.2018.8600985.
5.2.
2018
Titma, T.; Günther, U. L.; Ludwig, C.; Pikta, M.; Zemtsovskaja, G.; Shin, M.-J.; Viigimaa, M.; Tanner, R.; Samoson, A. (2018). The metabolic profile of ischemic heart disease patients with or without previous MI by serum 1H NMR is similar. Eesti Arst, 97: 7th Baltic Atherosclerosis Congress, Tallinn, Estonia on April 6-7, 2018. Celsius Healthcare OÜ, 47−48. (Lisa 1).
5.2.
2018
Titma, T.; Shin, M.-J.; Ludwig, C.; Günther, U. L.; Pikta, M.; Zemtsovskaja, G.; Viigimaa, M.; Tanner, R.; Samoson, A. (2018). The metabolic pattern could be useful for better understanding of the etiology of cardiovascular diseases. 1st Nordic Metabolomics Conference, Örebro, Sweden: 1st Nordic Metabolomics Conference, Örebro (Sweden), 26.-28. August 2018. Örebro Universitet: Örebro University, 92−93.
5.2.
2018
Pikta, M.; Kütt, M.; Schneider, S.; Zolotarjova, V.; Viigimaa, M.; Marandi, T.; Arjakse, J.; Banys, V. (2018). Qualitative screening of DOAC-induced anticoagulation in emergency clinical situations. Clinical Chemistry and Laboratory Medicine (CCLM), 56(11):: 5th EFLM-UEMS European Joint Congress in Laboratory Medicine: Laboratory Medicine at the Clinical Interface Antalya, Turkey, October 10-13, 2018. Ed. Gillery, P.; Lackner, K. J.; Lippi, G.; Melichar, B.; Payne, D. A.; Schlattmann, P.; Tate, J. R. European Federation of Clinical Chemistry and Laboratory Medicine (EFLM, eA303 .10.1515/cclm-2018-1038.
1.1.
2017
Ferrari, Roberto; Aguiar, Carlos; Alegria, Eduardo; Bonadonna, Riccardo C; Cosentino, Francesco; Elisaf, Moses; Farnier, Michel; Ferrières, Jean; Filardi, Pasquale Perrone; Hancu, Nicolae; Kayikcioglu, Meral; Mello E Silva, Alberto; Millan, Jesus; Reiner, Željko; Tokgozoglu, Lale; Valensi, Paul; Viigimaa, Margus; Vrablik, Michal; Zambon, Alberto; Zamorano, José Luis ... Catapano, Alberico L (2017). Current practice in identifying and treating cardiovascular risk, with a focus on residual risk associated with atherogenic dyslipidaemia. European heart journal supplements : journal of the European Society of Cardiology, 18 (Suppl C), C2−C12.10.1093/eurheartj/suw009.
1.1.
2017
Kaldmäe, Margit; Zemtsovskaja, Galina; Abina, Jelena; Land, Tiit; Viigimaa, Margus (2017). Prevalence of cardiovascular disease risk factors in Tallinn, Estonia. Medicina, 53 (4), 268−276.10.1016/j.medici.2017.07.002.
1.1.
2017
Giugliano, R. P.; Mach, F.; Zavitz, K.; Kurtz, C.; Im, K.; Viigimaa, M. et al. (2017). Cognitive Function in a Randomized Trial of Evolocumab. New England Journal of Medicine, 377, 633−643.10.1056/NEJMoa1701131.
1.1.
2017
Sabatine, M. S.; Giugliano, R. P.; Keech, A.C.; Honarpour, N.; Viigimaa, M. et al (2017). Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. New England Journal of Medicine, 376, 1713−1722.10.1056/NEJMoa1615664.
1.3.
2017
Viigimaa, M. (2017). Revolutsioon ateroskleroosi ravis: LDL-kolesterooli sisalduse maksimaalne vähendamine bioloogilise raviga. Eesti Arst, 96(4), 233−237.
1.3.
2017
Viigimaa, M. (2017). Kas 2017. aasta muudab hüpertensiooni ravi eesmärkväärtusi? Eesti Arst, 96(3), 161−164.
3.1.
2017
Pilt, K.; Silluta, S.; Kööts, K.; Karai, D.; Meigas, K.; Viigimaa, M. (2017). Investigation of photoplethysmographic signal augmentation index estimation differences between fingers. EMBEC & NBC 2017: Joint conference of the European Medical and Biological Engineering Conference (EMBEC) and the Nordic-Baltic Conference on Biomedical Engineering and Medical Physics (NBC), Tampere, Finland, in 11-15 June 2017. _EditorsAbbr Eskola H., Väisänen O., Viik J., Hyttinen J. Springer, 819−822. (IFMBE Proceedings; 65).10.1007/978-981-10-5122-7_205.
3.1.
2017
Silluta, S.; Pilt, K.; Elja, B.; Kööts, K.; Meigas, K.; Viigimaa, M. (2017). Stroke volume assessment by impedance cardiography: Comparative analysis with transthoracic echocardiography. EMBEC & NBC 2017: Joint conference of the European Medical and Biological Engineering Conference (EMBEC) and the Nordic-Baltic Conference on Biomedical Engineering and Medical Physics (NBC), Tampere, Finland, in 11-15 June 2017. _EditorsAbbr Eskola H., Väisänen O., Viik J., Hyttinen J. Springer, 398−401. (IFMBE Proceedings; 65).10.1007/978-981-10-5122-7_100.
5.2.
2017
Shin, M.; Titma, T.; Ludwig, C.; Günther, U. L.; Pikta, M.; Zemtsovskaja, G.; Viigimaa, M.; Tanner, R.; Samoson, A. (2017). The Metabolic Profile of Ischemic Heart Disease by Serum 1H NMR. The Toxicologist: Late-Breaking Supplement, a supplement of Toxicological Sciences, 151: 56th Annual Meeting of the Society of Toxicology. US: Oxford University Press, 154. (1; 2).
5.2.
2017
Pikta, M.; Saks, K.; Lepik, K.; Zemtsovskaja, G.; Villemson, K.; Bautista, H.; Nouadje, G.; Viigimaa, M.; Banys, V. (2017). Assessment of biological response to desmopressin using von willebrand factor multimers analysis. Clinical Chemistry and Laboratory Medicine, 55, .S727.
1.1.
2016
Zanchetti, Alberto; Liu, Lisheng; Mancia, Giuseppe; Parati, Gianfranco; Grassi, Guido; Stramba-Badiale, Marco; Silani, Vincenzo; Bilo, Grzegorz; Corrao, Giovanni; Zambon, Antonella; Scotti, Lorenza; Zhang, Xinhua; Guan, Ting Rui; Zhang, Yuqing; Zhang, Xuezhong; Berge, Eivind; Redon, Josep; Narkiewicz, Krzysztof; Dominiczak, Anna; Nilsson, Peter ... , (2016). Continuation of the ESH-CHL-SHOT trial after publication of the SPRINT: rationale for further study on blood pressure targets of antihypertensive treatment after stroke. Journal of Hypertension, 34 (3), 393−396.10.1097/HJH.0000000000000853.
1.1.
2016
Vedin, Ola; Hagström, Emil; Budaj, Andrzej; Denchev, Stephan; Harrington, Robert A; Koenig, Wolfgang; Soffer, Joseph; Sritara, Piyamitr; Stebbins, Amanda; Stewart, Ralph Ha; Swart, Henk P; Viigimaa, Margus; Vinereanu, Dragos; Wallentin, Lars; White, Harvey D; Held, Claes (2016). Tooth loss is independently associated with poor outcomes in stable coronary heart disease. European Journal of Preventive Cardiology, 23 (8), 839−846.10.1177/2047487315621978.
1.1.
2016
Catapano AL, Graham I, De Backer G, Wiklund O, Viigimaa M, et al (2016). 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. European Heart Journal, 37 (39), 2999−3058.
1.1.
2016
Wallentin L, Held C, Armstrong PW, Cannon CP, Davies RY, Viigimaa M, et al. (2016). Lipoprotein-Associated Phospholipase A2 Activity Is a Marker of Risk But Not a Useful Target for Treatment in Patients With Stable Coronary Heart Disease. Journal of the American Heart Association, e003407−e003407.
1.1.
2016
Aguiar C, Alegría E, Bonnadonna RC, Catapano AL, Consentido F, Viigimaa M, et al. (2016). Versión Española del Grupo de trabajo sobre Dislipemia Aterogénica. Clínica e Investigación en Arteriosclerosis, 87−93.
1.1.
2016
Pattaro, Cristian; Teumer, Alexander; Gorski, Mathias; Chu, Audrey Y; Li, Man; Mijatovic, Vladan; Garnaas, Maija; Tin, Adrienne; Sorice, Rossella; Li, Yong; Taliun, Daniel; Olden, Matthias; Foster, Meredith; Yang, Qiong; Chen, Ming-Huei; Pers, Tune H; Johnson, Andrew D; Ko, Yi-An; Fuchsberger, Christian; Tayo, Bamidele ... Fox, Caroline S (2016). Genetic associations at 53 loci highlight cell types and biological pathways relevant for kidney function. Nature Communications, 7 (10023), 10023−10023.10.1038/ncomms10023.
1.1.
2016
Galina Zemtsovskaja, Andrei Samarin, Jelena Abina, Kalju Meigas, Margus Viigimaa (2016). Determinants and a Predictive Equation for the Aortic Length Estimation. International Journal of Innovative Research in Science, Engineering and Technology, 5 (3), 3336−3350.DOI:10.15680/IJIRSET.2016.0503115.
1.1.
2016
Lankin, V. Z; Konovalova, G. G; Tikhaze, A. K; Shumaev, K. B; Belova Kumskova, E. M; Grechnikova, M. A; Viigimaa, M. (2016). Aldehyde inhibition of antioxidant enzymes in the blood of diabetic patients. Journal of Diabetes, 8 (3), 398−404.10.1111/1753-0407.12309.
1.1.
2016
Ferrari, R.; Aguiar, C.; Alegria, E.; Bonadonna, R.C.; Cosentino, F.; Elisaf, M.; Farnier, M.; Ferrières, J.; Filardi, P.P.; Hancu, N.; Kayikcioglu, M.; Mello E Silva, A.; Millan, J.; Reiner, Z.; Tokgozoglu, L.; Valensi, P.; Viigimaa, M.; Vrablik, M.; Zambon, A.; Zamorano, J.L. ... (2016). Current practice in identifying and treating cardiovascular risk, with a focus on residual risk associated with atherogenic dyslipidaemia. European Heart Journal, Supplement, 18, C2−C12.10.1093/eurheartj/suw009.
1.2.
2016
Misjuk, Mikola; Kaldmäe, Margit; Annuk, Margus; Viigimaa, Margus (2016). CHARACTERISTICS OF LEISURE SPORTS ACTIVITY IN A POPULATION WITH HIGH CARDIOVASCULAR DISEASE MORTALITY. Baltic Journal of Health and Physical Activity, 8 (1), 7−17.
1.3.
2016
Viigimaa M (2016). Traditsioonilised ja uued ravimid aterogeense düslipideemia ravis. Eesti Arst, 299−306.
1.3.
2016
Pikta, M.; Zolotareva, V.; Tõnne, J.; Viigimaa, M.; Banys, V. (2016). Implementation and Verification of New VWF:Ac Assay System with Components from Different Manufacturers. Laboratorine Medicina, 4, 185−188.
1.3.
2016
Lilles, Eli (2016). Uudiseid AHA kongressilt: hüpertensiooni ravi peaks enamikul patsientidest olema agressiivsem. Perearst, (2016) jaanuar, lk. 19-23 : foto, 19−23.
1.3.
2016
Viigimaa, Margus (2016). Huvitavat AHA kongressist. Perearst, (2016) detsember, lk. 73-77 : foto, 73−77.
5.1.
2016
Pikta, M.; Tõnne, J.; Tirkkonen, N.; Zolotarjova,V.; Titova, T.; Marandi, T.; Arjakse, J.; Viigimaa, M. (2016). Rivaroxaban: evaluation of analytical performance. Clin Chem Lab Med 2016; 54(10): eA259–eA260. De Gruyter, .DOI10.1515/cclm-2016-0657.
5.1.
2016
Galina Zemtsovskaja, Julia Borissova, Küllike Palk, Ulvi Sorro, Katrin Gross-Paju, Vadim Brjalin, Mihhail Zemtsovski, Katrin Nõukas, Katrin Eino, Katrin Tammeväli, Viive Pille, Katrin Rebane, Kristi Lepik, Merike Luman, Margus Viigimaa (2016). The importance of front-line tests in diagnosis of porphyrias: 12 years of experience in North Estonia Medical Centre. Clinical Chemistry and Laboratory Medicine (CCLM): The 4th Joint EFLM-UEMS Congress “Laboratory Medicine at the Clinical Interface” Warsaw, Poland, 21th–24th September, 2016. De Gruyter: De Gruyter, 143. ( Volume 54; Issue 10).DOI:10.1515/cclm-2016-0657.
5.1.
2016
Galina Zemtsovskaja, Mihhail Zemtsovski, Merike Luman, Margus Viigimaa (2016). Lipid profile in a patient with familial hyperlipidemia during 18 years of treatment. Clinical Chemistry and Laboratory Medicine (CCLM): The 4th Joint EFLM-UEMS Congress “Laboratory Medicine at the Clinical Interface” Warsaw, Poland, 21th–24th September, 2016. De Gruyter, 72. (Volume 54, Issue 10).DOI:10.1515/cclm-2016-0657.
5.2.
2016
Zemtsovskaja, Galina; Pikta, Marika; Borissova, Julia; Palk, Küllike; Sorro, Ulvi; Gross-Paju, Katrin; Brjalin, Vadim; Zemtsovski, Mihhail; Nõukas, Katrin; Eino, Katrin; Tammeväli, Katrin; Pille, Viive; Lotkova, Olga; Lepik, Kristi; Luman, Merike; Viigimaa, Margus (2016). Brain-to-brain loop concept in application to porphyrias: 10-year experience at North Estonia Medical Centre. Eesti Arst, 95 (Supplement 1). Eesti Arst, 61.
5.2.
2016
Zemtsovskaja, Galina; Pikta, Marika; Borissova, Julia; Palk, Küllike; Sorro, Ulvi; Gross-Paju, Katrin; Brjalin, Vadim; Zemtsovski, Mihhail; Nõukas, Katrin; Eino, Katrin; Tammeväli, Katrin; Pille, Viive; Lotkova, Olga; Lepik, Kristi; Luman, Merike; Viigimaa, Margus (2016). Investigation of porphyrias: 10-year experience at the North Estonia Medical Centre. Eesti Arst, 95 (Supplement 1), 61.
6.6.
2016
Viigimaa, M. (2016). ACC konverents: ülevaade värsketest arengutest kardioloogias. Perearst, (2016) mai, lk. 69-71 : foto, 69−71.
1.1.
2015
Fadl Elmula, Fadl Elmula M; Rebora, Paola; Talvik, Anneli; Salerno, Sabrina; Miszkowska-Nagórna, Eliza; Liu, Xiaoqiu; Heinpalu-Kuum, Marika; Comotti, Tommaso; Larstorp, Anne C; Rostrup, Morten; Świerblewska, Ewa; Valsecchi, Maria Grazia; Kjeldsen, Sverre E; Viigimaa, Margus; Narkiewicz, Krzysztof; Parati, Gianfranco; Laurent, Stéphane (2015). A randomized and controlled study of noninvasive hemodynamic monitoring as a guide to drug treatment of uncontrolled hypertensive patients. Journal of Hypertension, 33 (12), 2534−2545.10.1097/HJH.0000000000000749.
1.1.
2015
Lankin, Vadim Z; Konovalova, Galina G; Tikhaze, Alla K; Shumaev, Konstantin B; Belova Kumskova, Elena M; Grechnikova, Maria A; Viigimaa, Margus (2015). Aldehyde inhibition of antioxidant enzymes in the blood of diabetic patients. Journal of Diabetes, 1−7.10.1111/1753-0407.12309.
1.1.
2015
Huffman, JE; Albrecht, E; Teumer, A; Mangino, M; Kapur, K; Johnson, T; Kutalik, Z; Pirastu, N; Pistis, G; Lopez, LM; Haller, T; Salo, P; Goel, A; Li, M; Tanaka, T; Dehghan, A; Ruggiero, D; Malerba, G; Smith, AV; Nolte, IM ... Vitart, V. (2015). Modulation of genetic associations with serum urate levels by body-mass-index in humans. PLoS ONE, 3, e0119752−e0119752.10.1371/journal.pone.0119752.
1.1.
2015
Locke, AE.; Kahali, B.; Berndt, SI.; Justice, AE.; Pers, TH.; Day, FR.; Powell, C.; Vedantam, S.; Buchkovich, ML.; Yang, J.; Croteau-Chonka, DC.; Esko, T.; Fall, T.; Ferreira, T.; Gustafsson, S.; Kutalik, Z.; Luan, J.; Mägi, R.; Randall, JC.; Winkler, TW. ... Speliotes, EK. (2015). Genetic studies of body mass index yield new insights for obesity biology. Nature, 518 (7538), 197−206.10.1038/nature14177.
1.1.
2015
Aguiar, Carlos; Alegria, Eduardo; Bonadonna, Riccardo C; Catapano, Alberico L; Cosentino, Francesco; Elisaf, Moses; Farnier, Michel; Ferrières, Jean; Filardi, Pasquale Perrone; Hancu, Nicolae; Kayikcioglu, Meral; Mello E Silva, Alberto; Millan, Jesus; Reiner, Željko; Tokgozoglu, Lale; Valensi, Paul; Viigimaa, Margus; Vrablik, Michal; Zambon, Alberto; Zamorano, José Luis ... Ferrari, Roberto (2015). A review of the evidence on reducing macrovascular risk in patients with atherogenic dyslipidaemia: A report from an expert consensus meeting on the role of fenofibrate-statin combination therapy. Atherosclerosis. Supplements, 19, 1−12.10.1016/S1567-5688(15)30001-5.
2.3.
2015
Kaldmäe, Margit; Viigimaa, Margus; Land, Tiit; Annuk, Margus (2015). Biomarkers for cardiovascular disease in Estonian adults. (Doktoritöö, Tallinna Ülikool). Tallinn: Tallinna Ülikool.
3.1.
2015
Pilt, Kristjan; Kööts, Kristina; Meigas, Kalju; Šamarin, Andrei; Zemtsovskaja, Galina; Viigimaa, Margus (2015). The Aortic Pulse Wave Velocity Estimation for Arterial Stiffness Assessment. IFMBE Proceedings, 45: MBEC 2014, Dubrovnik, 7-11 September 2014. IFMBE, 294−297.
3.1.
2015
Pilt, K.; Leier, M.; Silluta, S.; Koots, K.; Meigas, K.; Viigimaa, M. (2015). Pulse wave registration from radial artery using photoplethysmographic method. 37th Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC): 37th Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC), Milan, Italy, 25-29 August 2015. IEEE, 6425−6428.10.1109/EMBC.2015.7319863.
4.1.
2015
Viigimaa, Margus; Vlachopoulos, Charalambos; Doumas, Michael (2015). Erectile dysfunction in hypertension and cardiovascular disease : a guide for clinicians. Cham [etc.]: Springer.
5.1.
2015
Tikhaze, A.; Lankin, V.; Konovalova, G.; Zemtsovskaja, G.; Pikta, M.; Viigimaa, M. (2015). A common molecular mechanism of vascular wall injure in atherosclerosis and diabetes. Cardiology 2015;131(suppl 1). 43−44.DOI:10.1159/000431390.
5.1.
2015
Pikta, M.; Zemtsovskaja, G.; Zemtsovski, M.; Duishvili, D.; Tikhaze, A., Lankin, V.; Viigimaa, M. (2015). Level of plasma coenzyme Q10 in patients on statin treatment. Cardiology 2015;131(suppl 1). 36.DOI:10.1159/000431390.
5.1.
2015
Zemtsovski, M.; Zemtsovskaja, G; Pikta, M; Luman, M;Viigimaa, M (2015). Benefit from lipoprotein apheresis in severe case of coronary heart disease patient with high level of lipoprotein (a). Cardiology, 131 (Suppl 1), 35−36.
5.1.
2015
Pikta, M.; Viigimaa, M.; Pilt, K.; Kööts, K.; Meigas, K. (2015). Early diagnosis of cardiovascular diseases using Arteriograph (TensioMed, Hungary). Cardiology 2015;131(suppl 1). 32.DOI:10.1159/000431390.
5.1.
2015
Zemtsovskaja, G.; Zemtsovski, M.; Abina, J.; Samarin, A.; Meigas, K.; Viigimaa, M. (2015). Correlation between aortic stiffness and conventional risk factors with coronary atherosclerosis. Cardiology, 131 (Suppl 1) (1), 39−P-31.
1.1.
2014
Fox, K.; Ford, I.; Steg, P.G.; Tardif, J-C.; Viigimaa, M et al. (2014). Ivabradine in stable coronary artery disease without clinical heart failure. New England Journal of Medicine, 371(12):1091−1099.
1.1.
2014
Jensen-Urstad, Mats; Viigimaa, Margus; Sammul, Sirje; Lenhoff, Hanna; Johansson, Jan (2014). Impact of smoking: All-cause and cardiovascular mortality in cohort of 55-year-old Swedes and Estonians. Scandinavian Journal of Public Health, 42(8):780−785.
1.1.
2014
Ryden, L.; Grant, PJ.; Anker, SD.; Berne, C.; Cosentino, F.; Danchin, N.; Deaton, C.; Escaned, J.; Hammes, HP.; Huikuri, H.; Marre, M.; Marx, N.; Mellbin, L.; Ostergren, J.; Patrono, C.; Seferovic, P.; Sousa, M.; Taskinen, MR.; Tendera, M.; Tuomilehto, J. ... Xuereb, RG. (2014). ESC Guidelines on diabetes, pre- diabetes, and cardiovascular diseases developed in collaboration with the EASD - Summary. Diabetes and Vascular Disease Research, 11, 133−173.10.1177/1479164114525548.
1.1.
2014
Kaldmäe, Margit; Viigimaa, Margus; Zemtsovskaja, Galina; Kaart, Tanel; Abina, Jelena; Annuk, Margus (2014). Prevalence and determinants of hypertension in Estonian adults. Scandinavian Journal of Public Health, 42 (6), 504−510.10.1177/1403494814532565.
1.1.
2014
White, HD.; Held, C.; Stewart, R.; Tarka, E.; Brown, R.; Davies, RY.; Budaj, A.; Harrington, RA.; Steg, PG.; Ardis-Sino, D.; Armstrong, PW.; Avezum, A.; Aylward, PE.; Bryce, A.; Chen, H.; Chen, MF.; Corbalan, R.; Dalby, AJ.; Danchin, N.; De Winter, RJ. ... Wallentin, L. (2014). Darapladib for Preventing Ischemic Events in Stable Coronary Heart Disease. New England Journal of Medicine, 370, 1702−1711.10.1056/NEJMoa1315878.
1.1.
2014
Zanchetti, A.; Liu, LS.; Mancia, G.; Parati, G.; Grassi, G.; Stramba-Badiale, M.; Silani, V.; Bilo, G.; Corrao, G.; Zambon, A.; Scotti, L.; Zhang, XH.; Wang, HY.; Zhang, YQ.; Zhang, XZ.; Guan, TR.; Berge, E.; Redon, J.; Narkiewicz, K.; Dominiczak, A. ... Ford, G. (2014). Blood pressure and LDL-cholesterol targets for prevention of recurrent strokes and cognitive decline in the hypertensive patient: design of the European Society of Hypertension-Chinese Hypertension League Stroke in Hypertension Optimal Treatment randomized trial. Journal of Hypertension, 32, 1888−1897.10.1097/HJH.0000000000000254.
1.1.
2014
Mancia, G.; Fagard, R.; Narkiewicz, K.; Redon, J.; Zanchetti, A.; Bohm, M.; Christiaens, T.; Cifkova, R.; De Backer, G.; Dominiczak, A.; Galderisi, M.; Grobbee, DE.; Jaarsma, T.; Kirchhof, P.; Kjeldsen, SE.; Laurent, S.; Manolis, AJ.; Nilsson, PM.; Ruilope, LM.; Schmieder, RE. ... Zannad, F. (2014). 2013 ESH/ESC Practice Guidelines for the Management of Arterial Hypertension. Blood Pressure, 23, 3−16.10.3109/08037051.2014.868629.
1.1.
2014
Pilt, Kristjan; Meigas, Kalju; Kööts, Kristina; Viigimaa, Margus (2014). Photoplethysmographic signal rising front analysis for the discrimination of subjects with increased arterial ageing. Proceedings of the Estonian Academy of Sciences, 63 (3), 221−226.10.3176/proc.2014.3.03.
1.1.
2014
Zanchetti, A.; Liu, LS.; Mancia, G.; Parati, G.; Grassi, G.; Stramba-Badiale, M.; Silani, V.; Bilo, G.; Corrao, G.; Zambon, A.; Scotti, L.; Zhang, XH.; Wang, HY.; Zhang, YQ.; Zhang, XZ.; Guan, TR.; Berge, E.; Redon, J.; Narkiewicz, K.; Dominiczak, A. ... Ford, G. (2014). Blood pressure and low-density lipoprotein-cholesterol lowering for prevention of strokes and cognitive decline: a review of available trial evidence. Journal of Hypertension, 32, 1741−1750.10.1097/HJH.0000000000000253.
1.1.
2014
Lankin, V.; Konovalova, G.; Tikhaze, A.; Shumaev, K.; Kumskova, E.; Viigimaa, M. (2014). The initiation of free radical peroxidation of low-density lipoproteins by glucose and its metabolite methylglyoxal: a common molecular mechanism of vascular wall injure in atherosclerosis and diabetes. Molecular and Cellular Biochemistry, 395, 241−252.10.1007/s11010-014-2131-2.
1.1.
2014
Viigimaa, Margus; Vlachopoulos, Charalambos; Lazaridis, Antonios; Doumas, Michael. (2014). Management of erectile dysfunction in hypertension: Tips and tricks. World Journal of Cardiology, 6, 908−15.10.4330/wjc.v6.i9.908.
1.1.
2014
Pilt, Kristjan; Meigas, Kalju; Ferenets, Rain; Temitski, Kristina; Viigima, Margus (2014). Photoplethysmographic signal waveform index for detection of increased arterial stiffness. Physiological Measurement, 35, 2027−2036.10.1088/0967-3334/35/10/2027.
1.1.
2014
Viigimaa, M.; Erglis, A.; Latkovskis, G.; Mäeots, E.; Petrulioniene, Z.; Slapikas, R.; Gocentiene, A.; Bramlage, P.; Brudi, P. (2014). Prevalence of dyslipidemia in statin-treated patients in the Baltic states (Estonia, Latvia, and Lithuania): Results of the Dyslipidemia International Study (DYSIS). Medicina-Lithuania, 50 (1), 44−53.10.1016/j.medici.2014.05.003.
1.1.
2014
Kristensen SD, Knuuti J, Saraste A, Anker S, Bøtker HE, Viigimaa M, et al. (2014). 2014 ESC/ESA Guidelines on non-cardiac surgery: cardiovascular assessment and management: The Joint Task Force on non-cardiac surgery: cardiovascular assessment and management of the European Society of Cardiology (ESC) and the European Society of Anaesthesiology (ESA). European Journal of Anaesthesiology, 517−573.
1.1.
2014
Kristensen SD, Knuuti J, Saraste A, Anker S, Bøtker HE, Viigimaa M, et al. (2014). 2014 ESC/ESA Guidelines on non-cardiac surgery: cardiovascular assessment and management: The Joint Task Force on non-cardiac surgery: cardiovascular assessment and management of the European Society of Cardiology (ESC) and the European Society of Anaesthesiology (ESA). European Heart Journal , 2383−2431.
1.3.
2014
Viigimaa, M. (2014). Mida on uut Ameerika äsja ilmunud südameveresoonkonnahaiguste preventsiooni juhendites? Eesti Arst, 103.
3.1.
2014
Viigimaa, Margus; Vlachopoulos, Charalambos; Doumas, Michael (2014). Erectile Dysfunction in Hypertension and Cardiovascular Disease. In: Viigimaa, Margus; Vlachopoulos, Charalambos; Doumas, Michael (_EditorsAbbr). Erectile Dysfunction in Hypertension and Cardiovascular Disease (1−249).. Springer.
3.1.
2014
Viigimaa, Margus (2014). Lifestyle Modification in Erectile Dysfunction and Hypertebnsion. In: Viigimaa, Margus; Vlachopoulos, Charalambos; Doumas, Michael (_EditorsAbbr). Erectile Dysfunction in Hypertension and Cardiovascular Disease (167−174).. Springer.
1.1.
2013
Pilt, Kristjan; Ferenets, Rain; Meigas, Kalju; Lindberg, Lars-Göran; Temitski, Kristina; Viigimaa, Margus (2013). New Photoplethysmographic Signal Analysis Algorithm for Arterial Stiffness Estimation. The Scientific World Journal, 2013, 9 pp.
1.1.
2013
Kottgen, A.; Albrecht, E.; Teumer, A.; Vitart, V.; Krumsiek, J.; Hundertmark, C.; Pistis, G.; Ruggiero, D.; O'Seaghdha, CM.; Haller, T.; Yang, Q.; Tanaka, T.; Johnson, AD.; Kutalik, Z.; Smith, AV.; Shi, JL.; Struchalin, M.; Middelberg, RPS.; Brown, MJ.; Gaffo, AL. ... Gieger, C. (2013). Genome-wide association analyses identify 18 new loci associated with serum urate concentrations. Nature Genetics, 45 (2), 145−154.10.1038/ng.2500.
1.1.
2013
Mancia, Giuseppe; Fagard, Robert; Narkiewicz, Krzysztof; Redon, Josep; Zanchetti, Alberto; Bohm, Michael; Christiaens, Thierry; Cifkova, Renata; De Backer, Guy; Dominiczak, Anna; Galderisi, Maurizio; Grobbee, Diederick E.; Jaarsma, Tiny; Kirchhof, Paulus; Kjeldsen, Sverre E.; Laurent, Stephane; Manolis, Athanasios J.; Nilsson, Peter M.; Ruilope, Luis Miguel; Schmieder, Roland E. ... Zannad, Faiez. (2013). The guidelines of ESH/ESC Guidelines for hypertension in 2013. Kardiologia polska, S27−S116.
1.1.
2013
Mancia, Giuseppe; Fagard, Robert; Narkiewicz, Krzysztof; Redon, Josep; Zanchetti, Alberto; Böhm, Michael; Christiaens, Thierry; Cifkova, Renata; De Backer, Guy; Dominiczak, Anna; Galderisi, Maurizio; Grobbee, Diederick E; Jaarsma, Tiny; Kirchhof, Paulus; Kjeldsen, Sverre E; Laurent, Stéphane; Manolis, Athanasios J; Nilsson, Peter M; Ruilope, Luis Miguel; Schmieder, Roland E ... Wood, David A. (2013). 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). European Heart Journal, 34 (28), 2159−2219.10.1093/eurheartj/eht151.
1.1.
2013
Mancia, Giuseppe; Fagard, Robert; Narkiewicz, Krzysztof; Redon, Josep; Zanchetti, Alberto; Boehm, Michael; Christiaens, Thierry; Cifkova, Renata; De Backer, Guy; Dominiczak, Anna; Galderisi, Maurizio; Grobbee, Diederick E.; Jaarsma, Tiny; Kirchhof, Paulus; Kjeldsen, Sverre E.; Laurent, Stephane; Manolis, Athanasios J.; Nilsson, Peter M.; Miguel Ruilope, Luis; Schmieder, Roland E. ... Windecker, Stephan. (2013). 2013 ESH/ESC Guidelines for the management of arterial hypertension. Blood Pressure, 193−278.10.3109/08037051.2013.812549.
1.1.
2013
Ryden, Lars; Grant, Peter J; Anker, Stefan D; Berne, Christian; Cosentino, Francesco; Danchin, Nicolas; Deaton, Christi; Escaned, Javier; Hammes, Hans-Peter; Huikuri, Heikki; Marre, Michel; Marx, Nikolaus; Mellbin, Linda; Ostergren, Jan; Patrono, Carlo; Seferovic, Petar; Uva, Miguel Sousa; Taskinen, Marja-Riita; Tendera, Michal; Tuomilehto, Jaakko ... Xuereb, Robert G. (2013). ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). European Heart Journal, 34, 3035−87.10.1093/eurheartj/eht108.
1.1.
2013
Doumas, M.; Viigimaa, M.; Papademetriou, V. (2013). Combined Antihypertensive Therapy and Sexual Dysfunction: Terra Incognita. Cardiology, 232−234.10.1159/000351696.
1.1.
2013
Mancia, G.; Fagard, R.; Narkiewicz, K.; Redon, J.; Zanchetti, A.; Bohm, M.; Christiaens, T.; Cifkova, R.; De Backer, G.; Dominiczak, A.; Galderisi, M.; Grobbee, DE.; Jaarsma, T.; Kirchhof, P.; Kjeldsen, SE.; Laurent, S.; Manolis, AJ.; Nilsson, PM.; Ruilope, LM.; Schmieder, RE. ... Zannad, F. (2013). 2013 ESH/ESC Guidelines for themanagement of arterial hypertension The Task Force for the management ofarterial hypertension of the European Society ofHypertension (ESH) and of the European Society of Cardiology (ESC). Journal of Hypertension, 1281−1357.
1.1.
2013
Mancia, G.; Fagard, R.; Narkiewicz, K.; Redon, J.; Zanchetti, A.; Bohm, M.; Christiaens, T.; Cifkova, R.; De Backer, G.; Dominiczak, A.; Galderisi, M.; Grobbee, DE.; Jaarsma, T.; Kirchof, P.; Kjeldsen, SE.; Laurent, S.; Manolis, AJ.; Nilsson, PM.; Ruilope, LM.; Schmieder, RE. ... Zannad, F. (2013). 2013 Practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC). Journal of Hypertension, 1925−1938.
1.1.
2013
Viigimaa M, Talvik A, Wojciechowska W, Kawecka-Jaszcz K, et al. (2013). Identification of the hemodynamic modulators and hemodynamic status in uncontrolled hypertensive patients. Blood Pressure, 362−370.10.3109/08037051.2013.782900.
1.1.
2013
Rydén L, Grant PJ, Anker SD, Berne C, Cosentino F, Danchin N,viigimaa M, et al. (2013). Grupa Robocza Europejskiego Towarzystwa Kardiologicznego (ESC). Kardiologia polska, 319−394.
1.1.
2013
Mancia, G.; Fagard, R.; Narkiewicz, K.; Redon, J.; Zanchetti, A.; Bohm, M.; Christiaens, T.; Cifkova, R.; De Backer, G.; Dominiczak, A.; Galderisi, M.; Grobbee, D.E.; Jaarsma, T.; Kirchhof, P.; Kjeldsen, S.E.; Laurent, S.; Manolis, A.J.; Nilsson, P.M.; Ruilope, L.M.; Schmieder, R.E. ... Zannad, F. (2013). The task force for the management ofarterial hypertension of the european society ofhypertension (esh) and of the european society of cardiology (esc). Journal of Hypertension, 31, 1281−1357.10.1097/01.hjh.0000431740.32696.cc.
1.1.
2013
Mancia, G.; Fagard, R.; Narkiewicz, K.; Redon, J.; Zanchetti, A.; Böhm, M.; Christiaens, T.; Cifkova, R.; Backer, G.D.; Dominiczak, A.; Galderisi, M.; Grobbee, D.E.; Jaarsma, T.; Kirchhof, P.; Kjeldsen, S.E.; Laurent, S.; Manolis, A.J.; Nilsson, P.M.; Ruilope, L.M.; Schmieder, R.E. ... Zannad, F. (2013). 2013 ESH/ESC clinical practice guidelines for the management of arterial hypertension. Revista Espanola de Cardiologia, 66, 880.e1−880.e4.10.1016/j.recesp.2013.07.016.
1.3.
2013
Viigimaa, Margus. (2013). Lipoproteiiniga seostunud fosfolipaas A2 kui uus sõltumatu kardiovaskulaarne riskitegur ja ravi sihtmärk. Eesti Arst, 92, 92−97.
3.1.
2013
Pilt, Kristjan; Meigas, Kalju; Temitski, Kristina; Viigimaa, Margus (2013). The effect of local cold and warm exposure on index finger photoplethysmographic signal waveform. Conference proceedings of the IEEE Engineering in Medicine and Biology Society (Conf. Proc. IEEE Eng. Med. Biol. Soc.): 35th Annual International Conference of the IEEE EMBS. IEEE, 2300−2303.
3.1.
2013
Pilt, Kristjan; Meigas, Kalju; Temitski, Kristina; Viigimaa, Margus (2013). The analysis of finger photoplethysmographic waveform in healthy volunteers and diabetes patients. IFMBE Proceedings, 38: International Symposium on Biomedical Engineering and Medical Physics, Riia, 10-12 Oktoober 2012. IFMBE, 55−58.
3.5.
2013
Pikta M., Zemtsovskaja G., Viigimaa M., Zemtsovski M., Metsik P. (2013). COMPLETE ATHERO PANEL TO DETERMINE RISK OF CORONARY ARTERY DISEASE. Abstract book: The 46th Nordic Coagulation Meeting: Tromsö.
1.1.
2012
Perk J, De Backer G, Gohlke H, Graham I, Reiner Ž, Viigimaa M, et al. (2012). European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). Turk Kardiyoloji Dernegi Arsivi, 1−76.
1.1.
2012
Okada, Y; Sim, X; Go, MJ; Wu, JY; Gu, D; Takeuchi, F; Takahashi, A; Maeda, S; Tsunoda, T; Chen, P; Lim, SC; Wong, TY; Liu, J; Young, TL; Aung, T; Seielstad, M; Teo, YY; Kim, YJ; Lee, JY; Han, BG ... Gieger, C. (2012). Meta-analysis identifies multiple loci associated with kidney function-related traits in east Asian populations. Nature Genetics, 44 (8), 904−909.10.1038/ng.2352.
1.1.
2012
Vaverkova, Helena; Viigimaa, Margus; Farnier, Michel; Averna, Maurizio; Missault, Luc; Dong, Qian; Shah, Arvind; Johnson-Levonas, Amy O.; Brudi, Philippe. (2012). Lipid-Altering Efficacy of Ezetimibe/Simvastatin 10/20 mg Compared to Rosuvastatin 10 mg in High-Risk Patients with and without Type 2 Diabetes Mellitus Inadequately Controlled Despite Prior Statin Monotherapy. Cardiovascular Therapeutics, 30 (2), 61−74.10.1111/j.1755-5922.2010.00181.x.
1.2.
2012
Viigimaa, M.; Doumas, M.; Vlacholpoulos, C. et al. (2012). Nadcisnienie tetnicze a zaburzenia czynnosci seksualnych: czas podjac dzialania. Choroby Serca i Naczyn, (9)1−6.
3.1.
2012
Temitski, Kristina; Lauri, Jaana; Pilt, Kristjan; Meigas, Kalju; Viigimaa, Margus (2012). Assessment of algorithms for detecting an arterial pulse pressure wave equiphase point. Conference Publications: 13th Biennial Baltic Electronics Conference (BEC), Tallinn, 3-5 Oktoober 2012. IEEE, 191−194.
3.1.
2012
Viigimaa, Margus; Lazaridis, Antonios; Doumas, Michael (2012). Management of sexual dysfunction in hypertensive patient. In: Ambrosioni, E:; Borghi, C. (_EditorsAbbr). Cardiology and Clinical Practice (53−60).. Springer.
3.1.
2012
Viigimaa, Margus;l Doumas, Michael (2012). Sexual function in untreated and treated hypertension. In: Berbari, Adel; Mancia, Giuseppe (_EditorsAbbr). Special Isues in Hypertension (389−399).. Springer.
3.1.
2012
Pilt, Kristjan; Meigas, Kalju; Temitski, Kristina; Viigimaa, Margus (2012). Second derivative analysis of forehead photoplethysmographic signal in healthy volunteers and diabetes patients. IFMBE Proceedings, 39: World Congress on Medical Physics and Biomedical Engineering, Peking, 26-31 Mai 2012. IFMBE, 410−413.
3.5.
2012
Pikta, M; Banys, V; Olovjankina, N; Viigimaa, M; Tõnne, J; Titova, T. (2012). Samples storage time influence on whole blood impedance aggregometry results. Abstract book: The 45th Nordic Coagulation Meeting: Stockholm.
6.4.
2012
Ehala-Aleksejev, Kristel; Ausmees, Kristo; Pomerants, Marko; Viigimaa, Margus (2012). Ülekaal ja mehe tervis. [Tartu]: Uomoprint.
6.7.
2012
Kalda, Ruth; Viigimaa, Margus; Irs, Alar; Meren, Mari; Uuetoa, Tiina; Luman, Merike; Muda, Piibe; Oona, Marje; Jaanson, Eret; Martinson, Katrin; Põldema, Ingrid; Ridaste, Kadri; Palm, Kairit; Habicht, Triin; Teeäär, Tuuli; Saluse, Janek; Kropotuhhina, Irina; Heidmets, Lenne-Triin; Laidmäe, Erki; Esnar, Kersti (2012). Täiskasvanute kõrgvererõhktõve käsitlus esmatasandil: Eesti ravijuhend. Eesti Haigekassa, Tartu Ülikool 2012.
1.1.
2011
Viigimaa, M.; Doumas, M.; Vlachopoulos, C. et al. (2011). Hypertension and sexual dysfunction: time to act. Journal of Hypertension, 403−407.
1.1.
2011
Grassi, G.; Cifkova, R.; Laurent, S.; Viigimaa, M., et al. (2011). Blood pressure control and cardiovascular risk profile in hypertensive patients from central and eastern European countries: results of the BP-CARE study. European Heart Journal, 218−225.
1.1.
2011
Averna, M.; Missault, L.; Vaverkova, H.; Farnier, M.; Viigimaa, M. et al. (2011). Lipid-altering efficacy of switching to ezetimibe/simvastatin 10/20 mg versus rosuvastatin 10 mg in hihg-risk patients with and without metabolic syndrome. Diabetes and Vascular Disease Research, 1−9.
1.1.
2011
Vaverkova, H.; Farnier, M.; Averna, M.; Missault, L.; Viigimaa, M.; Dong, Q.; Shah, A.; Johnson-Levonas, A.O.; Brudi, P. (2011). Switching from statin monotherapy to ezetimibe/simvastatin or rosuvastatin modifies the relationships between apolipoprotein B, LDL cholesterol, and non-HDL cholesterol in patients at high risk of coronary disease. Clinical Biochemistry, 44, 627−634.10.1016/j.clinbiochem.2011.02.008.
1.1.
2011
Kaldmäe, Margit; Zilmer, Mihkel; Viigimaa, Margus; Zemtsovskaja, Galina; Tomberg, Karel; Kaart, Tanel; Annuk, Margus. (2011). Cardiovascular disease risk factors in homeless people. Upsala Journal of Medical Sciences, 116 (3), 200−207.10.3109/03009734.2011.586737.
1.1.
2011
Lankin, Vadim; Viigimaa, Margus; Tikhaze, Alla; Kumskova, Elena; Konovalova, Galina; Abina, Jelena; Zemtsovskaya, Galina; Kotkina, Tatyana; Yanushevskaya, Elena; Vlasik, Tatyana (2011). Cholesterol-rich low density lipoproteins are also more oxidized. Molecular and Cellular Biochemistry, 355, 187−191.
1.1.
2011
Johnson, T.; Gaunt, T.R.; Newhouse, S.J.; Padmanabhan, S.; Tomaszewski, M.; Kumari, M.; Morris, R.W.; Tzoulaki, I.; O'Brien, E.T.; Poulter, N.R.; Sever, P.; Shields, D.C.; Thom, S.; Wannamethee, S.G.; Whincup, P.H.; Brown, M.J.; Connell, J.M.; Dobson, R.J.; Howard, P.J.; Mein, C.A. ... The Cardiogenics Consortium, The Global BPgen Consortium (2011). Blood Pressure Loci Identified with a Gene-Centric Array. American Journal of Human Genetics, 89 (6), 688−700.10.1016/j.ajhg.2011.10.013.
1.1.
2011
Putku, M.; Kepp, K.; Org, E.; Sõber, S.; Comas, D.; Viigimaa, M.; Veldre, G.; Juhanson, P.; Hallast, P.; Tõnisson, N.; Shaw-Hawkins, S.; Caulfield, M.J.; Khusnutdinova, E.; Kožich, V.; Munroe, P.B.; Laan, M. (2011). Novel polymorphic AluYb8 insertion in the WNK1 gene is associated with blood pressure variation in Europeans. Human Mutation, 32 (7), 806−814.10.1002/humu.21508.
1.1.
2011
The International Consortium for Blood Pressure Genome-Wide Association Studies, incl. Sõber, S.; Snieder, H.; Org, E.; Veldre, G.; Viigimaa, M.; Laan, M. (2011). Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature, 478 (7367), 103−109.10.1038/nature10405.
1.1.
2011
Org, Elin; Veldre, Gudrun; Viigimaa, Margus; Juhanson, Peeter; Putku, Margus; Rosenberg, Mai; Tomberg, Kärt; Uuetoa, Tiina; Laan, Maris (2011). HYPEST study: Profile of hypertensive patients in Estonia. BMC Cardiovascular Disorders, 11 (55), x−x.10.1186/1471-2261-11-55.
1.1.
2011
Averna, M.; Missault, L.; Vaverkova, H.; Farnier, M.; Viigimaa, M.; Dong, Q.; Shah, A.; Johnson-Levonas, A.O.; Taggart, W.; Brudi, P. (2011). Lipid-altering efficacy of switching to ezetimibe/simvastatin 10/20 mg versus rosuvastatin 10 mg in high-risk patients with and without metabolic syndrome. Diabetes and Vascular Disease Research, 8, 262−270.1479164111418136.
3.1.
2011
Pilt, Kristjan; Meigas, Kalju; Viigimaa, Margus; Temitski, Kristina (2011). Possibility to use Finapres signal for the estimation of aortic pulse wave velocity. IFMBE Proceedings, 37: EMBEC 2011, Budapest, 14-18 September 2011. IFMBE, 524−527.
3.1.
2011
Pilt, Kristjan; Meigas, Kalju; Viigimaa, Margus; Temitski, Kristina (2011). Possibility to use Finapres signal for augmentation index estimation. IFMBE Proceedings, 34: NBC 2011, Aalborg, 14-17 juuni 2011. IFMBE, 25−28.
5.2.
2011
Kaldmäe, Margit; Zilmer, Mihkel; Viigimaa, Margus, Zemtsovskaja, Galina; Tomberg, Karel; Kaart, Tanel; Annuk, Margus. (2011). Südame-veresoonkonna haiguste riskifaktorite määramine kodututel. Teaduskonverentsi teesid: Eesti XXII Keemiapäevade teaduskonverents, 14-15 aprill 2011 Tartu. Toim. Eesti Keemia Selts, Eesti Biokeemia Selts, Tartu Ülikooli Keemia Instituut. Tartu: Tartu Ülikooli Kirjastus, 36.
6.2.
2011
Aaviksoo, Evelyn; Hedman, Anu; Kaljusaar, Heli; Keskpaik, Lauri; Kõrv, Janika; Lukman, Aet; Luman, Merike; Minajeva, Ave; Muda, Piibe; Suurorg, Lagle; Uuetoa, Tiina; Viigimaa, Margus (2011). Hüpertensiooni aastaraamat. Tallinn: MTÜ Eesti Hüpertensiooni Ühing; OÜ Paar.
1.1.
2010
Viigimaa, M.; Vaverkova, H.; Farnier, M.; Averna, M.; Missault, L.; Hanson, M.E.; Dong, Q.A.; Shah, A.; Brudi, P. (2010). Ezetimibe/Simvastatin 10/20 mg versus Rosuvastatin 10 mg in high-risk hypercholesterolemic patients stratified by prior statin treatment potency. Lipids in Health and Disease, 9, 1−8.10.1186/1476-511X-9-127.
1.1.
2010
Tikhaze, A. K.; Viigimaa, M.; Konovalova, G. G.; Kumskova, E. M.; Abina, E. A.; Zemtsovskaya, G.; Yanushevskaya, E. V.; Vlasik, T. N.; Lankin, V. Z. (2010). Interrelation between Malonyl Dialdehyde-Dependent Modi. cation and Cholesterol Content in Low-Density Lipoproteins. Bulletin of Experimental Biology and Medicine, 149 (2), 184−186.doi.org/10.1007/s10517-010-0903-6.
1.1.
2010
Viigimaa, M; Abina, J; Zemtsovskaya, G; Tikhaze, A; Konovalova, G; Kumskova, E; Lankin, V. (2010). Malondialdehyde-modified low-density lipoproteins as biomarker for atherosclerosis. Blood Pressure, 164−168.10.3109/08037051.2010.484158.
1.1.
2010
Kepp, K.; Org, E.; Sober, S.; Kelgo, P.; Viigimaa, M.; Veldre, G.; Tonisson, N.; Juhanson, P.; Putku, M.; Kindmark, A.; Kozich, V.; Laan, M. (2010). Hypervariable intronic region in NCX1 is enriched in short insertion-deletion polymorphisms and showed association with cardiovascular traits. BMC Medical Genetics, 11 (15), 1−15.10.1186/1471-2350-11-15.
1.1.
2010
Olsen, Michael H.; Mallion, Jean-Michel; Rahn, Karl-Heinz; Erdine, Serap; Viigimaa, Margus; Laurent, Stephane; Agabiti-Rosei, Enrico; Mancia, Giuseppe; Schmieder, Roland E.; Cifkova, Renata; Dominiczak, Anna; Kjeldsen, Sverre E.; Redon, Josep; Zanchetti, Alberto; Nilsson, Peter; Narkiewicz, Krzysztof (2010). Agreement within Europe about antihypertensive treatment and education - results from the European Society of Hypertension questionnaire. Journal of Hypertension, 28 (7), 1593−1594.10.1097/HJH.0b013e32833b7b08.
1.1.
2010
Stergiou, G.S.; Myers, M.G.; Reid, J.L.; Burnier, M.; Narkiewicz, K.; Viigimaa, M.; Mancia, G. (2010). Setting-up a Blood Pressure and Vascular Protection Clinic: Requirements of the European Society of Hypertension. Journal of Hypertension, 28, 1780−1781.10.1097/HJH.0b013e32833d1e01.
1.1.
2010
Mancia, G.; Laurent, S.; Agabiti-Rosei, E.; Ambrosioni, E.; Burnier, M.; Caulfield, M.J.; Cifkova, R.; Clément, D.; Coca, A.; Dominiczak, A.; Erdine, S.; Fagard, R.; Farsang, C.; Grassi, G.; Haller, H.; Heagerty, A.; Kjeldsen, S.E.; Kiowski, W.; Mallion, J.M.; Manolis, A. ... (2010). European guidelines on the management of hypertension: The European Society of Hypertension position statement (2009). Nadcisnienie Tetnicze, 14, 1−47.
2.2.
2010
Viigimaa, Margus; Adamson, Agne; Ots, Madis (2010). Südameinvestor. [Tallinn]: Menu Kirjastus.
3.1.
2010
Pilt, K.; Meigas, K.; Viigimaa, M.; Kaik, J.; Kattai, R.; Karai, D. (2010). Arterial pulse waveform dependence on applied pressure. Proc. of the Biennial Baltic Elect. Conf.: 12th Biennial Baltic Electronics Conference (BEC2010). IEEE, 277−280.
3.1.
2010
Pilt, Kristjan; Meigas, Kalju; Viigimaa, Margus; Kaik, Jüri; Kattai, Rain; Karai, Deniss. (2010). Arterial Pulse Transit Time Dependence on Applied Pressure. IFMBE Proceedings, 29: MEDICON 2010. IFMBE, 406−409. (3).
3.1.
2010
Pilt, Kristjan; Meigas, Kalju; Viigimaa, Margus; Temitski, Kristina; Kaik, Jüri. (2010). An Experimental Measurement Complex for Probable Estimation of Arterial Stiffness. Conference proceedings of the IEEE Engineering in Medicine and Biology Society (Conf. Proc. IEEE Eng. Med. Biol. Soc.): 32nd Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE, 194−197.
5.2.
2010
Putku, M.; Kepp, K.; Org, E.; Sõber, S.; Comas, D.; Viigimaa, M.; Veldre, G.; Kelgo, P.; Hallast, P.; Tõnisson, N.; Juhanson, P.; Khusnutdinova, E.; Kožich, V.; Laan, M. (2010). Novel polymorphic AluYb8 insertion in WNK1 Gene associated with blood pressure regulation. Journal of Hypertension, 28: 20th Annual Meeting of the European-Society-of-Hypertension, Oslo, Norway, June 18-21, 2010. Lippincott Williams & Wilkins, E347−E348.
6.3.
2010
Sak, K.; Viigimaa, M. (2010). Tervislik eluviis on heaolu alus. Kodutohter, 8, 16−19.
1.1.
2009
Varis, Juha; Karjalainen, Sampo; Korhonen, Krista; Viigimaa, Margus; Port, Kristjan; Kantola, Ilkka (2009). Experiences of Telemedicine-Aided Hypertension Control in the Follow-Up of Finnish Hypertensive Patients. Telemedicine Journal and e-Health, 15 (8), 764−769.10.1089/tmj.2009.0029.
1.1.
2009
Sõber, S.; Org, E.; Kepp, K.; Juhanson, P.; Eyheramendy, S.; Gieger, C.; Lichtner, P.; Klopp, N.; Veldre, G.; Viigimaa, M.; Döring, A.; Putku, M.; Kelgo, P.; Shaw-Hawkins, S.; Howard, P.; Onipinla, A.; Dobson, R.J.; Newhouse, S.J.; Brown, M.; Dominiczak, A. ... Laan, M. (2009). Targeting 160 candidate genes for blood pressure regulation with a genome-wide genotyping array. PLOS ONE, 4 (6), 1−13.10.1371/journal.pone.0006034.
1.1.
2009
Org, E.; Eyheramendy, S.; Juhanson, P.; Gieger, C.; Lichtner, P.; Klopp, N.; Veldre, G.; Döring, A.; Viigimaa, M.; Sõber, S.; Tomberg, K.; Eckstein, G.; Kelgo, P.; Rebane, T.; Shaw-Hawkins, S.; Howard, P.; Onipinla, A.; Dobson, R.J.; Newhouse, S.J.; Brown, M. ... Laan, M. (2009). Genome-wide scan identifies CDH13 as a novel susceptibility locus contributing to blood pressure determination in two European populations. Human Molecular Genetics, 18 (12), 2288−2296.10.1093/hmg/ddp135.
1.1.
2009
Farnier, M.; Averna, M.; Missault, L.; Viigimaa, M. (2009). Lipid-altering efficacy of ezetimibe/simvastatin 10/20 mg compared with rosuvastatin 10 mg in high-risk hypercholesterolaemic patients inadequately controlled with prior statin monotherapy - The IN-CROSS study. International Journal of Clinical Practice, 547−559.
1.1.
2009
Newhouse, S.; Farrall, M.; Wallace, C.; Hoti, M.; Burke, B.; Howard, P.; Onipinla, A.; Lee, K.; Shaw-Hawkins, S.; Dobson, R.; Brown, M.; Samani, N.J.; Dominiczak, A.F.; Connell, J.M.; Lathrop, G.M.; Kooner, J.; Chambers, J.; Elliott, P.; Clarke, R.; Collins, R. ... Munroe, P.B. (2009). Polymorphisms in the WNK1 Gene Are Associated with Blood Pressure Variation and Urinary Potassium Excretion. PLOS ONE, 4 (4), 1−14.10.1371/journal.pone.0005003.
1.1.
2009
Maneia, G.; Laurent, S.; Agabiti-Rosei, E.; Ambrosioni, E.; Burnier, M.; Caulfield, M.J.; Cifkova, R.; Clément, D.; Coca, A.; Dominiczak, A.; Erdine, S.; Fagard, R.; Farsang, C.; Grassi, G.; Haller, H.; Heagerty, A.; Kjeldsen, S.E.; Kiowski, W.; Mallion, J.M.; Manolis, A. ... Zanchetti, A. (2009). Reappraisal of European guidelines on hypertension management: A European Society of Hypertension Task Force document. Journal of Hypertension, 27, 2121−2158.10.1097/HJH.0b013e328333146d.
2.2.
2009
Viigimaa, Margus; Jaanson, Eret; Gross, Lilli (2009). Õnnelik süda : kuidas vältida haigestumist südame-veresoonkonnahaigustesse? [Tallinn]: Celsius Healthcare.
5.1.
2009
Org, E.; Kepp, K.; Veldre, G.; Viigimaa, M.; Juhanson, P.; Putku, M.; Kelgo, P.; Rebane, T.; Rosenberg, M.; Uuetoa, T.; Laan, M. (2009). Strategies for studying epidemiological and genetic factors for essential hypertension using Estonian HYPEST sample. In: Journal of Hypertension (S450−S450). Elsevier.
1.1.
2008
Redon, J.;Cifkova, R.;Laurent, S.;Nilsson, P.;Narkiewicz, K.;Erdine, S.;Mancia, G.;Viigimaa, M. (2008). The metabolic syndrome in hypertension: European society of hypertension position statement. Journal of Hypertension, 1891−1900.
1.1.
2008
Fox, K.;Ford, I.;Steg, G.;Tendera, M.;Robertson, M.;Ferrari, R.; Group author: Beautiful study group (incl. Eha, J.) (2008). Heart Rate as prognostic risk factor in patients with coronary artery disease and left ventricular systolic dysfunction ( BEAUTIFUL ): a subgroup analysis of a randomised controlled trial. Lancet, 372 (9641), 817−821.10.1016/S0140-6736(08)61171-X.
1.1.
2008
The Beautiful Study Group, ( incl. Eha, J. ) (2008). The BEAUTIFUL study: randomized trial of ivabradine in patients with stable coronary artery disease and left ventricular dysfunction - baseline characteristics of the study population. Cardiology, 110 (4), 271−282.10.1159/000112412.
1.1.
2008
Fox, K.; Ford, I.; Steg, G.; Tendera, M.; Ferrari, R.; The Beautiful study group ( incl. Eha, J. ) (2008). Ivabradine for patients with stable coronary artery disease and left ventricular systolic dysfunction ( BEAUTIFUL ): a randomised, double blind, placebo controlled trial. Lancet, 372 (9641), 807−816.10.1016/S0140-6736(08)61170-8.
1.1.
2008
Juhanson, P.; Kepp, K.; Org, E.; Veldre, G.; Kelgo, P.; Rosenberg, M.; Viigimaa, M.; Laan, M. (2008). N-acetyltransferase 8, a positional candidate for blood pressure and renal regulation: resequencing, association and in silico study. BMC Medical Genetics, 9 (25), 1−12.10.1186/1471-2350-9-25.
1.1.
2008
Caulfield, M.J.; Munroe, P.B.; O'Neill, D.; Witkowska, K.; Charchar, F.; Doblado, M.; Evans, S.; Eyheramendy, S.; Onipinia, A.; Howard, P.; Shaw-Hawkins, S.; Dobson, R.J.; Wallace, C.; Newhouse, S.J.; Brown, M.; Connell, J.M.; Dominiczak, A.; Farrall, M.; Lathrop, G.M.; Samani, N. ... Cheeseman, C. (2008). SLC2A9 Is a High-Capacity Urate Transporter in Humans. PLOS Medicine, 5 (10), 0001−0015.10.1371/journal.pmed.0050197.
1.1.
2008
Viigimaa, M.; Narkiewicz, K.; Kjeldsen, S.E.; Hedner, T. (2008). New ESH Hypertension Excellence centers approved. Blood Pressure, 178−180.
1.2.
2008
Hlimonenko, Irina; Meigas, Kalju; Viigimaa, Margus; Temitski, Kristina (2008). Aortic and Arterial Pulse Wave Velocity in Patients with Coronary Heart Disease of Different Severity. Estonian Journal of Engineering, 14 (2), 167−176.
2.1.
2008
Mancia, G.;Grassi, G; Kjeldsen, SE., Viigimaa M. et al. (2008). Manual of Hypertension of the European Society of Hypertension. Information Press.
3.1.
2008
Hlimonenko, Irina; Meigas, Kalju; Viigimaa, Margus; Temitski, Kristina (2008). Augmentation Index in Different Severity Coronary Heart Disease Patients. IFMBE Proceedings, 20. Springer, 242−244.
3.1.
2008
Erdine S, Viigimaa M (2008). Compliance to treatment of hypertension. In: Mancia G, Grassi G, Kjeldsen S (_EditorsAbbr). Manual of Hypertension of The European Society of Hypertension (354−360). Informa healthcare.
5.1.
2008
Veldre, G.; Viigimaa, M.; Org, E.; Juhanson, P.; Kelgo, P.; Rebane, T.; Laan, M. (2008). HYPEST, first hypertension targeted sample collection in Estonian population. Journal of Hypertension, 26: 18th Scientific Meeting of the European-Society-of-Hypertension/22nd Scientific Meeting of the International-Society-of-Hypertension, Berlin, Germany, JUN 14-19, 2008. Lippincott Williams & Wilkins, 107−107.
5.1.
2008
Kurvinen, E.; Nueganen, K.; Viigimaa, M.; Veske, A.; Aasvee, K. (2008). Matrix metalloproteinase-9 polymorphism in relation to cardiovascular disease complications in patients of type 2 diabetes mellitus. European Journal of Human Genetics, 16(Suppl 2): European Human Genetics Conference 2008, Barcelona, Spain, May 31 - June 3, 2008. 326.
5.1.
2008
Šamarin, A.; Mesikepp, A.; Brand, R.; Nazarenko, S.; Viigimaa, M. (2008). Arterial hypertension and significant coronary artery stenosis: detection by 64 row computed tomography. Journal of Hypertension, 26 (S1), S285.
5.2.
2008
Aasvee, K.; Jauhiainen, M.; Viigimaa, M.; Tupits, H; Sundvall, J.; Kurvinen, E. (2008). Põletikumarkerid ja lipoproteiine remodelleerivad valgud II tüüpi diabeedi (T2DM) haigetel. Eesti Arst, 87(9): TÜ Arstiteaduskonna Päevad 2008, Tartu, 9-10 oktoober 2008. 668−669.
5.2.
2008
Kurvinen, E; Viigimaa, M.; Tupits, H.; Sundvall, J.; Jauhiainen, M.; Aasvee, K. (2008). Lipiidide ainevahetuse näitajate ja süsteemse kroonilise põletiku markerite seos insuliiniresistentsuse väljendumuse astmega. Eesti Arst, 87(9): TÜ Arstiteaduskonna Päevad 2008, Tartu, 9-10 oktoober 2008. 664−665.
5.2.
2008
Laan, M.; Org, E.; Eyheramendy, S.; Gieger, C.; Juhanson, P.; Lichtner, P.; Veldre, G.; Tomberg, K.; Viigimaa, M.; Klopp, N.; Munroe, P.; Shaw-Hawkins, S.; Caulfield, M.J.; investigators, B.R.I.G.H.T; Illig, T.; Wichmann, H.-E.; Meitinger, T. (2008). Genome-wide association study with blood pressure traits. HGM 2008 Programme and Abstract book: HGM 2008: Human Genome meeting; Hyderabad, India; 27-30 Sep 2008. 67−67.
5.2.
2008
Zemtsovskaja, G.; Krjukova, V.; Zemtsovski, M.; Minosenko, A.; Viigimaa, M. (2008). Correlation of N-terminal pro B-type natriuretic peptide with clinical NYHA staging, ventricular ejection fraction and left atrial volume index. Proceedings of the 9th Baltic congress on laboratory medicine. 39.
1.1.
2007
Nilsson, P.M.; Journath, G.; Palm, K.; Viigimaa, M. (2007). Risk factor control in treated hypertensives from Estonia and Sweden. Why the difference? Blood Pressure, 16 (5), 301−304.10.1080/08037050701517224.
1.1.
2007
Mancia, G.; De Backer, G.; Dominiczak, A.; Cifkova, R.; Fagard, R.; Germano, G.; Grassi, G.; Heagerty, AM.; Kjeldsen, SE.; Laurent, S.; Narkiewicz, K.; Viigimaa, M. et al. (2007). Practice guidelines 2007 for the treatment of arterial hypertension. Giornale italiano di cardiologia, 389−479.
1.1.
2007
Mancia, G.; De Backer, G.; Dominiczak, A.; Cifkova, R.; Fagard, R.; Germano, G.; Grassi, G.; Heagerty, AM.; Kjeldsen, SE.; Laurent, S.; Narkiewicz, K.; Viigimaa, M. et al. (2007). ESH/ESC 2007 Guidelines for the management of arterial hypertension. Revista española de cardiología, 968−994.
1.1.
2007
Mancia, G.; De Backer, G.; Dominiczak, A.; Cifkova, R.; Fagard, R.; Germano, G.; Grassi, G.; Heagerty, AM.; Kjeldsen, SE.; Laurent, S.; Narkiewicz, K.; Viigimaa, M. et al. (2007). 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). European Heart Journal, 1462−1536.
1.1.
2007
Viigimaa, M.; Farsang, C.; Kjeldsen, SE.; Narkiewicz, K.; Mancia, G. (2007). ESH Hypertension Excellence Centres: a new strategy to combat an old foe. Journal of Hypertension, 1744−1748.
1.1.
2007
Mancia, G.; De Backer, G.; Dominiczak, A.; Cifkova, R.; Fagard, R.; Germano, G.; Grassi, G.; Heagerty, AM.; Kjeldsen, SE.; Laurent, S.; Narkiewicz, K.; Viigimaa, M. et al. (2007). 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Journal of Hypertension, 1105−1187.
1.1.
2007
Kepp, K.; Juhanson, P.; Kozich, V.; Ots, M.; Viigimaa, M.; Laan, M. (2007). Resequencing PNMT in European hypertensive and normotensive individuals: no common susceptibilily variants for hypertension and purifying selection on intron 1. BMC Medical Genetics, 8 (47), 1−9.
1.2.
2007
Zemtsovskaja, G.; Zemtsovski, M.; Siimann-Häelme, Ü.; Viigimaa, M (2007). N-terminal pro-brain natriuretic peptide - association with extent of CHF in clinical practice. Clinical Chemistry and Laboratory Medicine, 166.
3.1.
2007
Hlimonenko, Irina; Meigas, Kalju; Viigimaa, Margus; Temitski, Kristiina. (2007). Assessment of Pulse Wave Velocity and Augmentation Index in Different Arteries in Patients with Severe Coronary Heart Disease. In: Proceedings of the 29th Annual International Conference of the IEEE EMBS (1703−1706).. IEEE.
5.1.
2007
Kantola, I.; Karjalainen, S; Korhonen, K.; Viigimaa, M.; Port, K. (2007). Home monitoring of blood pressure supported by tele-monitoring system. Journal of Hypertension, 25 (S2): 17th European Meeting on Hypertension, Milan, Italy, Jun 15-19, 2007. S29.
5.2.
2007
Viigimaa, Margus (2007). Programme and abstracts : 4th Baltic Atherosclerosis Congress : September 27-29, 2007, Tallinn, Estonia. Baltic Atherosclerosis Congress(4 :2007 :Tallinn). [Tallinn: Frens Conference Services,.
5.2.
2007
Viigimaa, Margus (2007). Programme and abstracts : 4th Baltic Atherosclerosis Congress : September 27-29, 2007, Tallinn, Estonia. Baltic Atherosclerosis Congress(4 :2007 :Tallinn). [Tallinn: Frens Conference Services,.
5.2.
2007
Zemtsovski, M.; Viigimaa, M.; Zemtsovskaja, G. (2007). Treating of dyslipidaemia to goal - situation in North Estonia Regional Hospital. Proceedings of the 4th Baltic atherosclerosis congress. 61.
1.3.
2006
Viigimaa, Margus; Välkmann, Reet (2006). LDL-aferees väljendunud hüperkolesteroleemia ravis. Eesti Arst, 8, 523−528.
1.3.
2006
Ani, Ülle; Viigimaa, Margus; Kipper, Taivo; Pruunsild, Toomas; Jõgi, Rain (2006). Nikotiinisõltuvuse ravi bupropiooniga kroonilise bronhiidiga haigetel. Eesti Arst, 85 (6), 354−361.
1.3.
2006
Viigimaa, M.; Eha, J.; Hedman, A.; Kampus, P.; Liiver, A.; Maaroos, J.; Marandi, T.; Mesikepp, A.; Muda, P.; Ristimäe, T.; Roose, M.; Suurorg, L.; Teesalu, R.; Tiik, M.; Tupits, H.; Vokk, R.; Zemtsovski, M. (2006). Eesti südame- ja veresoonkonnahaiguste preventsiooni juhend. Eesti Arst, 85 (3), 183−216.
1.3.
2006
Teesalu, Rein; Viigimaa, Margus; Kiudma, Tarvo; Sinisalu, Väino (2006). Südamepuudulikkuse ravi tänapäeval : eksperdihinnangud. Eesti Arst, 10, 689−696.
2.3.
2006
Sammul, Sirje (2006). Hüpertooniatõve diagnoosiga patsientide tervisekäitumine ning perearsti ja pereõe osa selle kujundamisel : magistritöö rahvatervishoius. (Tartu Ülikool.; Tervishoiu instituut.; ). Tartu: Tartu Ülikool.
6.6.
2006
Siidirätsep, Kai;Viigimaa, Margus (2006). Intensiivne mees : Margus Viigimaa : [intervjuu südamearstiga, TTÜ professoriga]. Tervisplus, 46−48.
1.1.
2005
Port, K.; Palm, K.; Viigimaa, M. (2005). Daily usage and efficiency of remote home monitoring in hypertensive patients over a one-year period. Journal of Telemedicine and Telecare, 1 (11), 34−36.
1.2.
2005
Viigimaa M, Hansen S, Shipilova T, Pšenitšnikov I, Kalle A, Puusaag M. (2005). Effect of lisinopril on twenty-four-hour blood pressure in patients with mild to moderate hypertension. Seminars in Cardiology, 11, 106−109.
1.3.
2005
Hansen, Sirje; Šipilova, Tatjana; Pšenitšnikov, Igor; Puusaag, Maie; Kalle, Anneli; Viigimaa, Margus (2005). Lisinopriili ööpäevane vererõhku langetav efektiivsus kerge ja keskmise raskusastmega arteriaalse hüpertensiooni patsientidel. Eesti Arst, 7, 461−465.
6.6.
2005
Viigimaa, Margus (2005). Kõrgvererõhktõve globaalne koormus : ülemaailmse info analüüs. Lege Artis, 17−18,
6.6.
2005
Hansen, Sirje; Šipilova, Tatjana; Pšenitšnikov, Igor; Puusaag, Maie; Kalle, Anneli; Viigimaa, Margus (2005). Lisinopriili vererõhku langetav toime arteriaalse hüpertensiooni patsientidel. Lege Artis, 8, 32.
1.3.
2004
Ragun, Ulvi; Jagomägi, Kersti; Raamat, Rein; Viigimaa, Margus (2004). Õlavarrelt vererõhu mõõtmise protseduuri mõju keskmisele arteriaalsele rõhule hüpertoonikutel. Eesti Arst, 2, 81−86.
1.3.
2004
Soopõld, Üllar; Maarandi, Toomas; Ainla, Tiia (2004). ST-segmendi elevatsiooniga ägeda müokardiinfarkti Eesti ravijuhend : kuukirja Eesti Arst lisa. Viigimaa, Margus; Eha, Jaan; Laks, Toivo... Tartu: Eesti Arst.
1.3.
2004
Soopõld, Ü.; Marandi, T.; Ainla, T.; Liiver, A.; Elmet, M.; Laanoja, J.; Peeba, M.; Ristimäe, T.; Viigimaa, M., Eha, J.; Laks, T.; Reinold, A.; Serka, T.; Teesalu, R.; Vahula, V., Voitk, J. (2004). ST-segmendi elevatsiooniga ägeda müokardiinfarkti Eesti ravijuhend. Eesti Arst, 12(L), 2−47.
3.3.
2004
Soopõld, Ü.; Marandi, T.; Ainla, T.; Liiver, A.; Elmet, M.; Laanoja, J.; Peeba, M.; Ristimäe, T.; Viigimaa, M.; Eha, J.; Laks, T.; Reinold, A.; Serka, T.; Teesalu, R.; Vahula, V.; Voitk, J. (2004). St-segmendi elevatsiooniga ägeda müokardiinfarkti Eesti ravijuhend. Tartu: Eesti Arst.
1.1.
2003
Port, K.; Palm, K.; Viigimaa, M. (2003). Self-reported compliance of patients receiving antihypertensive treatment: use of a telemonitoring home care system. Journal of Telemedicine and Telecare, 9, S65−S66.
1.2.
2003
Välkmann R, Jõudu T, Hansen S, Viigimaa M. (2003). Effects of fenofibrate on platelet aggragation in patients with combined hyperlipidemia. Seminars in Cardiology, 9 (1), 24−27.
1.3.
2003
Viigimaa, Margus (2003). Patsient, perearst, kardioloog. Tohtrile : ajakiri arstidele, 4, 22−:.
1.3.
2003
Ragun, Ulvi; Jagomägi, Kersti; Raamat, Rein; Viigimaa, Margus (2003). Õlavarrelt vererõhu mõõtmise protseduuri mõju keskmisele arteriaalsele rõhule ja pulsisagedusele. Eesti Arst, 9, 649.
5.1.
2003
Viigimaa, M.; Kask, A.; Tiganik, V.; Johansson, J. (2003). Cardiovascular risk factors in 55-year-old women and men in Tartu (Estonia) and Stockholm (Sweden). Atherosclerosis Supplements, 4 (2), 110−110.
6.2.
2003
Uusküla, Maido; Teesalu, Rein; Viigimaa, Margus (2003). Distantskoolitusprogramm "Kardioloogia aktuaalsed küsimused" [Võrguteavik]. [Tartu: Tartu Ülikooli Kliinikum.
1.1.
2002
Johansson, J.; Viigimaa, M.; Jensen-Urstad, M.; Krakau, I.; Hansson, LO. (2002). Risk factors for coronary heart disease in 55-and 35-year-old men and women in Sweden and Estonia. Journal of Internal Medicine, 252 (6), 551−560.
2.2.
2002
Knox, S; Viigimaa, M.; Unden, AL; Elofsson, S.; Johansson, J (2002). Psychosocial Factors and Cardiovascular Risk in the Est-West Divide: The Swestonia Study. In: Heart Disease:Enviroment, Stress and Gender. Nato Science Series (138-152)..
3.4.
2002
Viigimaa, Margus; Jõudu, Tiiu; Välkmann, Reet; Hansen, Sirje (2002). Comparison of effects of fenofibrate and ciprofibrate on plasma lipids and platelet aggregation in patients with combined hyperlipidemia. Proceedings of the Department of Cardiology, 5, 54−58.
5.1.
2002
Muda, P.; Ristimae, T.; Viigimaa, M. (2002). Arterial hypertension among middle-aged Estonians - Prevalence and risk factors. Journal of Hypertension, 20, S85−S85.
5.2.
2002
Viigimaa, Margus (2002). Südame-veresoonkonna haiguste ennetamise programm aastateks 2002-2006. Üle-eestiline teaduskonverents "Tervise edendamine Eestis VI" : 20.-21. märts 2002 a., [Tartu] : konverentsi ettekannete teesid. 64.
6.2.
2002
Viigimaa, Margus (2002). Südamepuudulikkusega haige ravi diureetikumidega. Eesti Arst, 6, 376.
6.2.
2002
Viigimaa, Margus (2002). Kommentaar hüpertooniatõve ja südamepuudulikkuse ravi igapäevase käsitluse uuringule. Hippokrates, 90.
1.1.
2001
Unden, AL.; Elofsson, S.; Viigimaa, M.; Johansson, J.; Knox, S. (2001). A psychosocial comparison of 35- and 55-year-old men and women in Sweden and Estonia: The Swestonia cardiovascular risk factor study. International Journal of Behavioral Medicine, 8 (2), 149−162.
1.3.
2001
Viigimaa, Margus; Palm, K.; Port, Kristjan; Hansen, S.; Laasik, T.; Siim, K. (2001). Arteriaalse hüpertensiooniga patsientide monitoorimine kodujälgimisseadme Docobo abil. Eesti Arst, 12, 591−595.
1.3.
2001
Viigimaa, M.; Tiganik, V (2001). Doppleri ultraheliuuring unearterite aterosklerootilise protsessi hindamisel. Eesti Arst, 1, 35−40.
1.3.
2001
Tiganik, Valeri; Viigimaa, Margus (2001). Unearterite Doppler-spektrogrammide uuring kardiovaskulaarsete haiguste puhul. Eesti Arst, 3, 150−155.
1.3.
2001
Hämmal, Jaanus; Tikk, Viive; Tikk, Harald; Viigimaa, Margus; Kuusik, Sirje (2001). [Oomega]-3-rasvhapete sisalduse suurendamisest linnukasvatussaadustes. Agraarteadus, XII (1), 14−50.
3.4.
2001
Tikk, Harald; Viigimaa, Margus; Tikk, Viive; Hämmal, Jaanus (2001). The effect of consumption of omega-3 fatty acid enriched quail eggs on blood characteristics in hypercholesterolemic men. Proceedings of the IX Baltic Poultry Conference: Tartu, 14th of September 2001, 27.
3.4.
2001
Zemtsovskaja, G.; Ivanov, A.; Melnitchuk, A.; Zemtsovsky, M.; Viigimaa, M. (2001). Comparision of directly deterrnined and calculated LDL cholesterol concentrations in patients of various risk categories. Abstract book: 14 IFCC and European Congress of Clinical Chemistry and Laboratory Medicine, Prague.
5.1.
2001
Allikmets, K.; Starkopf, A.; Svensson, S.; Pokk, T.; Hedner, T.; Viigimaa, M. (2001). Ambulatory blood pressure monitoring in a population of an Estonian island: initial results from the SELECT project. European Heart Journal, 22, 103−103.
5.2.
2001
Tikk, Harald; Viigimaa, Margus; Tikk, V; Hämma, J (2001). The effect of consumption of omega-3 fatty acid enriched guail eggs on blood characteristics in hypercholesterolemic men. Proceedings of the IX Baltic Poultry Conference. 12−14.
5.2.
2001
Viigimaa, Margus (2001). Südame isheemiatõve preventsioon Eestis. Eesti Arst, 6, 332−333.
6.2.
2001
Viigimaa, M.; Aasvee, K.; Eha, J.; Laks, T.; Lember, M.; Maaroos, H.; Mesikepp, A.; Podar, T.; Roose, M.; Saava, M.; Sulling, T.; Suurorg, L.; Teesalu, R.; Tupits, H.; Tur, I.; Uusküla, M.; Vahisalu, R.; Voloz, O.; Välkmann, R.; Zemtsovski, M. (2001). Eesti Lipiidijuhised. (1−24). Eesti Haigekassa : WHO CINDI Programm, 2001.
6.3.
2001
Viigimaa, Margus (2001). Ženšenn annab jõudu. Tervis Pluss, 5, 72.
6.3.
2001
Viigimaa, Margus; Holvandus, Juune (2001). Müstiline kolesterool. Kodutohter, 9, 20−22.
6.3.
2001
Siidirätsep, Kai; Viigimaa, Margus; Aarsalu, Helle; Varendi, Tarmo (2001). Oma arst öökapil : [südameseireaparaat Docobo]. Tervis Pluss, 6, 32−34.
6.3.
2001
Viigimaa, Margus (2001). Miks ei tohi palju soola süüa? Tervis Pluss, 6, 34.
6.3.
2001
Viigimaa, Margus; Holvandus, Juune (2001). Kes palju teeb, see rohkem jõuab : [vestlus kardioloogiga]. Kodutohter, 9, 18−22.
1.1.
2000
Viigimaa, M.; Allikmets, K.; Parik, T.; Skards, J.; Franken, A.; Hass, G. (2000). Tasosartan and hydroclorothiazide as combination therapy in the treatment of severe essential hypertension: Comparison with enalapril. Cardiovascular Drugs and Therapy, 14 (4), 447−449.
3.3.
2000
Viigimaa, M.; Allikmets, K.; Goldštein, G.; Jaagus, H.; Laan, M.; Maaroos, J.; Nazarenko, S.; Ojamaa, M.; Ristimäe, T.; Teesalu, R.; Volož, O. (2000). Arteriaalne hüperetensioon - praktilised aspektid. Tartu: Tartumaa Trükikoda.
3.4.
2000
Viigimaa, Margus; Jõudu, Tiiu; Hämmal, Jaanus; Tikk, Harald; Tikk, Viive (2000). The effect consumption of omega-3-enriched quail eggs on lipid metabolism and platelet aggregation in healthy volunteers. Proceedings of the Department of Cardiology at the University of Tartu, 90−95.
5.1.
2000
Allikmets, K.; Ristimae, T.; Viigimaa, M. (2000). Electrocardiographic detection of left ventricular hypertrophy in severe essential hypertension: Correlations between different models. Journal of Hypertension, 18, S28−S28.
6.2.
2000
Viigimaa, Margus; Allikmets, Kristina; Jaagus, Helgi; Laan, Mari; Maaroos, Jaak; Goldšteine, Gundega; Nazarenko, Sergei; Ojamaa, Maie; Ristimäe, Tiina; Teesalu, Rein; Volož, Olga (2000). Arteriaalne hüpertensioon - praktilised aspektid. Tartu: Eesti Hüpertensiooni Ühing.
6.2.
2000
Viigimaa, Margus; Allikmets, Kristina; Goldšteine, Gundega; Jaagus, Helgi; Maaroos, Jaak; Nazarenko, Sergei; Ojamaa, Maie; Ristimäe, Tiina; Volož, Olga (2000). Eesti hüpertensioonijuhised 1999. Tartu: Eesti Hüpertensiooni Ühing.
6.3.
2000
Viigimaa, Margus (2000). AKE-inhibiitorid vähendavad suremust veel paremini kui loodeti : kõrgvererõhu alandajatest. Hippokrates, 256−257.
6.3.
2000
Murutar, Kati; Hermlin, Toomas; Viigimaa, Margus (2000). Suust sisse läinud haiguse väljaajamine : [südame veresoonte sondeerimisest]. Tervis, 6, 44−46.
6.3.
2000
Viigimaa, Margus (2000). Valud südames. Tervisetrend, 10, 58.
6.6.
2000
Viigimaa, Margus (2000). Kõik apteegid mõõtma : vererõhku. Eesti Rohuteadlane, 30−31.
1.1.
1999
Allikmets, K.; Parik, T.; Viigimaa, M. (1999). The renin-angiotensin system in essential hypertension: Associations with cardiovascular risk. Blood Pressure, 8 (2), 70−78.
1.1.
1999
Viigimaa, M. (1999). The Baltic atherosclerosis journal. Clinical Chemistry and Laboratory Medicine, 37 (8), 841−841.
1.3.
1999
Ojamaa, M.; Siim, K.; Viigimaa, M. (1999). Arteriaalse rõhu näitajate ööpäevane jälgimine firma SpaceLabs Medical ja Meditech monitoridega Tartu Ülikooli Kardioloogiakliinikus. Eesti Arst, 78 (2), 111−117.
3.3.
1999
Viigimaa, M.; Allikmets, K.; Golstein, G; Jaagus, H.; Maaroos, J.; Nazarenko, S.; Ojamaa, M.; Ristimäe, T.; Volozh, O (1999). Eesti Hüpertensioonijuhised. Eesti Hüpertensiooni Ühing.
3.5.
1999
Viigimaa, Margus; Kask, Anne; Johansson, Jan (1999). Psühhosotsiaalsete tegurite osa kardiovaskulaarse riskifaktorina Tartu-Stockholmi kardiovaskulaarsete riskifaktorite uuringus. Haigestumist ja tervenemist soodustavad psühhosotsiaalsed tegurid : interdistsiplinaarne konverents : 13.-14. november 1998. Tallinn: Tallinna Pedagoogikaülikooli Kirjastus, 133−138.
5.1.
1999
Viigimaa, M.; Valkman, R. (1999). Lipid-lowering and antiaggregatory efficacy of atorvastatin in coronary heart disease patients with combined hyperlipidemia. Atherosclerosis, 144, 24−24.
5.1.
1999
Viigimaa, M.; Kask, A.; Tiganik, V.; Johansson, J. (1999). Comparison of the lipid profile and eating habits of 35-year-and 55-year old inhabitants of the city of Tartu (Estonia). Atherosclerosis, 144, 176−176.
5.1.
1999
Viigimaa, M.; Kask, A.; Tiganik, V.; Johansson, J. (1999). A comparison of blood pressure levels, lipid profiles and smoking habits between 35-year olds in Tartu (Estonia) and Stockholm (Sweden). Hypertension, 33 (5), 1320−1320.
5.2.
1999
Viigimaa, Margus; Paesüld, M (1999). Maarjamõisa polikliiniku südamehaiguste ennetamise kabinetis ja Kärdla südametoas konsulteeritud elanike kardiovaskulaarsete riskitegurite võrdlus. Eesti Sisearstide Seltsi X Kongress, 20.-22. mai 1999, Sakala keskus, Tallinn : programm ja teeside kogumik. 55.
5.2.
1999
Zemtsovskaja, G.; Zemtsovski, M.; Viigimaa, M. (1999). The effect of atorvastatin on plasma total antioxidant capasity. Proceedings of the Free radical processes Congress.
5.2.
1999
Viigimaa, Margus; Korrovits, V (1999). Verapamiil-trandolapriili kombinatsiooni vererõhku langetav ja mikroalbuminuuriat vähendav toime II tüüpi diabeediga hüpertoonikutel. Eesti Sisearstide Seltsi X Kongress, 20.-22. mai 1999, Sakala keskus, Tallinn : programm ja teeside kogumik, 54.
6.3.
1999
Klemet, Andres; Viigimaa, Margus (1999). Üks kloun saja arsti asemel : nalja tähtsusest. Tervisetrend, 1, 49−50.
6.3.
1999
Larin, Lea; Viigimaa, Margus (1999). Terviseks! : punane vein on tõeline elupikendaja. Anne, 11, 62−64.
6.3.
1999
Siidirätsep, Kai; Viigimaa, Margus (1999). Vererõhk : kord kõrge, kord madal : [südamearst Margus Viigimaa nõuandeid]. Tervis, 1, 30−32.
6.3.
1999
Ojamaa, Maie; Siim, Kadri; Viigimaa, Margus (1999). Arteriaalse rõhu näitajate ööpäevane jälgimine firma SpaceLabs Medical ja Meditech monitoridega Tartu Ülikooli Kardioloogiakliinikus. Eesti Arst, 2, 111−117.
6.3.
1999
Viigimaa, Margus (1999). Kuidas mõõta vererõhku. Tervis, 1, 33−34.
6.3.
1999
Adorf, Margit; Kull, Mart; Mehik, Heidi; Viigimaa, Margus; Raidma, Liis (1999). Külm kalkun ehk sõda suitsu vastu : suitsetamisest arstide kommentaaridega. Tervis, 2, 10−14.
6.6.
1999
Viigimaa, Margus (1999). Hüpertensiooni monoteraapia versus kombineeritud ravi. Eesti Arstide Liidu Teataja, 12, 8.
6.6.
1999
Viigimaa, Margus (1999). Kardioloogiakliiniku aastakonverentsilt. Hippokrates, 4, 199.
6.6.
1999
Ani, Ülle; Viigimaa, Margus; Sepper, Ruth (1999). Suitsetamisest ja mitte ainult kui nuhtlusest mitte-suitsetajatele ... Hippokrates, 9, 550−555.
1.1.
1998
Viigimaa, M.; Skards, J.; Parik, T.; Allikmets, K.; Franken, A.; Häss, G. (1998). Combination therapy with tasosartan and hydrochlorthiazide in severe essential hypertension: comparison with enalapril. In: Journal of Hypertension..
1.1.
1998
Viigimaa, M.; Valkman, R.; Kask, A.; Joudu, T. (1998). Effect of ciprofibrate on platelet aggregation in patients with combined hyperlipidemia. Platelets, 9, 265−267.
2.2.
1998
Viigimaa, M.; Maaroos, H.; Lember, M.; Lipand, A.; Tohver, M.; Kelk, J.; Maaroos, J.; Mehilane, L.; Valvere, V.; Sarapuu, H.; Voloz, O.; Birkenfeldt, R. (1998). Soovitused perearstile haiguste ennetamiseks. . Tartu: Tartumaa Trükk.
2.2.
1998
Viigimaa, M.; Dominiczak, M. (1998). Development of cardiovaskular prevention in Estonia. In: The Fats of Life..
3.3.
1998
Viigimaa, M.; Maaroos, H.-I.; Lember, M.; Lipand, A.; Tohver, M.; Kelk, J.; Maaroos, J.; Mehilane, L.; Valvere, V.; Sarapuu, H.; Volozh, O.; Birkenfeldt, R. (1998). Soovitused perearstile haiguste ennetamiseks. Tartu: Tartu Ülikool.
3.4.
1998
Ojamaa, Maie; Viigimaa, Margus; Siim, Kadri; Kullus, Ruth (1998). Ambulatory blood pressure monitoring in young males with borderline hypertension. Proceedings of the Department of Cardiology at the University of Tartu, 44−52.
3.4.
1998
Aab, Alar; Zemtsovskaja, Galina; Zemtsovski, Mihhail; Viigimaa, Margus (1998). Lipids and lipoproteins investigation in the Tartu University Hospital. Proceedings of the Department of Cardiology at the University of Tartu, 7−10.
5.1.
1998
Parik, T.; Allikmets, K.; Zilmer, K.; Zilmer, M.; Viigimaa, M.; Teesalu, R. (1998). Associations between oxidative stress, Von Willebrand factor and plasminogen activator Inhibitor 1 in essential hypertension. Journal of Hypertension, 16, S203−S203.
5.1.
1998
Ojamaa, M.; Viigimaa, M.; Slim, K.; Kullus, R. (1998). Ambulatory blood pressure monitoring in young males with borderline hypertension. Journal of Hypertension, 16, S216−S216.
5.2.
1998
Aab, A.; Zemtsovskaja, G.; Zemtsovski, M.; Viigimaa, M. (1998). Lipids and Lipoproteins investigation in Tartu University Hospital. Proceedings of the 1 Baltic Lipid Conference and VI Estonian Heart Health Conference, Tallinn.
1.3.
1997
Viigimaa, M.; Zemtsovski, M.; Lind, M. (1997). Perekondliku hüperkolesteroleemia pikaajaline ravi simvastatiiniga. Eesti Arst, 60−61.
5.1.
1997
Viigimaa, M.; Zemtsovski, M.; Lind, M. (1997). Effect of relative low dose simvastatin on lipid profile in patients with familial hypercholesterolemia. Abstract book of the Seventh International Symposium on cardiovascular pharmacotherapy, Jerusalem, Israel, June 1997: Seventh International Symposium on cardiovascular pharmacotherapy, Jerusalem, Israel, June 1997. 97.
5.2.
1997
Viigimaa, Margus; Kask, Anne; Johansson, Jan (1997). Vere lipiididesisalduse ja toitumisharjumuste võrdlus Tartu keskealistel elanikel. Üle-eestiline teaduskonverents "Tervise edendamine Eestis, 17.-18. aprill 1997.a. : konverentsi ettekannete teesid. 67−68.
6.2.
1997
Viigimaa, Margus (1997). Südametervise käsiraamat. Tallinn: Eesti Tervisekasvatuse Keskus.
6.2.
1997
Viigimaa, Margus; Dominiczak, Marek (1997). Preventiivkardioloogia : õpik. Tartu: Elmatar Publishing House.
1.1.
1996
Viigimaa, M.; Frölich, J.C. (1996). Platelet aggregation, sensitivity to prostaglandin E1 and tromboxane A2 release in recombinant hirudin- and heparin-anticoagulated blood. Blood Coagulation & Fibrinolysis, 7 (2), 259−261.
1.1.
1996
Viigimaa, M.; Tsikas, D.; Frolich, JC. (1996). Platelet aggregation, sensitivity to prostaglandin E(1) and thromboxane A(2) release in recombinant hirudin- and heparin-anticoagulated blood. Blood Coagulation & Fibrinolysis, 7 (2), 259−261.
1.3.
1996
Jagomägi, K.; Viigimaa, M.; Hendrikson, E.; Talts, J.; Raamat, R.; Teesalu, R. (1996). Arteriaalse vererõhu ja südame löögisageduse variaabelsuse määramine funktsionaalsete testide ajal südamelihase infarkti ägedas faasis. Eesti Arst, 75 (2), 105−108.
3.4.
1996
Viigimaa, Margus; Saareoja, Jelena (1996). Prospective study on APC-resistance in patients with acute myocardial infarction. Proceedings of the Department of Cardiology at the University of Tartu, 119−126.
5.2.
1996
Zemtsovski, M.; Zemtsovskaja, G.; Viigimaa, M. (1996). Laboratory control of simvastatin therapy in coronary heart disease patients. Proceedings of the 3rd Baltic Congress of Laboratory Medicine, Jurmala.
6.4.
1996
Lemne, Carola; Lorenz, Karin; Viigimaa, Margus (1996). Vererõhk ja sinu tervis : teavet organismi talitlusest. Tartu: Intermaag.
1.1.
1995
Viigimaa, M.; Joudu, T.; Keis, U.; Saareoja, Y.; Teesalu, R. (1995). Platelet-aggregation, thromboxane a(2), prostacyclin generation and platelet sensitivity to prostacyclin during the first month after myocardial-infarction. Platelets, 6 (6), 402−407.
3.1.
1995
Viigimaa, M.; Zemtsovski, M.; Kiho, U. (1995). Prophylaxis of venous thromboembolism in orthopaedic surgery. Problems in contemporary surgery (141−148).. Tartu: Tartu Ülikool. (Tartu Ülikooli Toimetised ; 969).
3.2.
1995
Viigimaa, M.; Zemtsovski, M. (1995). Blood serum lipids, lipoproteins and thrombocyte aggregation in acute myocardial infarction and unstable angina pectories. II Annual Copenhagen Atherosclerosis conference, 1995. Final programme and abstracts. 49.
3.4.
1995
Viigimaa, M.; Zemtsovski, M.; Välkmann, R. (1995). Simvastatiinravi efektiivsus II tüüpi hüperlipideemiaga südame isheemiatõve haigetel. Eeasti Sisearstide Seltsi IX Kongress. Teesid 1995..
3.4.
1995
Zemtsovski, M.; Zemtsovskaja, G.; Viigimaa, M. (1995). Blood Lipids and Lipoproteins in patients with angiographically determined atherosclerosis of coronary arteries. Abstract book: ll-th IFCC European Congress of Clinical Chemistry, Tampere, Finland.
5.1.
1995
Viigimaa, M.; Saareoja, Y. (1995). Prospective-study on activates protein-c resistance in patients with acute myocardial-infarction. Thrombosis and Haemostasis, 73 (6), 1374−1374.
6.2.
1995
Viigimaa, Margus (1995). Hüperlipideemia käsiraamat. Tartu: Tartu Ülikool.
6.4.
1995
Viigimaa, Margus; Allikmets, Kristina; Parik, Triin (1995). Tea oma kolesterooliväärtust! : meelespea. Tartu: Tartumaa.
1.2.
1994
Viigimaa, M.; Jôudu, T.; Hendrikson, E.; Shandrik, Y.; Teesalu, R. (1994). Antiaggregative therapy with acetylsalicylic acid and diclofenac in patients with acute myocardial infarction. Upsala Journal of Medical Sciences, 99 (2), 131−138.
2.3.
1994
Viigimaa, Margus (1994). Primary haemostasis, antiaggregative and anticoagulant treatment of acute myocardial infarction. (Tartu Ülikool, Arstiteaduskond). Tartu: University of Tartu.
3.2.
1994
Viigimaa, M.; Zemtsovski, M. (1994). Changes in blood coagulation and fibrinolysis parameters in patients with acute myocardial infarction. Laboratory Medicine, Vilnius 1994.
3.4.
1994
Saareoja, Jelena; Jõudu, Tiiu; Viigimaa, Margus (1994). Effect of recombinant hirudin and heparin on platelet aggregation in coronary artery disease patients. Proceedings of the Department of Cardiology at the University of Tartu, 104−108.
3.4.
1994
Ojamaa, Maie; Ulst, Kai; Viigimaa, Margus (1994). Lung perfusion scanning as a screening method in diagnostics of pulmonary embolism in cardiology department. Proceedings of the Department of Cardiology at the University of Tartu, 72−75.
3.4.
1994
Ristimäe, Tiina; Viigimaa, Margus; Teesalu, Rein (1994). Sequential changes in cardiac index in 35 male-patients with first myocardial infarction. Proceedings of the Department of Cardiology at the University of Tartu, 86−103.
5.2.
1994
Zemtsovski, M.; Viigimaa, M.; Zemtsovskaja, G.; Shandrik, J. (1994). Blood coagulation factors after thrombolytic therapy in patients with acute myocardial infarction. University Research in Medicine, Proceedings of the Meeting, 1994, Tartu. 18.
1.1.
1993
Viigimaa, M.; Ohnogi, H.; Hattori, R.; Yui, Y.; Kawai, C. (1993). Antithrombotic effect and reperfusion by low molecular weight heparin in a canine model of coronary artery thrombosis. Japanese circulation journal, 57 (6), 553−557.
1.1.
1993
Viigimaa, M.; Ohnogi, H.; Hattori, R. (1993). Antithrombotic effect and reperfusion by low-molecular-weight heparin in a canine model of coronary-artery thrombosis. Japanese circulation journal, 57 (6), 553−557.
1.1.
1992
Lopp, M.; Kobzar, G.; Bergmann, N.; Pehk, T.; Lopp, A.; Valimae, T.; Viigimaa, M.; Lille, U. (1992). Synthesis and antiaggregative activity of novel omega-achiral carba-analogs of prostacyclin. European Journal of Medicinal Chemistry, 27 (2), 155−159.
6.7.
1979
Viigimaa, Margus (1979). Müokardiinfarkti morfogenees ja tüsistused : referatiivne võistlustöö. Tartu: Tartu Riiklik Ülikool.
25.08.2019
Detailne otsing
  • Leitud 10 kirjet
ProgrammLiikNumberNimiProjekti algusProjekti lõppVastutav täitjaAsutusFinantseerijapoolne rahastamine
MUUIN567Biomeditsiinitehnika inseneride uuendatud ning tööjõuvajadusi arvestav kõrghariduse ja kutsekvalifikatsioonisüsteem Eestis01.06.200530.03.2008Kalju MeigasTallinna Tehnikaülikool; Tallinna Tehnikaülikool, TTÜ Tehnomeedikum, Biomeditsiinitehnika instituut, Biomeditsiinitehnika õppetool191 209,40 EUR
IUTIUT19-2Biooptilised ja bioelektrilised signaalid meditsiinitehnikas01.01.201431.12.2019Ivo FridolinTallinna Tehnikaülikool, TTÜ Tehnomeedikum, Biomeditsiinitehnika instituut; Tallinna Tehnikaülikool, Infotehnoloogia teaduskond, Tervisetehnoloogiate instituut528 000,00 EUR
SFSF0140027s07Biosignaalide interpreteerimine meditsiinitehnikas01.01.200731.12.2012Ivo FridolinTallinna Tehnikaülikool, TTÜ Tehnomeedikum790 451,10 EUR
TKTAR16013DB (2014.2020.4.01.15-0018)Eesti Infotehnoloogia Tippkeskus01.01.201601.03.2023Ivo FridolinTallinna Tehnikaülikool, TTÜ Tehnomeedikum177 736,00 EUR
TKTAR8077DBIntegreeritud elektroonikaüsteemide ja biomeditsiinitehnika tippkeskus07.07.200831.08.2015Ivo FridolinTallinna Tehnikaülikool; Tallinna Tehnikaülikool, TTÜ Tehnomeedikum, Biomeditsiinitehnika instituut1 125 100,66 EUR
TKAlamprojektTAR16013 (EXCITE) (TK148)IT Tippkeskus EXCITE01.09.201601.03.2023Maarja KruusmaaTallinna Tehnikaülikool, Infotehnoloogia teaduskond, Biorobootika keskus; Cybernetica AS2 642 075,15 EUR
RITA1AlamprojektRITA1/01-42-02Personaalmeditsiini kliinilised juhtprojektid rinnavähi ja südame-veresoonkonna haiguste täppisennetuses 01.01.201831.12.2020Margus ViigimaaSA Põhja-Eesti Regionaalhaigla0,00 EUR
MUULMIN15035Personaalmeditsiini rakendamiseks digitaalsete otsustustoe lahenduste arendusuuring30.03.201530.06.2015Peeter RossTallinna Tehnikaülikool114 190,00 EUR
MUUBF109Rootsi-Eesti südame-veresoonkonna haiguste riskitegurite uuringu SWESTONIA järeluuring16.10.200831.12.2009Margus ViigimaaTallinna Tehnikaülikool; Tallinna Tehnikaülikool, TTÜ Tehnomeedikum, Biomeditsiinitehnika instituut, Meditsiinifüüsika õppetool18 534,38 EUR
MUUBF49Tallinna 20-64 a elanike südame-veresoonkonna haiguste riskitegurite selgitamine CINDI progammis01.01.200731.12.2009Margus ViigimaaTallinna Tehnikaülikool; Tallinna Tehnikaülikool, TTÜ Tehnomeedikum, Biomeditsiinitehnika instituut23 583,40 EUR